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Abstract 
Nuclear pre-mRNA splicing is the process by which the non-coding introns 
are removed from pre-mRNA and the coding exons are joined together to produce 
mature mRNA. Splicing takes place on a large multicomponent complex called the 
spliceosome, which is made up of small nuclear ribonucleoprotein particles (snRNPs) 
and a host of other factors. The PRP2 protein of Saccharomyces cerevisiae is a non-
snRNP factor required for the first cleavage-ligation step of splicing. PRP2 has 
protein sequence motifs characteristic of the DEAD/H-box family of putative ATP-
dependent RNA helicases. It has been demonstrated to have RNA-dependent 
ATPase activity. PRP2 interacts only transiently with the spliceosome. This 
transient interaction has hindered biochemical studies of the interactions between 
PRP2 and other splicing components. A genetic approach, through the isolation of 
dominant negative mutants, has been used to try to identify interacting proteins and 
to study the role of PRP2 in the splicing reaction. Dominant negative PRP2 proteins 
are those which, when overproduced, cause inhibition of splicing even in the 
presence of wild-type PRP2. 
Four dominant negative mutants of PRP2 were produced by site-directed 
mutagenesis of the conserved ATP-binding motif (Motif A) of PRP2. These 
mutants, when overproduced in a wild-type yeast strain caused a growth inhibition 
due to inhibition of splicing, leading to an accumulation of pre-mRNA. In vitro 
analysis of cell-free splicing extracts showed that splicing was inhibited in the 
presence of the dominant negative proteins. The splicing inhibition could be 
alleviated if enough wild-type PRP2 was present in the extracts. The dominant 
negative mutants caused accumulation of the fully assembled but inactive 
spliceosome. Immunoprecipitation with anti-PRP2 antibodies showed that one 
mutant protein (PRP2) was stably associated with the spliceosome. In contrast, 
another mutant protein (PRP2T),  appeared not to be associated with the 
spliceosome, suggesting that it was sequestering some other essential splicing factor 
outside the splicing complex. 
Using an affinity column, two of the dominant negative proteins have been 
purified. Assays have shown that neither protein can bind poly U RNA and that 
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both show negligible ATPase activity. Both purified proteins can inhibit the activity 
of a wildLtype splicing extract and prevent the formation of the active spliceosome. 
This inhibition may be caused because the mutant proteins are sequestering another 
essential splicing factor or because they become "stuck" in the spliceosome, 
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1.1 RNA splicing 
It was in 1977 that the suggestion was first made that the non-coding 
sequences (introns) that interrupted eukaryotic transcripts were removed by an RNA 
splicing mechanism. Viral transcription workers presented direct evidence for the 
existence of introns. On hybridisation to the corresponding cDNA, viral early 
transcripts formed large displacement loops. This was demonstrated in adenovirus 
(Berget et al, 1977; Chow et al, 1977; Lewis et a!, 1977) and in SV40 late gene 
transcripts (Aloni et al, 1977). It was also observed that in adenovirus, the same 5' 
leader could be attached to several different rRNA transcripts. In order to explain 
the looping of the pre-mRNA it was proposed that the intervening sequences (which 
formed the loops) were excised from the pre-mRNA and that the adjacent coding 
regions or exons, were ligated to produce the mature transcript. This mechanism, 
termed RNA splicing involved a series of cleavage-ligation reactions to excise the 
introns and join the exons in the correct order to produce a mature transcript. 
Comparison of restriction fragment size in the rabbit and mouse /3-globin gene DNAs 
and cDNAs showed the existence of additional restriction sites and larger than 
expected fragments in the genomic DNA compared to the cDNA (Jeffreys and 
Flavell, 1977; Tilghman et al, 1978). This was further evidence for removal of 
parts of the mRNA after transcription (the discovery of introns is reviewed in 
Witowski, 1988). 
1.1.1 The main classes of intron 
In the research that followed to try to fully understand the mechanism and to 
identify cis- and trans-acting factors, four distinct classes of introns were defined, 
each with a different splicing mechanism, or requiring different factors. The 
characteristics of the four different classes are summarised below. 
1 
tRNA introns (Peebles et al, 1979) 
tRNA genes may contain a single intron which is always located one 
nucleotide downstream of the anticodon triplet (Penman et a!, 1991). In 
Saccharomyces cerevisiae only 20% of the tRNA genes are interrupted (Abelson, 
1991). Splicing occurs in two steps. First, ATP-independent endonuclease cleavage 
removes the intron to produce two half molecules (Knapp et al, 1979). Then, the 
two half molecules are joined by a tRNA ligase which requires both ATP and GTP 
for efficient function (Apostol et al, 1991). 
Group I introns (Cech and Bass, 1986) 
RNA-catalysed (autocatalytic) splicing of precursor RNAs which occurs in 
the absence of ATP. Mg and guanosine are required for the reaction. The intron 
has a complex secondary and tertiary structure. Group I splicing was first shown 
in Tetrahymena rRNA precursors. It is also seen in Physarum and fungal, plant, 
bacteriophage and bacterial pre-mRNAs. 
Group II introns (Cech and Bass, 1986) 
Autocatalytic splicing, similar to Group I but the sequences and secondary 
structures of the Group II introns differ from Group I introns. Group II introns are 
found in fungal mitochondrial and chioroplast genes. There is evidence now for the 
existence of self splicing introns in forerunners of mitochondria in eubacteria (Ferat 
and Michel, 1993). Some group II introns have open reading frames (ORFs) and the 
proteins encoded by these ORFs are related to the reverse transcriptases of 
retroviruses (Michel and Lang, 1985). This is evidence for intron mobility and 
transposition. It is possible that group II introns have spread by reverse splicing into 
heterologous RNAs, reverse transcription and recombination of the complementary 
DNA into the intronless copy. The transpositional activity of introns is an important 
factor in the evolutionary theory of the existence of introns because it supports the 
theory that nuclear pre-mRNA introns descended from group II introns originally 
found in the genome of mitochondrial precursors (Cavalier-Smith, 1985). This 
theory is further supported by the identification of a fifth class of intron- group III 
(reviewed in Copertino and Hallick, 1993). Group III introns are generally U-rich 
and appear to be evolutionarily related to group II introns. They have a similar 
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secondary structure and are spliced out via a lariat intermediate, but it is thought that 
they may require trans-acting RNAs for splicing. Group III introns have been found 
in Euglena and Astasia. Euglena chioroplast genes are also interrupted by 
"twintrons", or introns within introns. These may be two group II introns or two 
group III introns or a mixture of both classes. Twintrons provide more evidence for 
the transposable activity of introns. 
(iv) Nuclear pre-mRNA introns 
A complex mechanism which requires ATP and a large selection of trans-
acting factors which are involved in splice site recognition, orientation of the pre-
mRNA and the splicing reaction itself. Splicing takes place on a large 
multicomponent complex called the spliceosome. (For reviews of nuclear pre-mRNA 
splicing see: Padgett et a!, 1986; Sharp, 1987; Green, 1991; Moore et al, 1993, 
Rymond and Rosbash, 1993). 
1.1.2 Group H and nuclear pre-mRNA introns may be evolutionarily related 
The similarity that is seen between the intermediates and products of group 
II and nuclear pre-mRNA splicing provides strong, yet indirect evidence that the two 
splicing processes may be evolutionarily related (reviewed in Jacquier, 1990). 
Almost all group II introns can be folded into a common structure of six stem-loops 
(domains Ito VI) (Michel et al, 1989). It is hypothesised that in nuclear introns, the 
group II subdomains have been detached to become separately encoded. So, nuclear 
pre-mRNA introns would be group II introns which had lost all the information 
required to identify splice sites and the branch point. This is supplied instead, in 
trans by the snRNPs and other factors (section 1.3.2). The splice site consensus and 
lariat branch-point sequences of group II and nuclear introns are similar and splicing 
occurs by the same two-step reaction (section 1.2). Both types of intron are excised 
via lariat intermediates, using internal adenosines as cis-acting nucleophiles (section 
1.2). The secondary structure through cis-base pairing in domain VI of group II 
introns stabilises the unpaired adenosine, in nuclear introns, the trans U2 snRNA-
branch-point interaction stabilises the nucleophile. The U6/U2 interaction may 
correspond to the group II catalytic domain V, one of the most diagnostic features 
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of group II introns which is absolutely required for 5' cleavage (Jarrell et a!, 1988). 
Working on the psaA gene of Chiamydomonas reinhardii, Goldschmidt-
Clermont et al (1991) showed that the trans splicing of the three separate psaA 
transcripts which are encoded by widely scattered loci, required an additional locus 
(tscA). The tscA gene did not have a significant ORF but Goldschmidt-Clermont et 
al (1991) suggested that the small RNA produced on transcription was required for 
the splicing of two of the psaA exons. The three RNAs together are hypothesised 
to form a structure similar to that of the group II intron. This may be evidence of 
an intermediate evolutionary stage between the group II self-splicing intron and the 
nuclear intron which requires five other RNAs for splicing. 
The significant similarities between group II and nuclear introns have led to 
the proposal that nuclear pre-mRNA splicing may be an RNA-catalysed process 
(Cech, 1983). 
Although little is known about the specific functions of the sequences of the 
catalytic core of group II introns, nuclear pre-mRNA splicing has been the subject 
of extensive research both in mammals and in S. cerevisiae (yeast) and by using a 
combination of biochemical and genetic techniques, both cis- and trans-acting factors 
essential for nuclear pre-mRNA splicing have been identified. The rest of this 
chapter is concerned mainly with nuclear pre-mRNA splicing. 
1.2 The splicing mechanism 
It is thought that all introns in nuclear pre-mRNA transcripts are removed by 
the same two-step mechanism (figure 1.1) Step 1 involves cleavage at the 5' end of 
the intron (5' splice site) to yield a 5' exon intermediate (exon 1) with a free 3' -OH 
end. At the same time, the intron forms a lariat structure as a result of an unusual 
2'-5' phosphodiester bond between the 5' end of the intron and a conserved 
adenosine residue near the 3' end (the branch point). The branched intron is still 
attached to the 3'exon (exon 2). The second step of the reaction involves cleavage 
at the 3' end of the intron (3' splice site) and concurrently, ligation of the two exons 
to produce the mature mRNA and the excised lariat-intron. The lariat-intron is 
subsequently linearised by a debranching enzyme and degraded. 
4 
Figure 1.1 The two steps of pre-mRNA splicing 
Each step involves a transesterification reaction as indicated by the arrows. The 
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ATP hydrolysis is required for both steps of the splicing reaction, but none 
of the phosphates in the spliced products is actually derived from exogenous ATP. 
The splice-site phosphates are conserved in the products (Padgett et al, 1984; Lin 
et al, 1985). Additionally, the cleavage and ligation events of each step cannot be 
separated into two distinct reactions. Thus, it is proposed that the reaction proceeds 
via two transesterification steps, each involving nucleophilic attack by -OH groups 
from the branch point and 5' splice site, to displace 3' oxygens at the 5' splice site 
and 3' splice site respectively. Splicing of group I and II introns also involves two 
transesterification reactions (Kruger et al, 1982; McSwiggen and Cech, 1989) and 
this is consistent with the notion that pre-mRNA splicing may be an RNA catalysed 
process. The ATP requirement in splicing must therefore be for the use of the 
trans-acting factors involved in the splicing reaction. A number of essential splicing 
factors do have proteins sequence motifs characteristic of RNA-dependant ATPases 
(Schwer and Guthrie, 1991; Chen and Lin, 1990). 
1.3 Splicing in yeast and mammals 
Despite similar mechanisms for their removal, mammalian and yeast introns 
differ in conserved primary sequence motifs, size and frequency in genes. 
The primary sequences defining 5' and 3' splice sites and the branch points 
of S. cerevisiae introns are much more highly conserved than those in mammalian 
introns. The degeneracy of intron sequence in mammals may allow for a less 
constrained splicing system leading to use of alternative splice sites in, for example, 
tissue specific gene expression. This flexibility can be seen in vitro because 
mammalian splicing extracts can accurately remove introns from yeast and plant 
transcripts (Ruskin et a!, 1986; Brown et a!, 1986). However, the greater sequence 
constraints in yeast systems do not allow the splicing of mammalian transcripts 
(Beggs et a!, 1980; Langford et a!, 1983) and no example of alternative splicing in 
yeast has been found. 
Introns of S. cerevisiae are'much shorter on average and occur less frequently 
than mammalian introns. The introns are generally less than 400 bp in length 
(Rymond and Rosbash, 1993) and most interrupted yeast genes contain only one 
intron, an exception being MATaJ which has two small introns (Miller, 1984). 
Mammalian genes often contain multiple, large introns. The extremely low 
frequency of introns within the S. cerevisiae genome (3-5% of the sequenced nuclear 
encoded genes) compared to the mammalian genome has given rise to two possible 
explanations. Firstly, S. cerevisiae may have lost most of the original introns during 
evolution. Fink (1987) observed that of the few (17) yeast genes which did contain 
introns, all but one (MAT41) had a single intron at the 5' end of the gene. He 
speculated that most yeast genes are in fact pseudogenes which have lost introns 
through homologous recombination with cDNAs produced by a cellular reverse 
transcriptase. Since, for homologous recombination to remove an intron it is 
necessary to have cross-overs on either side of the intron, 3' and more central 
introns could easily be lost during recombination of the gene with a cDNA. Reverse 
transcription is likely to be terminated before reaching the 5' end of the RNA (which 
corresponds to the 5' end of the gene), so the cDNA might not extend far past the 
intron site and recombination would not be favoured. MATa1 which has two introns 
has two differently spliced transcripts one of which includes an intron, so there is 
selective pressure to retain that intron. 
The second explanation is that the genomes of other eukaryotic cells have 
"acquired " introns during evolution. This may be due to transposable element 
insertion. Cavalier -Smith (1985 and references therein) suggested that the 
transposable elements may insert into a gene and due to a mutation in their 
excisionase protein, be able to be removed only from RNA. The mutant excisionase 
retains its sequence specificity so that other transposons can also be removed from 
other RNAs by the mutant excisionase. Thus, there is positive selection to retain the 
transposon with the mutant excisionase and introns will increase in the genome 
because they can be removed from transcripts and are no longer harmful insertions. 
Later on, this splicing ability could be used to produce different transcripts for 
different proteins from the same transcriptional unit by alternative splicing. 
Selection pressure on organisms to have a short cell cycle, perhaps by cutting down 
on RNA processing supports the observation that there are very few introns in yeast 
compared to mammals. The remaining yeast introns, of course, may have important 
regulatory functions although an intronless actin gene has no apparent adverse affect 
on growth of S. cerevisiae (Ng et al, 1985). 
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1.3.1 Splice site sequence requirements. 
The sites involved in the transesterification reactions of splicing are defined 
by consensus sequences primarily within the intron and at the 5' and 3' ends. A 
comparison of intron sequences from yeast and mammals is shown in table 1.2. 
YEAST 	S. cerevisiae MAMMAL 
5' SPLICE SITE R74/G 1 T98A96T89G1 T G79/G1OOT1OOR93A74G85Y66  
3' SPLICE SITE Y98A 100G 100 C78A 1OOG !OO 
BRANCHPOINT T94A98C 1 T100A11ØØC 1Ø0A74 Y89NY83T69R79AIOOC72N 
Table 1.2 
Splice site consensus sequences (from Rymond and Rosbash, 1993). 
Subscript numbers show the percentage conservation of bases, / indicates the 
cleavage site. 
1.3.1.1 5'splice site 
In higher eukaryotes, almost all introns have the dinucleotide GT at their 5' 
ends. Mutations of either of these nucleotides results in complete inactivation of the 
5' splice site (Montell et a!, 1982; Treisman et al, 1982; Wieringa et al, 1983). It 
was shown that mutations at other positions of the 5' splice site could activate cryptic 
splice sites elsewhere in the pre-mRNA (reviewed in Green, 1986). In yeast 
systems, 5' splice site mutations usually lead to complete loss of splicing activity. 
Some mutations of the GT dinucleotide can cause aberrant cleavage which leads to 
the accumulation of "dead-end" lariat intermediates (Newman et al, 1985; Fouser 
and Friesen, 1986; Jacquier and Rosbash, 1986; Vijayraghavan et al, 1986). 
Mutations of the invariant G nucleotide at position +5 of the intron leads to aberrant 
5' cleavage at nucleotides either upstream or downstream of the authentic site 
(Parker and Guthrie, 1985; Fouser and Friesen, 1986). Several of the yeast splice 
site mutants also display a decreased ability to form a complete splicing complex 
(Vijayraghavan et al, 1986). 
1.3.1.2 3 1splice site region 
In mammals the 3' splice site region is defined by three separate sequence 
elements; the branchpoint, the polypyrimidine tract and the 3' splice site itself. The 
3' splice site region may extend up to 100 nucleotides into the intron upstream of the 
3' end. 
The branchpoint in yeast has the absolutely conserved TACTAAC sequence 
which is 20-60 bp upstream of the 3' splice site (Green, 1986; Padgett, 1986). The 
final A residue of the sequence is the site of the 2'-5' phosphodiester bond of the 
intron lariat. Deletion of this sequence or specific base changes can completely 
abolish splicing in vivo (Jacquier and Rosbash, 1986; Langford et al, 1984) and in 
vitro (Newman et al, 1985). Some single base changes do allow a low level of 
splicing in some assays. If the branchpoint A is mutated to C, then a low level of 
splicing activity is seen and the intron branch is formed at the normal location (that 
is: to the cytidine rather than adenosine) (Jacquier and Rosbash, 1986). The excised 
introns are very stable. An A to G change at the branchpoint causes a major 
accumulation of lariat intermediate (Fouser and Friesen, 1986) and very little step 
2 occurred. Fouser and Friesen (1986) proposed that recognition of the branchpoint 
A is important for the later steps of the splicing reaction. This stringent sequence 
requirement may explain why mammalian pre-mRNA5 cannot be spliced in yeast 
cells (Beggs et al, 1980; Langford et al, 1983). The mammalian branchpoint is less 
well conserved but does still have the absolutely conserved branchpoint A residue. 
The polypyrimidine tract is usually found between the branchpoint and the 
3' splice point. It is more pronounced in mammals than in yeast. Analysis of 
mammalian polypyrimidine tracts by Reed (1989) showed that maximal efficiencies 
of lariat formation required a polypyrimidine tract adjacent to the branchpoint. Reed 
(1989) also observed that efficient lariat formation could be specified in two distinct 
ways, one which required the 3'AG dinucleotide splice junction and one that did not. 
In introns with a short polypyrimidine tract (14 nucleotides), an adjacent AG is 
essential but, in contrast, the AG is not required in the presence of a longer 
polypyrimidine tract (26 nucleotides). Reed hypothesised that splicing factors 
required for efficient splicing may bind to the 3' splice site region and that the 
different lengths of polypyrimidine tract or the distance of the AG from the 
polypyrimidine tract may affect the binding of such factors and hence, splicing 
activity. In mammals, U2AF, which is required for complex assembly binds to the 
polypyrimidine tract (Ruskin et al, 1988). In yeast, a U-rich tract can increase the 
usage of a distal 3' splice site (Patterson and Guthrie, 1991). 
In both mammals and yeast the 3' splice site itself consists of the final AG 
dinucleotide of the intron. If the AG dinucleotide is mutated then the next, 
downstream AG is used instead (Reed and Maniatis, 1985; Aebi et al, 1986; Reed 
1989). 
1.3.2 Trans-acting factors. 
1.3.2.1 snRNPs 
Four small nuclear ribonucleoproteins (snRNPs) make up the core of the 
spliceosome. SnRNPs are highly abundant in mammalian cells (105106  copies per 
cell) and they have been extensively studied in such cells (Lührmann, 1990). The 
four snRNPs, Ui, U2, U5 and U4/U6 are named after the snRNA(s) which they 
carry. The U4/U6 snRNP carries two snRNAs, U4 and U6 which are directly 
associated by Watson and Crick base pairing. Each snRNP also has a core of 
structural polypeptides. Nine mammalian core proteins have been identified: B, 
B',D 1 , D2 , D3 , E, F, G and G'. Some of these core proteins have 'Sm' epitopes 
which are the antigenic determinants of antibodies produced by patients suffering 
from systemic lupus erythematosus, an auto-immune disease (Learner and Steitz, 
1979). By using anti-Sm serum from these patients, it was possible to show that 
yeast snRNPs contained cross-reacting peptides (Siliciano et al, 1987(b); Tollervey 
and Mattaj, 1987). Thus, at least some of the mammalian core proteins are 
conserved in yeast. A yeast gene for a protein 40% identical to mammalian D 1 has 
been cloned (Rymond, 1993) and a yeast homologue to D 3 has also been identified 
(Roy and Woolford, pers. comm.). With the exception of U6, all mammalian 
snRNAs contain the Sin binding site (RAU4 GR) and a 2,2,7-trimethyl-guanosine 
cap (m 3G cap) at the 5' end (Mattaj, 1988). U6 has a -y-monomethylated 
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triphosphate cap structure (Singh and Reddy, 1989). 
The yeast equivalents of the five snRNAs (Ui, U2, U4, U5 and U6) were 
difficult to identify. This was partly due to their low abundance in yeast and the 
lack of conservation of the primary sequence between yeast and mammals so that 
cross-hybridisations with mammalian snRNAs was not successful. The exception is 
U6, which is highly conserved (Brow and Guthrie, 1988). 
The first yeast splicing snRNAs were verified by denaturing gel 
electrophoresis analysis of yeast splicing complexes (Pikielny and Rosbash, 1986). 
This method identified three spliceosome-related snRNAs: snR14 and the two 
products of the snR7 gene. snR14 is the yeast equivalent of mammalian U4 snRNA 
and snR7 is the yeast equivalent of U5 snRNA (Patterson and Guthrie, 1987; 
Siliciano eta!, 1987(a)). Ui and U2 snRNAs can be immunoprecipitated as snRNPs 
from splicing reactions using anti-Sm. antibodies (Pikielny et a!, 1986; Siliciano et 
a!, 1987(b)). Ui and U2 snRNAs are very much larger than their mammalian 
counterparts (Ares, 1986; Kretzner et a!, 1987; Siliciano et a!, 1987(b)). The extra 
nucleotides have unknown function and most can be deleted with little or no effect 
on splicing (Igel and Ares, 1988; Shuster and Guthrie, 1988; Liao et a!, 1990; 
Siliciano et a!, 1992). The yeast Ui, U2, U4 and U5 snRNAs are m 3G capped 
(Wise et al, 1983) and possess the Sm binding site. The yeast U6 analogue is 
strongly conserved in length and sequence compared to its mammalian counterpart 
(Brow and Guthrie, 1988). 
1.3.2.2 The spliceosome cycle 
The spliceosome cycle was described originally by the kinetics of appearance 
of different complexes in splicing reactions in vitro and the analysis of the splicing 
intermediates and snRNAs they contained (Konarska and Sharp, 1986, 1987; 
Pikielny et a!, 1986; Cheng and Abelson, 1987). The validity of the cycle has been 
confirmed by studying the complexes which accumulated in reactions deficient in 
particular snRNPs and proteins. The order in which the snRNPs assemble onto the 
pre-mRNA is conserved in vitro in yeast and mammals. Addition of the snRNP 
components during spliceosome assembly is ordered and each step depends on the 
successful completion of the previous step. Apart from Ui, all snRNP binding steps 
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Figure 1.3 The spliceosome cycle 
This figure shows the order of assembly of the spliceosome from the five snRNP 
components. 
El and E2 represent the exons and IVS is the intron. 
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require ATP. Ui binds first at the 5' splice site, followed by U2 which interacts 
with the branchpoint sequence. U4/U6 and U5 join the spliceosome complex as a 
pre-assembled tri-5nRNP. After the tri-snRNP has bound, there is a destabilisation 
of the U4/U6 dimer which occurs immediately before or during step 1. After the 
splicing reaction, the spliceosome disassembles and all the components are presumed 
to recycle in vivo, to form other spliceosomes although this is not observed in vitro. 
The spliceosome cycle is summarised in figure 1.3. 
Spliceosome assembly involves many RNA:RNA interactions. Ui snRNA 
base-pairs with the 5' splice site (Learner et al, 1980; Rogers and Wall, 1980) and 
can affect 5' splice site choice in both mammals (Aebi et al, 1986; Zhuang and 
Weiner, 1986) and yeast (Séraphin et al, 1988; Siliciano and Guthrie, 1988). There 
is a base-pairing interaction between U2 and the branchpoint in both yeast and 
mammals (Parker et al, 1987; Wu and Manley, 1989; Zhuang et a!, 1989). Cross-
linking experiments by Hausner et al (1990) showed an interaction between U6 and 
U2 which can only occur after U4/U6 destabilisation (Fortner et al, 1994). Newman 
and Norman (1991; 1992) have shown that US snRNA can base pair with exon 
sequences at both the 5' and 3' splice sites in yeast, this may contribute to splice site 
selection. 
As the results presented in this thesis are not concerned with snRNPs or the 
spliceosome complex, this has only been briefly discussed. This area of splicing is 
discussed more fully in recent reviews by Lührmann (1990), Beggs (1993), Moore 
et al (1993), Rymond and Rosbash (1993). 
1.3.2.3 PRP proteins 
The powerful genetic approaches, both classical and molecular that are 
offered by S. cerevisiae have been used to identify many non-snRNP trans-acting 
factors required for yeast pre-mRNA splicing. As splicing is an essential function, 
most mutations affecting the splicing machinery will result in cell death. To 
overcome this problem, conditional lethal mutants, which are lethal only under 
particular conditions (such as high temperatures) have been studied. 
The first mutants to be isolated were originally thought to affect ribosome 
biosynthesis (Hartwell et al, 1970). It was later shown that they were defective in 
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pre-mRNA splicing (Rosbash et a!, 1981) and that ribosome synthesis was affected 
due to the presence of introns within the ribosomal protein genes. Some recent 
screens have been carried out to specifically isolate pre-mRNA splicing mutants. 
The mutants isolated had a conditional lethal phenotype and accumulated either pre-
mRNA, splicing intermediates or excised intron-lariat product under the non-
permissive conditions (Vijayraghavan and Abelson, 1989; Strauss and Guthrie, 
1991). Since the screens have identified new complementation groups and have not 
isolated mutants of all the previously identified genes, it is predicted that these 
screens have not been saturating and that more genes remain to be identified. Over 
35 complementation groups of pre-mRNA splicing mutants are currently known. 
The genes coding for these complementation groups have been termed PRP 
(precursor RNA processing) and PRP proteins are involved in all stages of the 
splicing reaction. Most of the PRP genes known have been identified in large 
screens of temperature-sensitive mutations in yeast. Others have been identified 
because they can suppress temperature-sensitive pip mutants or snRNA or pre-
mRNA mutants or because they cause synthetic lethal phenotypes with other mutants 
(reviewed in Ruby and Abelson, 1991). Most pip mutants accumulate pre-mRNA 
but a few either accumulate the intron-lariat-exon2 intermediate or intron-lariat 
product, suggesting that these mutant pip genes are affecting step 2 or the release 
of the spliced exons and excised intron 
Wild-type PRP genes are cloned by complementation of the mutant phenotype 
by using yeast genomic DNA plasmid libraries. All PRP genes which have been 
isolated are single copy. 
Many PRP proteins have been assigned to particular stages of the splicing 
reaction (Rosbash et al, 1981; Lustig et al, 1986) and/or localised to particular 
snRNPs. For example, PRP2 and PRP16 are required for steps 1 and 2 respectively 
(Lin et a!, 1987; Schwer and Guthrie, 1991). PRP17 and PRP18 are also required 
at step 2 (Vijayraghavan et al, 1989; Vijayraghavan and Abelson, 1990). PRP22 is 
required for release of the spliced message from the spliceosome (Company et al, 
1991) and PRP26 is the lariat-intron debranching enzyme required for intron 
degradation after splicing (Chapman and Boeke, 1991). PRP3, PRP4 and PRP6 are 
associated with the U4/U6 snRNP (Banroques and Abelson, 1989; Peterson-Bjorn 
et a!, 1989; Abovich et a!, 1990). PRP8 is a U5 snRNP component (Last et a!, 
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1986; Lossky et a!, 1987). 
The predicted amino acid sequences of some PRP proteins contian conserved 
motifs characteristic of particular protein functions or structures. PRP2, PRP6, 
PRP9 and PRP1 1 all have zinc finger-like motifs (Chen and Lin, 1990; Legrain and 
Choulika, 1990). Zinc finger motifs are characteristic of protein-protein or protein-
nucleic acid interaction domains seen for example in TFIIIA (Berg, 1987). PRP24 
has the RNP motif which is common to RNA binding proteins (Shannon and 
Guthrie, 1991). PRP5 (Dalbadie-McFarland and Abelson, 1990) and PRP28 (Strauss 
and Guthrie, 1991) have motifs characteristic of the DEAD-box family of putative 
ATP-dependent RNA helicases (Ray et al, 1985; Rozen et a!, 1989), while PRP2, 
PRP16 and PRP22 have motifs found in the related DEAH-box family (Chen and 
Lin, 1990; Burgess et a!, 1990; Company et a!, 1991, see section 1.4). 
1.4 Putative RNA helicases in splicing 
Recent evidence for RNA-RNA interactions (section 1.5) in the spliceosome 
suggests that there is a role for RNA helicases in splicing. It is predicted that they 
would drive RNA conformational changes or displacement at particular stages of the 
reaction. The helicases may also monitor the RNA conformation (Wasserman and 
Steitz, 1991). Processes such as these are likely to account for some of the ATP 
requirement of pre-mRNA splicing. There are five yeast splicing factors which 
share a number of highly conserved amino acid motifs characteristic of the 
DEAD/H-box family of ATP-dependent RNA helicases. These factors are: PRP2 
(Chen and Lin, 1990), PRP5 (Dalbadie-McFarland and Abelson, 1990), PRP16 
(Burgess et a!, 1990), PRP22 (Company et a!, 1991) and PRP28 (Strauss and 
Guthrie, 1991). About 30 members of the DEAD/H-box family have been identified 
to date, but only four of these, namely eIF-4A (Ray et a!, 1985; Rozen et a!, 1989), 
human p68 protein (Hirling et a!, 1989), the cylindrical inclusion protein of plum 
pox potyvirus (Lain et al, 1990) and the human analogue of Drosophila melanogaster 
maleless (Lee and Hurwitz, 1993) have been shown to have RNA helicase activity 
in vitro. Due to the highly conserved nature of the motifs, it is likely that the other 
members of the family will also have helicase activity. In some cases (eIF-4A, for 
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example), the proteins require a co-factor (eIF-4B, in this example). Both PRP2 
(Kim et al, 1992) and PRP16 (Schwer and Guthrie, 1991) have RNA-dependent 
ATPase activity in vitro but helicase activity has not yet been demonstrated. This 
may be due to co-factor requirements or a stringent RNA substrate specificity. 
Most of the detailed functional analysis of the DEAD/H-box proteins has been 
carried out on eIF-4A. By engineering a series of amino acid changes within various 
conserved motifs, Pause and Sonenberg (1992) were able to deduce functions for 
some of the motifs. Mutations of motifs I and II which are forms of the ATPase 
motifs A and B (Walker et al, 1982; Linder et al, 1989) affected ATP-binding 
and/or hydrolysis. Mutation of motif III caused loss of RNA helicase activity but 
a slight increase in ATPase activity was also observed. Motif III may be essential 
for the coupling of the ATPase and helicase activities, since mutations within this 
motif appear to uncouple the two activities so that one was abolished while the other 
increased. Mutations of motifs I, II and VI which changed the DEAD-box sequences 
to those observed in the DEAH-box subfamily gave some interesting results. An 
alanine to glycine change in the first residue of motif I increased the ATP-binding 
activity although ATPase activity remained the same and helicase activity was 
reduced. If the final aspartate (D) residue of motif II was changed to histidine (H), 
then ATP binding and hydrolysis activities were increased but helicase activity was 
reduced to 10% wild-type activity. If glutamine (OJ replaced histidine in motif VI, 
then ATP binding and hydrolysis were reduced and helicase activity was abolished. 
Interestingly, the double mutant (DEAD-'DEAH and HRIGR-QRIGR) had increased 
ATPase activity and helicase activity was restored to 10% wild-type activity. Pause 
and Sonenberg (1992) argued that 10% helicase activity was significant and indicated 
that members of the DEAH subfamily are probably helicases too. They proposed 
that histidine (motif II) and glutamine (motif VI) or aspartate (motif II) and histidine 
(motif VI) interact to effect the ATPase activity and that further interactions from 
other motifs (for instance the less well conserved PTRELA motif or the GG region 
which is not found in DEAR proteins) are required for helicase activity. Thus, a 
triple mutant in which all three motifs were altered to the DEAR consensus might 
have "wild-type" helicase activity. Mutational analysis has shown that motif VI is 
involved in an ATP hydrolysis-dependent RNA interaction during unwinding (Pause 
et al, 1993). The most highly conserved motifs and their functions as defined in 
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Figure 1.4 The major sequence motifs of the DEAD/H box family of putative 
ATP-dependent RNA helicases (after Schmid and Linder, 1992) 
Conserved regions are boxed, the functions of these regions have been deduced by 
mutational analysis of eIF-4A (Pause and Sonenberg, 1992). 
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eIF-4A are shown in figure 1.4. 
1.4.1 PRP5 and PRP28 
PRP5 and PRP28 are members of the DEAD-box family of putative RNA 
helicases. The initial binding of the snRNPs to the pre-mRNA involves 
conformational changes in several splicing components. Binding of the U2 snRNP 
to the pre-mRNA is an ATP-requiring step and PRP5 is required for U2 binding 
(Ruby and Abelson, 1991). Yeast spliceosomes cannot form when PRP5 is absent. 
After the U4/U6/U5 tri-snRNP joins the spliceosome, but prior to the first step of 
splicing, the U4/U6 association is destabilised. This is a major conformational 
change because the U4 and U6 RNAs are joined by 22 complementary base pairs. 
Thus, this step would require helicase activity. PRP28 is a candidate helicase 
protein because it is known to interact genetically with PRP24, a U6 snRNP protein 
(Strauss and Guthrie, 1991). 
1.4.2 PRP2, PRP16 and PRP22 
PRP2, PRP16 and PRP22 are members of the DEAR sub-family of putative 
RNA helicases. The amino acid sequences of the three proteins are similar over 
approximately 450 residues and the proteins are required for the three ATP-
dependant stages of splicing. PRP2 acts at step 1 (Lin et al, 1987), PRP16 at step 
2 (Schwer and Guthrie, 1991) and PRP22 is involved in the release of the spliced 
mRNA (Company et a!, 1991). The interaction of the PRP2 and PRP16 proteins 
with the splicing complexes is transient. Purification of both PRP2 protein (Kim et 
al, 1992; Plumpton et al, 1994) and PRP16 protein (Schwer and Guthrie, 1991) has 
allowed the biochemical activities to be investigated. 
1.4.2.1 PRP2 
The prp2-1 mutant was isolated in the original screen by Hartwell (1967). 
The PRP2 gene was cloned by complementation of the temperature-sensitive 
phenotype of aprp2-1 strain (Last et a!, 1984; Lee eta!, 1984; Soltyk eta!, 1984). 
PRP2 protein has a molecular weight of approximately lOOkDa (Lee et al, 1986) and 
the complete sequence of the gene is known (Chen and Lin, 1990). From the 
deduced protein sequence it was observed that PRP2 protein showed extensive 
homology to PRP16 and PRP22 proteins. PRP2 protein has sequence motifs 
characteristic of the DEAD/FT-box family of putative ATP-dependent RNA helicases, 
and also a putative zinc finger motif (Chen and Lin, 1990). 
Heat-inactivated prp2-1 extracts allow formation of the spliceosome but no 
splicing occurs. On addition of ATP and a complementary extract, splicing takes 
place as normal. Thus PRP2 is required for the first step of splicing but not for 
spliceosome assembly (Lin et a!, 1986). Using immunoprecipitation techniques, 
King and Beggs (1990) showed that PRP2 protein was associated only transiently 
with the spliceosome prior to and during step 1 of splicing, but that heat-inactivated 
prp2-1 protein did not seem to be associated with the spliceosome at all. PRP2 
protein has been purified (Kim et a!, 1992; Plumpton et a!, 1994). In assays, PRP2 
protein could hydrolyse all four nucleotide triphosphates in the presence of single 
stranded RNA (Kim et al, 1992). Kim et al (1992) investigated the effect of four 
different RNA homopolymers on the ATPase activity of PRP2. Poly(U) RNA was 
found to be the most effective. High concentrations of poly(A) RNA were also 
effective but poly(C) only weakly stimulated the ATPase activity and poly(G) was 
inactive at all concentrations tested. The ATPase activity was not stimulated by 
single-stranded DNA or double-stranded RNA. Kim et a!, (1992) showed that PRP2 
could hydrolyse dATP as efficiently as ATP. GTP, CTP and UTP were hydrolysed 
with 70-30% efficiency (as compared to ATP). These results all indicate that PRP2 
is a single-stranded RNA-dependent NTPase. As yet, no RNA unwinding activity 
has been demonstrated for PRP2 (Kim et a!, 1992; M. McGarvey, this lab), so 
despite lack of NTP specificity, it is possible that the RNA unwinding activity is 
very substrate-specific. 
Although PRP2 can enter the spliceosome in the absence of ATP, ATP 
hydrolysis is required for the first step of splicing (Kim and Lin, 1993; Teigelkamp 
et a!, 1994). PRP2 protein has been shown by UV-cross-linking to interact directly 
with the pre-mRNA in the spliceosome before step 1 of splicing and in the absence 
of ATP. The interaction requires a spliceable pre-mRNA and an assembled 
spliceosome (Teigelkamp et a!, 1994). ATP hydrolysis disrupts the PRP2-pre-
mRNA contact and releases PRP2 from the spliceosome. Teigelkamp et a! (1994) 
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proposed that the pre-mRNA is the native cofactor in the spliceosome which 
stimulates ATP hydrolysis by PRP2 protein, and that PRP2 may promote the 
conformation change from splicing complex I (the fully assembled, but inactive 
spliceosome) to complex II (the active spliceosome) (Pikielny et at, 1986) by an 
RNA displacement or conformational change. 
A single amino acid change within the conserved SAT motif of PRP2 
produced a dominant negative protein which, when overproduced, even in the 
presence of wild-type PRP2, inhibited splicing (Plumpton et al, 1994). The SAT 
motif is thought to be required for RNA helicase activity (Pause and Sonenberg, 
1992). In this mutant, termed PRP2', the conserved serine had been changed to 
leucine. PRP2" had approximately 40% of wild-type level of ATPase activity. 
This decrease in activity was not thought to be sufficient to inhibit splicing 
completely, so Plumpton et at (1994) proposed that the dominant negative phenotype 
was primarily caused by some other defect, perhaps in the putative RNA helicase 
activity of PRP2. PRP2' entered the spliceosome and bound the pre-mRNA in the 
absence and presence of ATP (Plumpton et al, 1994; Teigelkamp et al, 1994). Thus 
the mutation in the SAT motif did not affect the binding of PRP2 to the pre-mRNA 
but instead may have affected pre-mRNA release. It may be that pre-mRNA is only 
released after a destabilisation event carried out by PRP2 in the spliceosome. 
1.4.2.2 PRP16 
PRP16 was isolated as prpl6-1, a suppressor of a branchpoint mutation 
(C259) in an actin-HIS4 gene fusion (Couto et at, 1987). Suppression of the 
branchpoint mutation occurred by increasing the frequency with which the mutant 
branchpoint was used. Unexpectedly, haploid cells carrying only the suppressor 
allele at the PRP16 locus were viable, implying that pip16-1 retained the ability to 
recognise a wild-type branchpoint. This recognition is inefficient because in the 
absence of wild-type, pip16-1 caused an increase in the amount of unspliced pre-
mRNA (Couto et at, 1987). Burgess et at (1990) showed that the prp16-1 mutation 
results from a single tyrosine to aspartate substitution near the ATP-binding motif 
of PRP16 protein. They proposed that suppression resulted from a change in the 
rate of ATP hydrolysis or binding. The pip16-1 mutant may have a relaxed 
branchpoint fidelity owing to a change in the speed of proofreading, which might be 
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determined by the length of time between intron recognition and commitment to a 
splicing step. This may in turn be determined by the time or rate of ATP 
hydrolysis. Burgess and Guthrie (1993) isolated five more alleles of pipl6 which 
allowed splicing of the mutant branchpoint. All suppressing mutations mapped near 
to motifs common to the DEAD/H box family and all mutant proteins tested showed 
a decrease in rate of ATP hydrolysis. They proposed that ATP hydrolysis normally 
activates a discard pathway for aberrant lariat intermediates and that a slower rate 
of ATP hydrolysis results in the incorrect intermediates having more time to be 
channelled to the productive (rather than discard) pathway, resulting in a decreased 
fidelity of splicing. 
PRP16 protein has been purified and shown to exhibit RNA-dependent 
ATPase activity (Schwer and Guthrie, 1991). It can hydrolyse all four NTPs and 
appears to promote a conformational change in the spliceosome (Schwer and Guthrie, 
1992(b)). In PRP 16-depleted splicing extracts, the first step of splicing occurred and 
intermediates (exon 1 and lariat-intron-exon 2) accumulated, this was evidence that 
PRP16 is only required for step 2 of the splicing reaction. Addition of purified 
PRP16 and ATP to the PRP16-depleted extracts allowed the splicing reaction to 
proceed to completion (Schwer and Guthrie, 1991). Schwer and Guthrie (1991) also 
showed that PRP16 bound to the spliceosome in the absence of ATP, but had only 
a transient interaction on addition of ATP. Schwer and Guthrie (1992(a)) showed 
that prpl6-1 is a dominant negative protein when overproduced. Purified prpl6-1 
has a greatly decreased ATPase activity but can still bind to the spliceosome with 
wild-type affinity. 
The results from the analysis of prpl6-1 and wild-type PRP16 proteins 
suggest that PRP16 has two roles in the spliceosome, one before step 1 involved in 
branchpoint recognition, and the other at step 2, possibly a destabilisation event. 
1.4.2.3 PRP22 
Less is known about PRP22. The conserved protein sequence motifs suggest 
that it is an ATPase. In prp22 cell extracts although mRNA is produced, it is not 
released from post-splicing complexes (Company et al, 1991). 
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1.5 RNA:RNA interactions in nuclear pre-mRNA splicing 
The occurrence of several putative RNA helicases that are essential for 
splicing suggests that the splicing reaction may be controlled by conformational 
changes within RNA molecules. Using the powerful techniques of yeast genetics and 
biochemical crosslinking, many snRNA:snRNA and snRNA:pre-mRNA interactions 
have been identified. The proposal that the transesterification reactions may be RNA 
catalysed has led to efforts to characterise the RNA:RNA interactions within the 
snRNPs and spliceosome. Several models have been proposed in which the RNA 
interactions in nuclear pre-mRNA splicing have been compared to the complex 
secondary structures of the autocatalytic group I and II introns. Figure 1.5 shows 
a schematic representation of some of these interactions. 
The RNA: RNA interactions within the snRNPs and spliceosome fall into four 
categories: (i) intramolecular structures formed between different segments of single 
snRNAs, most of which are thought to remain unchanged throughout the splicing 
reaction and are therefore probably not involved in the reaction itself (for reviews 
see: Guthrie and Patterson, 1988; Steitz et al, 1988, Baserga and Steitz, 1993). An 
internal stem-loop in U6, however, has to be destabilised before U2 binding (Fortner 
et a!, 1994), (ii) intermolecular interactions between two different snRNAs, (iii) 
intermolecular interactions between a snRNP and the pre-mRNA and (iv) interactions 
between specific nucleotides of the pre-mRNA. 
1.5.1 Intermolecular interactions between different snilNAs 
The best characterised intermolecular snRNA:snRNA interaction is the base-
pairing between U4 and U6 (Brow and Guthrie, 1988). The U4/U6 interaction 
domain is composed of two U6 regions which base-pair with two regions of U4. 
There is a large portion of U4 looped out between the base-paired stems, which 
forms a stem-loop structure (Brow and Guthrie, 1988). The base-pairing is thought 
to remain intact in U4/U6 and U4/U6/U5 snRNPs but to be disrupted before pre-
mRNA cleavage (Lamond et a!, 1988). It has been proposed that the U6 snRNA is 
part of the catalytic core of the spliceosome and that the U4/U6 base-pairing is to 
prevent U6 catalysis at inappropriate times (Guthrie and Patterson, 1988). Mutations 
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of U6 nucleotides within the U4/U6 interaction domain were shown to be lethal and 
the compensatory base changes in U4 which restored the base-pairing failed to 
suppress the lethal phenotype (Madhani et al, 1990). This suggested a function for 
U6 independent of its role in base-pairing to U4, but requiring the same region of 
the snRNA. So U4 may be acting as a negative regulator of U6 as proposed by 
Guthrie and Patterson (1988). 
There are also known to be two separate interactions between U2 and U6. 
One is a helix between the 3'end of U6 snRNA and the 5'end of U2 snRNA which 
is required in mammalian cells (Hausner et al, 1990; Datta and Weiner, 1991; Wu 
and Manley, 1991), but not in yeast (Bordonné and Guthrie, 1992; McPheeters and 
Abelson, 1992). This U2:U6 interaction is essential for spliceosome assembly in in 
vitro mammalian splicing systems (Wolff and Bindereiff, 1992). The second 
interaction was demonstrated by Madhani and Guthrie (1992). This base-pairing 
interaction is mutually exclusive with the U4/U6 interaction. The base-pairing to 
form two intermolecular helices connected by a two nucleotide bulge involves U6 
nucleotides previously involved in the U4/U6 interaction. The nucleotides in the two 
snRNAs which are required for these helices are adjacent to nucleotides involved in 
interactions with the pre-mRNA (at the 5' splice site for U6 and the branchpoint for 
U2). This positions the U2/U6 structure close to the important sites for the initial 
step of splicing. Parallels have been drawn between this structure and the 
conformation of group II introns at step 1 of splicing (Madhani and Guthrie, 1992) 
because the U2/U6 bulged helix is not only similar in structure to the domain V 
bulged helix of group II introns but because it also has some limited sequence 
identity. Domain V immediately precedes domain VI which is the branchpoint 
recognition helix, this domain could be represented by the U2 branchpoint interaction 
domain. McPheeters and Abelson (1992) however, drew parallels between the 
U2/U6 structure and the conformation of group I introns at step 2, when a similar 
bulged helix functions in binding the 3' splice site G of the intron. While the two 
models have not yet been tested, they are not mutually exclusive and the similarity 
observed may be due to evolutionary convergence rather than common ancestry. 
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Figure 1.5 The RNA:RNA interactions within the spliceosome 
A schematic representation of some of the proposed interactions between snRNAs 
and the pre-mRNA or other snRNAs. The snRNAs are marked. The U4/U6 
interaction is disrupted before the U2/U6 interaction is formed, the two interactions 















1.5.2 Intermolecular interactions between the pre-mRNA and a snRNA 
The initial proposal for snRNA involvement in splicing resulted after the 
discovery that there was complementarity between Ul snRNA and the 5' splice site 
(Learner et al, 1980; Rogers and Wall, 1980). The 5' end of the Ui snRNA base-
pairs with nucleotides at both the 5' and 3' splice sites. This has been seen in both 
yeast (Siliciano and Guthrie, 1988; Reich et al, 1992) and mammalian (Zhuang and 
Weiner, 1986) splicing systems. Although a U1-5' splice site interaction is essential 
for use of that site, it alone is insufficient to define the exact cleavage site (Séraphin 
et a!, 1988; Siliciano and Guthrie, 1988; Seraphin and Rosbash, 1990). The 
cleavage may be defined by interactions between the exon nucleotides and U5 
snRNA (Newman and Norman, 1991; 1992). 
U2 snRNA can base-pair with the branchpoint sequence to form a helix with 
the branchpoint A residue bulged out (Parker et al, 1987; Zhuang and Weiner, 
1989). 
Genetic analysis in yeast of the U5-pre-mRNA interactions have shown that 
U5 can interact with exon sequences at both the 5' and 3' splice sites (Newman and 
Norman, 1991; 1992). Some U5 snRNA mutations could activate cleavage at 
aberrant 5' splice sites if the normal 5'splice site had been mutated but not deleted 
(Newman and Norman, 1991). These results led to the proposal by Newman and 
Norman (1992) that, by forming base-paired interactions with nucleotides adjacent 
to both splice sites, the U5 snRNA functions to define the 5' cleavage site as well 
as to ensure the correct orientation of the two exons before ligation. Newman and 
Norman (1992) also speculated that U5 could be derived from the D3 stem loop of 
domain I of group II introns, as they have similar structure and function. 
U6 in yeast extracts has been UV-cross linked to intron sequences at the 5' 
splice site (Sawa and Abelson, 1992). This partially overlaps with the Ui binding 
site. Similar results were obtained in mammalian systems (Sawa and Shimura, 
1992). 
1.5.3 Pre-inRNA interactions 
The 5' splice site dinucleotide: GU is required for step 2 but not step 1 of 
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splicing, the products of step 1 accumulate when the 5' splice site is changed to GA, 
GG or AU (Aebi et al, 1987; Lamond et al, 1987). There is a small class of introns 
with AU at the 5' splice site, but all these introns end with AC (Jackson, 1991). 
Thus, the conserved Gs may interact in a way which could be mimicked by A-C 
interactions. Parker and Siliciano (1993) hypothesised that the 5' splice site GU and 
3' splice site AG could interact by non-Watson-Crick base pairing during the second 
step of splicing. Using a yeast actin gene and intron, they showed that if the 5' GU 
was mutated to AU or if the 3' AG was changed to AC, then splicing was blocked 
at step 2. The block could be overcome and splicing returned to 10% wild-type 
activity if both mutant sites were present together. Parker and Siliciano (1993) 
explained the low splicing activity by the observation that many of the mutant 
transcripts did not complete step 1 and that other guanosine base contacts than the 
5'-3' splice site may have been disrupted too. 
Such pre-mRNA-pre-mRNA interactions may be partly responsible for the 
proofreading activity exhibited by the spliceosome prior to step 2 of the splicing 
reaction. 
1.5.4 A role for RNA helicases in splicing 
The schematic diagram in figure 1.5 shows the dynamic nature of the 
spliceosome. That is, during spliceosome assembly and pre-mRNA splicing 
reactions the interactions between different RNAs change. The U2/U6 interaction, 
for example can only form if the U4/U6 interaction is destabilised and an 
intramolecular U6 loop has been melted (Fortner et al, 1994) Similarly, Ui, U5 and 
U6 have all been shown to interact at the 5' splice site so the Ui snRNA may have 
to be displaced before US and U6 can bind. 
This complex series of events would require stringent control. As the melting 
temperature of the U4/U6 helix is 53°C in vitro (Brow and Guthrie, 1988), it is 
unlikely that the destabilisation events are spontaneous. A trans-acting factor is 
probably required, likely candidates for such factors are the RNA helicases (section 
1.4). The ATP requirement for the splicing reaction could be to provide energy for 
the unwinding of the RNAs. As discussed in section 1.4, the putative RNA helicases 
PRP2 and PRP16 have RNA-dependent ATPase activity. 
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1.6 Genetic studies of yeast pre-mRNA splicing 
The powerful genetic approaches possible with yeast mean that once 
characterised, the prp splicing mutants can be used to identify other components 
which interact physically or functionally with each other. In this way, different 
components of the splicing reaction that have been independently isolated can be 
linked up and a detailed picture of the molecular interactions within the splicing 
reaction can be assembled. Various methods can be employed to do this, one of the 
most widely used is the isolation of trans-acting extragenic suppressors. Other 
methods include identification of synthetic lethal mutations or the generation of 
dominant negative mutants. 
Isolation of suppressors of mutations in intron sequences have provided 
insights into the mechanism of splice site selection, suppressors of mutations in genes 
encoding trans-acting factors have helped to elucidate the complex interactions 
involved in both spliceosome assembly and the splicing reaction itself. 
1.6.1 Suppressors of defects in trans-acting and cis-acting factors 
The search for extragenic suppressors has been useful not only for analysing 
interactions between known components, but also for identifying novel splicing 
factors. The conditional lethal splicing mutants are incubated under non-permissive 
conditions to select for pseudorevertants, that is, mutants which are able to grow 
under non-permissive conditions due to a change in a protein that interacts with the 
mutant protein rather than reversion to the normal wild-type protein. In order to 
isolate the suppressors, it is useful if they confer an additional phenotype on the cells 
(such as cold-sensitivity). Shannon and Guthrie (1991) used this approach to identify 
trans-acting factors required for the destabilisation/restabilisation of the U4/U6 
complex during the spliceosome cycle. They generated mutants in U4 which caused 
a conditional lethal phenotype (cold-sensitivity) in vivo and which destabilised the 
U4/U6 interaction in vitro. The most effective was a G14C change which disrupts 
base-pairing in one of the helical interaction domains. They then looked for 
extragenic suppressor mutation in genes other than the U6 snRNA gene that restored 
wild-type growth. One suppressor was identified that suppressed the cold-sensitive 
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phenotype of the G 14C mutation but caused a recessive temperature-sensitive growth 
defect. Using complementation analysis and a set of temperature sensitive splicing 
mutants, Shannon and Guthrie (1991) demonstrated that the suppressor was a mutant 
form of PRP24. They cloned and partially sequenced the PRP24 gene and found 
protein sequences indicative of RNA-binding proteins. Further analysis showed that 
PRP24 is associated normally with U6 snRNA, but in the G14C mutant, PRP24 was 
associated with both U6 and U4. Shannon and Guthrie (1991) proposed that PRP24 
has a role in the annealing of U4 and U6, perhaps by stabilising the unbound U6, 
and normally only binds transiently to the U4/U6 form. 
ssp8l is a cold-sensitive suppressor of the temperature-sensitive prp8-1 
mutation (Jamieson et al, 1991). It was isolated and sequenced by virtue of the cold-
sensitive phenotype. SSP8 1 has protein sequence motifs common to the DEAD-box 
family of putative ATP-dependent RNA helicases (section 1.5). Jamieson et al 
showed that SSP81 mapped to the DED1 gene which encodes a DEAD-box protein. 
The observation that increasing the cellular concentrations of PRP8 impaired the 
growth of spp8l cells led to the suggestion that PRP8 protein may sequester the 
essential DED1/SPP81 protein, thus limiting growth. Further genetic evidence 
suggested that PRP8 may also interact with another DEAD-box protein, PRP28. 
Strauss and Guthrie (1991) isolated a mutant allele of PRP8 (pip8-9) as a suppressor 
of the cold-sensitive pip28-1 mutation. They proposed that PRP28 may be involved 
in U4/U6 unwinding after the U4/U6 snRNP has become associated with U5, which 
contains PRP8 Lossky et al, 1987). PRP8 may act to stabilise the base paired form 
of U4/U6. 
An example of high copy number suppression is well demonstrated by the 
observation that multiple copies of the PRP3 gene can suppress the temperature-
sensitivity of several mutant prp4 alleles, but not the pp4:: TRP1 null allele which 
indicates that suppression is not by a bypass mechanism where PRP3 can functionally 
replace PRP4 (Last et al, 1987). Overexpression of PRP4 does not suppress prp3 
mutations but some cold sensitive suppressors of pip4 can suppress temperature 
sensitive pip3 mutants (Woolford, 1989). There is evidence from molecular studies 
that PRP3 and PRP4 are both associated with the U4/U6 snRNP (Banroques and 
Abelson, 1989; Peterson-Bjorn et al, 1989), so the two proteins may interact directly 
or indirectly at the molecular level. 
SPP2(SRN2) is a multiple copy suppressor of a prp2 temperature sensitive 
mutant (Last et al, 1987). SPP2 is unable to suppress the null allele of PRP2 so 
SPP2 does not act by bypassing PRP2 function. SPP2 is essential for splicing and 
spp2 temperature sensitive alleles are defective for splicing but can be suppressed by 
extra copies of PRP2. This reciprocal suppression provides strong evidence for a 
direct interaction between PRP2 and SPP2 (Kim and Woolford, pers. comm.). 
Suppression of intron mutations offers a convenient way to isolate proteins 
which may interact with the pre-mRNA or which are involved in ensuring that the 
cleavage-ligation reactions are carried out correctly. By looking for suppressors of 
a branch point mutation (C259), the PRP16 gene was identified (Couto et al, 1987, 
see also section 1.3.2.3). Newman and Norman (1991) used a similar approach to 
identify factors involved in 5' splice site recognition (section 1.5.2). By searching 
for suppressors of a 5' splice site mutation (G1-A) a dominant trans-acting 
suppressor was isolated which activated a cryptic splice site 12 nucleotides upstream. 
Cloning and sequencing identified this suppressor as a mutant form of U5 snRNA. 
Further analysis showed that a single U-'C base change in a conserved loop (loop 
I) was essential for the suppression. This provided evidence for the involvement of 
U5 loop I in defining the 5' splice site. 
1.6.2 Synthetic lethal mutations 
In a multicomponent system such as the spliceosome, it is likely that the 
activity of one component will be dependent on the integrity of another. Interacting 
factors can be identified by looking for combinations of mutations that are lethal 
together. Such synthetic lethality has been demonstrated for mutations in PRP3 and 
PRP4 (Woolford, 1989). Certain combinations of alleles of PRP24 and PRP28 are 
lethal (Strauss and Guthrie, 1991). PRP28 is a putative RNA helicase and PRP24 
is a U6-binding protein, so it has been proposed that both these proteins are involved 
in U4/U6 unwinding and reannealing. 
In an attempt to find factors that interact with the US snRNP, Frank et al 
(1992) looked for mutations in genes which synergised with partially functional 
alleles of U5 snRNA to produce a lethal phenotype. They isolated seven such 
mutant or synthetic lethal alleles (slul-slu7). Four of these: slul-1, slu2-1, slu4-1 
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and slu7-1 conferred splicing defects on their own. Since these mutants exhibited 
allele-specific synthetic lethality with particular US mutants, Frank et a! (1992) 
suggested that they associated either physically or functionally with US snRNA. 
Factors not interacting directly with U5 snRNA would not have shown such 
specificity. Two of the alleles, slu4-1 and slu7-1 were specifically defective in the 
second step of splicing and showed synergistic interactions with each other as well 
as with two other second step mutants pip16-2 and prpl8-l. Since a pip16-2 and 
pip18-1 combination was not lethal but prpl8-1 showed a synthetic lethality with U5 
snRNA mutations, Frank et al (1992) suggested that SLU4, SLU7, PRP18, PRP16 
and US interact functionally at step 2. Frank and Guthrie (1992) showed that SLU7 
mediated the efficiency but not specificity of 3' splice site choice in yeast and they 
proposed that SLU4, PRP18 and PRP16 perform a generic second step function. 
slul-1 and slu2-1 caused accumulation of unspliced pre-mRNA, so SLU1 and SLU2 
proteins may be essential for the first catalytic step of splicing. 
Synthetic lethal mutations offer an extremely powerful way to identify and 
elucidate interactions between different components of the splicing complex. 
1.6.3 Dominant negative mutations 
Another genetic approach for analysing complex systems is the generation of 
dominant negative mutations. Dominant negative alleles are those which, when 
overexpressed in vivo can compete with and inhibit the activity of the corresponding 
wild-type factor. Several models have been proposed to explain this phenotype 
(Herskowitz, 1987). Such proteins may be able to enter complexes in preference to 
the wild-type version but not carry out subsequent function, leading to frozen "dead-
end" complexes. This method of analysis is particularly useful for transient 
interactions. For example, the isolation of a dominant negative allele of PRP2 that 
blocked splicing by preventing the transition to the active spliceosome has allowed 
the normally transient interaction of PRP2 to be investigated biochemically 
(Plumpton et al, 1994; Teigelkamp et a!, 1994). The prp16-1 allele was dominant 
over wild-type when overexpressed (Schwer and Guthrie, 1992(a)). Although 
purified prpl6-1 protein bound to the spliceosome, it only weakly complemented the 
second step of splicing. Prpl6-1 had a greatly reduced RNA-stimulated ATPase 
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activity (10% wild-type) and remained bound to the intermediates of splicing even 
after the addition of ATP. ATPase activity is, therefore important for PRP16 
activity in splicing and Schwer and Guthrie (1992(a)) proposed that the ATP 
requirement is linked to the function and subsequent release of PRP16. 
Isolation of high copy number suppressors of dominant negative mutants 
should help to identify interacting factors. Although this method has not been 
applied to splicing as yet, suppressors of other dominant negative mutants for 
example dominant negative H-ras and RAS2 mutants (section 1.9) have been 
successfully isolated (Powers et al, 1989;1991; Schweighoffer et al, 1993). The 
suppressors have been shown to be nucleotide exchange factors with which RAS 
interacts and which are essential for wild-type RAS function. 
1.7 This thesis 
PRP2 has a transient interaction with the spliceosome which has hindered 
biochemical studies of its function. Using a random hydroxylamine mutagenesis 
approach, a single dominant negative mutant of PRP2 was isolated (Plumpton et a!, 
1994). The disadvantage of hydroxylamine mutagenesis is that only a limited 
number of amino acid changes will occur since hydroxylamine causes only transition 
mutations (that is: C-G to A-T). Additionally, random mutagenesis means that most 
of the mutations generated will be outside the interesting functional motifs and may 
have no noticeable effect on protein function. The one mutant isolated had a single 
amino acid change in the putative helicase motif. As yet, no assays are available to 
investigate the unwinding activity of PRP2, so this mutant is of limited use in 
defining the function of PRP2. 
Using site-directed mutagenesis, it is possible to make specific base changes 
at defined sites. This method offers a controlled approach to the analysis of the 
functional motifs of PRP2. There is evidence already that PRP2 is an ATPase, so 
mutation of the ATP-binding motif: GX4GKT (motif I) should produce mutant 
proteins defective in ATP binding and probably, ATPase activity. Analysis of such 
mutant proteins will provide information about the role of the ATP-binding and 
ATPase activities of PRP2 in splicing. The mutants made were produced by site- 
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directed mutagensis following similar mutagenesis done on the GTPase protein, H-
ras, which has the GX4GKS GTP-binding motif. 
The in vivo and in vitro characterisation of several mutants with different 
single amino acid changes within the conserved motif I is reported. 
In this thesis I present: 
Production of four dominant negative alleles of PRP2 by site-directed 
mutagenesis. All mutants cause inhibition of growth due to a splicing defect when 
they are overproduced in wild-type cells. 
Demonstration that the in vivo effect on splicing is also seen in vitro and that 
inhibition of splicing is caused by accumulation of inactive spliceosomes. 
Purification of two of the dominant negative proteins and the demonstration that 
they retain their inhibitory phenotype. 
Biochemical investigations of the two proteins showing that both have lost the 
ability to bind single-stranded RNA and that they have negligible RNA-stimulated 
ATPase activity. 
Preliminary results which suggest that overproduction of components of the 
RAS/adenylate cyclase pathway can suppress the dominant negative phenotype. 
The research presented in this thesis is based on work done on the mammalian H-ras 
protein and the yeast RAS2 protein. RAS is a GTPase involved in signal 
transduction and as such, is not known to be associated with pre-mRNA splicing. 
In order to interpret some of the results I obtained, it is necessary to understand a 
32 
little about GTPase proteins, so the final sections of this chapter are devoted to an 
overview of the current knowledge of GTPase proteins and, in particular, RAS. 
1.8 The GTPase protein superfamily 
The proteins in the GTPase superfamily share a common structural design and 
molecular mechanism. They are molecular switches which are turned on by binding 
GTP and turned off by hydrolysing GTP to GDP. GTPase proteins are remarkably 
versatile, different GTPase proteins sort and amplify transmembrane signals, direct 
the synthesis and translocation of proteins, control vesicular traffic in the cytoplasm 
and control differentiation and proliferation in animal cells. The three major classes 
of GTPase proteins are (i) the 21kDa products of the ras oncogenes and proto-
oncogenes (p2l'), (ii) proteins involved in ribosomal protein synthesis eg EF-Tu, 
the bacterial elongation factor and (iii) the a-subunits of the heterotrimeric signal 
transducing G-proteins. Crystal structures of the GTPases EF-Tu and p2lT  have 
been determined (Jurnak, 1985; la Cour et al, 1985; Pai et al, 1989; Pal et al, 
1990). In combination with biochemical and biophysical approaches, molecular 
genetics has been used to assign discrete functions of some GTPases to specific 
structural elements. 
1.8.1 The GTPase cycle 
There are three conformational states observed in the GTPase cycle (figure 
1.6). The inactive GDP-bound protein can release GDP to form the transient empty 
state. Under ambient cytoplasmic conditions, GTP is more likely to enter the empty 
guanine nucleotide binding site than GDP, converting the protein to the active (GTP-
bound) conformation. The active state reverts to the inactive state on hydrolysis of 
the bound GTP. 
In most GTPases the intrinsic GTP hydrolysis and GDP releasing activities 
are low. There are therefore, two classes of regulatory proteins associated with the 
GTPases: the guanine nucleotide release proteins (GNRPs) which catalyse release of 
bound GDP and promote binding of GTP, and the GTPase activating proteins 
(GAPs) which increase the rate of GTP hydrolysis. It is postulated that either a 
GNRP or a GAP could regulate the function of a GTPase by controlling the relative 
proportions of active and inactive protein present in a cell (for a review of the 
GTPase cycle see: Bourne et a!, 1990). 
Figure 1.6 The GTPase cycle 
The activation/inactivation cycle of GTPase proteins. The three states are shown. 
G represents the GTPase protein, GAP is the GTPase activating protein and GNRP 
is the guanine nucleotide release protein required for GDP/GTP exchange. 
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1.8.2 3-D structure and protein motifs 
Despite the fact that their primary sequences are only 30% identical, the 
crystal structures of p21Tu  (Pal et al, 1989; Pal et al, 1990) and EF-Tu (Jurnak, 
1985; La Cour et al, 1985) are remarkably similar. There is a hydrophobic core of 
six f-sheets connected by hydrophilic loops and a-helices. Five regions of the 
polypeptide chain, all associated with loops on one side of the protein are critical in 
GTP/GDP exchange, GTP-induced conformational change and GTP hydrolysis. The 
five regions have been designated G-1 to G-5 and their consensus sequences and 
functions are summarised in table 1.7. 
REGION CONSENSUS FUNCTION 
G-1 GX4GK(S/T) H-bonds to 0 and -y-phosphates of GTP/GDP. 
Mg 	binding to S/T. 
0-2 D-X-T Mg 	binding to T. 
G-3 DX2G Mg 	binding via D. 
G binds 'y-phosphate of GTP. 
G-4 04NKXD Stabilises GTP binding site via H-bonds to G- 
1. 
G-5 No consensus. GTPase Contacts GTP. 
subgroups may share a 
common sequence 
Table 1.7 
The consensus and structure of the G-1 to 0-5 regions of GTPase proteins. 
X=any residue, O=hydrophobic residue (Bourne et a!, 1991, and references 
therein). 
1.8.3 GTP binding 
The guanine nucleotide binding site is composed of the G-1 to 0-5 regions. 
Conserved residues from these regions are involved in extensive hydrogen bonding 
interactions both with other residues and with the guanine nucleotide rings. The 
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hydrogen bond interactions can be between side chains as well as main chain amide 
groups. The phosphate binding loop (G-1) is wrapped around the 9-phosphate group 
of the GTP with the four main chain nitrogens pointing towards the phosphate. 
Studies of elongation factors, G-proteins and p21 have shown that Mg" is essential 
for proper binding of the ligands, for GTPase activity and for the structural integrity 
of the proteins. The Mg" ion coordinates with the bound /3- and -y-phosphate 
groups of bound GTP as well as with three amino acids which are absolutely 
conserved in all small guanine nucleotide-binding proteins (Pai et al, 1989). 
1.8.4 Signal transduction 
The G-protein sub-family act as transducers in transmembrane signalling systems. 
The G-proteins functionally couple receptor stimulation to the regulation of 
amplifiers which may then activate second messenger systems (Gilman, 1987). The 
binding of extracellular signals to the receptor protein cause a conformational change 
in the receptor which allows it to activate the 0-protein. The activated G-protein 
binds GTP leading to a change in G-protein conformation so that it can, in turn 
activate the amplifier protein. Hydrolysis of GTP terminates this activation (signal 
transduction and 0-proteins are reviewed in Matsumoto et a!, 1989; Oilman, 1987). 
1.9 RAS proteins 
1.9.1 The RAS proteins 
The name ras is derived from rat sarcoma virus. Ras genes were first 
identified as the transforming principle of the Harvey and Kirsten strains of the rat 
sarcoma viruses which are acute transforming viruses (Harvey, 1964; Kirsten and 
Mayer, 1967). Transforming alleles of ras genes were first identified in human 
tumours in 1982 (reviewed in Barbacid, 1987). Despite the interest in understanding 
their transforming properties in order to gain insights into pathological mechanisms 
of growth control, it is important to realise that ras genes play an important role in 
normal cellular control too. The ras genes code for GTP-binding proteins (Scolnick 
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et al, 1979; Shih et al, 1980; Tamanoi et a!, 1984; Temeles et al, 1985) which have 
intrinsic GTPase activity (Temeles et al, 1985) and are associated with the plasma 
membrane (Willingham et a!, 1980; Willumsen et al, 1984; Fujiama and Tamanoi, 
1986). The ras proteins have significant sequence homologies with G-proteins 
suggesting that they participate in signal transduction across the cell membrane 
(Gilman, 1987). The ra.c genes are highly conserved in evolution (Ellis et al, 1981; 
Shilo and Weinberg, 198 1) and the S. cerevisiae RAS genes have a strong homology 
to mammalian ras genes (DeFeo-Jones et a!, 1983; Powers et al, 1984). In fact, 
yeast RAS proteins can transform mammalian cells (DeFeo-Jones et al, 1985) and 
mammalian ras proteins can support the growth of mutant yeast cells (DeFeo-Jones 
et al 1985; Kataoka et al, 1985). In yeast there are two genes, RAS1 and RAS2. 
The two genes encode proteins of 309 and 322 amino acids respectively (Powers et 
al 1984). The two proteins are nearly 90% homologous to each other over the first 
180 amino acids, but then diverge radically. In mammals there are at least three ras 
genes: H-ras, K-ras and N-ras which encode proteins of 188 or 189 amino acids 
(Capon et al, 1983; Shimizu et al, 1983(a), 1983(b); McGrath et al, 1983; 
Taparowsky et a!, 1983). In humans, once again, the proteins are similar over the 
first 170 amino acids before diverging radically. The region of the N-terminal 
domain which shows the greatest homology between yeast and mammalian ras also 
contains the amino acids which when mutated activate the transforming potential of 
mammalian ras proteins (positions: 12, 13, 59, 61 and 63) (Fasano et a!, 1984). The 
amino acids at the corresponding positions in yeast are the same (Powers et a!, 1984) 
and mutations at some of these positions (19, 66 and 68) cause low sporulation and 
growth arrest in yeast (Kataoka et a!, 1984) or aberrant RAS GTPase activity 
(Temeles et al, 1985). Neither RAS1 nor RAS2 is essential for vegetative growth in 
yeast, but a growth inhibition is observed if both RAS genes are deleted. Ras2 
mutants are viable but have a defect in gluconeogenic growth, accumulate excessive 
levels of storage carbohydrates and sporulate prematurely (Tatchell et a!, 1985; 
Fraenkel, 1985). Kataoka et al (1984) predicted that RAS proteins are probably 
required for the process by which diploids decide whether to arrest at G 1 , sporulate 
or progress through the next round of cell division. As sporulation in Bacillus 
subtilis can be induced by a drop in guanine nucleotide levels (Ochi et al, 1982), it 
seems reasonable to predict that the guanine nucleotide requirement may be 
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conserved between bacteria and yeast. 
It was observed that bcyl, a suppressor of adenylate cyclase deficient yeasts 
(Matsumoto et al, 1982) had an almost identical phenotype to RAS2r9  cells. 
Genetic studies showed that bcyl could suppress the lethal rasl, ras2 phenotype 
(Toda et al, 1985). Other observations that S. cerevisiae cells carrying the dominant 
RAS2" 9 mutant exhibit a four-fold increase in cAMP levels and that RAS1 ras2 and 
rasi ras2 bcyl strains have a four- to twenty-fold decrease in cAMP levels led to the 
proposal that S. cerevisiae RAS genes may code for regulatory proteins that control 
adenylate cyclase (Broek et al, 1985). The RAS 9 mutant has been shown to be 
constitutively activated and provides further evidence that RAS is a GTPase protein 
with the same activation/inactivation cycle depending on GTPase activity and 
GDP/GTP exchange (section 1.8.1; Broek et al,1985). RAS genes and adenylate 
cyclase are not functionally related in other eukaryotic systems. When mammalian 
epithelial and fibroblastic cell lines were transformed with retroviral ra.s oncogenes, 
a reduced adenylate cyclase activity was observed. Additionally, purified p21 did 
not activate adenylate cyclase in mammalian cell membranes (Beckner et al, 1985). 
Interestingly, the Schizosaccharomyces pombe ras gene product SPRAS is not 
involved with either growth rates or response to nutritional stress conditions, but 
instead, spras mutants lose their ability to mate (Fukui et al, 1986; Nadin-Davis et 
al, 1986). These mutants appear to repress rather than stimulate sporulation and 
they do not affect the intracellular levels of cAMP. 
The lack of ras and adenylate cyclase association in other eukaryotic 
organisms suggests that ras proteins may function in a variety of signal transduction 
pathways and that selection of one pathway over another may have occurred during 
evolution depending on the particular physiological requirements of each organism. 
For example, S. cerevisiae depends on intracellular levels of cAMP to progress from 
G1 to S and to switch from G to sporulation (Matsumoto et al, 1983), but there is 
no evidence for cAMP involvement in the S. pombe cycle. 
1.9.2 The RAS-adenylate cyclase pathway in yeast 
The products of the two RAS genes; RASJ and RAS2 have been shown to be 
positive regulators of adenylate cyclase (Broek et al, 1985). Experimental evidence 
suggests that the adenylate cyclase pathway is responsible for the switch between the 
resting state and progress through the cell division cycle in response to nitrogen 
availability (Boy-Marcotte et a!, 1987). The adenylate cyclase pathway is also 
activated in response to extracellular glucose or intracellular acidification and it is 
these two signals which appear to activate the RAS-cAMP system (Thevelein, 1992). 
The production of cAMP also requires the CDC25 protein (Broek et al, 1987; 
Robinson et a!, 1987). By analysing the l4S2°"89 mutant, Robinson et a! (1987) 
showed that CDC25 acts upstream of RAS. RAS' 8"' 19 is constitutively activated 
and eliminates the need for CDC25. Work on dominant negative yeast RAS mutants 
which had an increased affinity for GDP, so that they were unable to be activated 
by GTP, shed more light on the role of CDC25 (Powers et al, 1989). Powers et al 
(1989) showed that, in the presence of wild-type RAS, the dominant negative 
phenotype could be alleviated by overproduction of CDC25. They proposed that 
CDC25 was the GNRP for RAS. Their model predicts that CDC25 is involved in 
stabilising the nucleotide-free state of RAS. The dominant negative proteins with 
their increased affinity for GDP were binding to CDC25 but not releasing it, because 
they were unable to exchange GDP for GTP. The cellular CDC25 was thus 
sequestered by the dominant negatives and unavailable for use by the wild-type 
protein which then could not be activated. Overproduction of CDC25 produced 
enough protein to saturate the dominant negative and to activate wild-type RAS too. 
Van Aelst et a! (1990) showed that it is the C-terminal part of CDC25 which is 
required for RAS activation, and Gross et a! (1992(a)) have demonstrated that 
phosphorylation of CDC25 in response to glucose results in its dissociation from 
RAS. Thus CDC25 is thought to be part of the glucose sensor unit for the cAMP 
activation pathway. Figure 1.8 shows a schematic diagram of the activation cascade 
in the cAMP activation pathway. 
H-ras dominant negative mutants which were known to have increased affinity 
for GDP (Feig and Cooper, 1988; Farnsworth and Feig, 1991) could be suppressed 
by the C-terminal domain of the S. cerevisiae protein, SDC25 (Schweighoffer et a!, 
1993). The C-terminal domain of SDC25 has homology to CDC25 and has been 
shown to activate RAS1 and RAS2 (Crechet et a!, 1990; Damark et a!, 1991). 
These results suggest that mammalian exchange factors of the CDC25 class may be 
upstream regulators of H-ras. 
Figure 1.8 The RAS/adenylate cyclase pathway in yeast 
A schematic representation showing the roles of the major components of the 
adenylate cyclase pathway. 
IRA1 is the GAP for RAS, CDC25 is the GNRP for RAS. The two mutant forms 
of RAS which donot require CDC25 activation are also shown (RAS' 52 and 

















cellular growth control 
1.9.3 Mammalian ras 
Experiments such as the microinjection of a neutralising anti-ras antibody into 
cells have shown that mammalian ras is involved in transmitting growth and 
differentiation signals from receptor tyrosine kinases (Mulcahy et al, 1985; Smith 
et al 1986). Growth factors can promote the conversion from ras-GDP to ras-GTP 
by altering the balance between the respective GNRP and GAP activities (Satoh et 
a!, 1990; Gibbs et al, 1993). The amino acid substitutions in ras which have been 
identified in human cancers block the GAP-stimulated GTPase activity leading to the 
dominant oncogenic behaviour of the permanently activated ras oncoproteins (for 
a review of regulation of ras GTP-binding activity see: Rey and Hall, 1993). The 
dominant negative mutant H-ras 07 (Feig and Cooper, 1987) has been shown to 
prevent the activation of the cytosolic serine-threonine kin ases Raf- 1 and MAP 
kinase (mitogen activated protein kinase), (Robbins et al, 1992; deVries Smits et al, 
1992; Wood et al, 1992; Thomas et al, 1992). The expression of activated H-ras 
in vivo or in vitro can activate these protein kinases (Pelech and Sanghera, 1992) 
The cytosolic enzymes may function as part of a kinase cascade in which the MAP 
kinases are activated by a MAP kinase kinase (MAPKK) which is in turn 
phosphorylated and activated by the Raf-1 protein kinase. Moodie et al (1993) 
showed that only activated H-ras was associated with MAPKK and Raf-1 and that 
MAP kinase activity was only associated with activated H-ras. This result suggests 
that H-ras, in its activated form is responsible for activating Raf- 1 in response to 
extracellular signals. Membrane-bound ras is activated by ligands that bind to cell 
surface receptors via a ubiquitous pathway consisting of the GNIRPs SOS  or SOS2 
(Bowtell, 1992; Chardin et al, 1993) and the adaptor molecule Sem5 (Clark et al, 
1992), or via localised pathways that use tissue-specific GNRPs such as pl40Ras-
GRF in brain (Shou et al, 1992) and Vav in haematopoietic cells (Gulbins et al, 
1993). The GNRP pl40Ras-GRF has sequence homologies to CDC25, it promotes 
nucleotide exchange on ras but not on other members of the ras superfamily such as 
Rho or Ral (Shou et a!, 1992). In contrast, Vav has sequence homologies to Dbl, 
a GNIRP for CDC42 which is a member of the Rho family of GTP-binding proteins 
(Ron et a!, 1988). The ras activation pathway is very highly conserved, it is found 
in species as diverse as yeast, Drosophila and Caenorhabditis elegans. This suggests 
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that the ras pathway and kinase cascade are evolutionarily conserved because of the 
importance of cellular signalling for both growth and development (reviewed in: 
Marx, 1993). 
1.9.4 The phosphate binding loop of RAS 
The phosphate-binding loop is a motif commonly found in ATP and GTP-
binding proteins. The consensus sequence for the motif is quoted as: G(X 4)GKT/S 
and this consensus is a useful tool for screening protein databases for ATP and GTP-
binding proteins (Saraste et al, 1990). Mammalian and yeast RAS proteins have a 
phosphate binding motif at the N-terminal end of the sequence (Powers et al, 1984; 
Barbacid, 1987). The sequences are shown in figure 1.9. The crystal structure of 
the guanine nucleotide binding domain of H-ras has been determined (Pal et al, 
1989) and from this, it has been shown that Lys16 (K) may interact with the 'y -
phosphate of GTP as well as H-bonding with the main chain oxygens of residues 10 
and 11. Residues 13-16 and 17 and 18 form H-bonds with each other to form the 
loop structure. The amide nitrogen of residue 18 forms an H-bond with an oxygen 
from the a-phosphate group. Feuerstein et al (1987) showed that the metal ion in 
the p21 bound GDP-Mg complex has a monodentate coordination to the f3-
phosphate. In the GTP complex, Pai et al (1989) propose that the metal ion is 
bound as a bidentate 13--y-complex. Mutations of the Serl8 of H-ras which removed 
the -OH side chain led to the production of mutant H-ras proteins which bound GDP 
with a much higher affinity than usual (Feig and Cooper, 1988; Farnsworth and Feig 
1991) and it is proposed that this aberrant binding is due to improper complexing of 
the Mg ion. The same structural arrangement has been reported for the nucleotide 
binding loop of porcine adenylate kinase, an ATP binding protein (Reinstein et a!, 
1988 and references therein), so it is possible that this 3-13 structure is common to 
all phosphate binding loops in GTP and GDP binding proteins. 
1.9.5 RAS and PRP2 share the NTP binding consensus sequence 
PRP2 protein contains the phosphate binding loop consensus: GETGSGKT. 
By analogy with work on other ATPases such as eIF-4A, it is probably the ATP 
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consensus: GXXXXGK' 	residue 
numbers 
RAS1/2 GGGGVGKSA 17-25 
H-ras GAGGVGKSA 10-18 
PRP2 GETGSGKTT 245-254 
Figure 1.9 The NTP-binding motif 
The NTP-binding motif consensus is shown with the actual sequences found in 
RAS1/2 (yeast RAS), H-ras (mammalian RAS) and PRP2. The amino acids are 
represented by the single letter amino acid code, X corresponds to any residue. The 
residue numbers are shown where the first number refers to the initial G residue. 
binding domain (Rozen et a!, 1989). Because of the extensive research done to 
investigate its 3-D structure, function and activation cycle, RAS is a good protein to 
use as a model for the mode of action of other GTPases or ATPases. By following 
some work done with RAS to produce and characterise GTP binding mutants which 
were dominant negative and reproducing the same mutations in PRP2, I hoped that 
if the PRP2 mutants were also dominant negative, then some conclusions could be 
drawn about the biochemistry of PRP2 by analogy with RAS. 
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CHAPTER 2. 
Materials and Methods. 
2.1 MATERIALS. 
2.1.1 Suppliers of laboratory reagents. 
Standard laboratory reagents: Sigma, Fisons, BDH, Bio-Rad, Serva. 
Restriction endonucleases and other DNA modifying enzymes: Bethesda Research 
Laboratories, Boehringer Mannheim, New England Biolabs, Pharmacia. 
Radiochemicals: Amersham International, NEN DuPont. 
Deoxyribonucleotides and ribonucleotides: Pharmacia, Sigma. 
Acrylamide and N,N'-methylene bisacrylamide: BDH Chemicals ("Electran" grade), 
Scotlab ("Easigel" stock solution). 
Agarose: Appligene (molecular biology quality), Bethesda Research Laboratories 
(ultra-pure electrophoresis grade). 
Media reagents: Difco Laboratories, Sigma. 
2.1.2 Growth media. 
Unless otherwise stated quantities are for 1 litre volume. Solutions were 
autoclaved (section 2.2.2) and stored at room temperature. Antibiotics and amino 
acids were stored as filter sterilised, concentrated stocks and were added to growth 
media immediately prior to use. Bacto-agar was added to 2% (wlv) before 
autoclaving if plates were required. 
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2J21 E.coli media. 
Luria-Bertani medium (LB): lOg bacto-tryptone, 5g bacto-yeast extract, lOg NaCl, 
adjusted to pH7.2 with NaOH. 
LB-amp: LB containing 0. lg/i ampicillin. 
M9 medium: 6g Na2HPO4 , 3g KH2PO4 , 0.5g NaCl, ig N}L4C1, 0.25g MgSO4 .7H20, 
2g glucose. Amino acids and other nutritional requirements were added (20mg each), 
after autoclaving. 
2XYT: lOg bacto-peptone, lOg bacto-yeast extract, 5g NaCl. 
2.1.2.2 Yeast media. 
YPDA: lOg bacto-yeast extract, lOg bacto-peptone, 20g glucose, 20mg adenine 
sulphate. 
YMG1u: 6.7g yeast nitrogen base without amino acids, 20g glucose, supplemented 
with amino acids as required to 20mg/i. 
YMGalRaf: 6.7g yeast nitrogen base without amino acids, 20g galactose, 20g 
raffinose, supplemented with amino acids as required to 20mg/l. 
YMGluCas/YMGalRafCas: YMG1u or YMGalRaf plus lOg vitamin assay casamino 
acids. After autoclaving, tryptophan, adenine, and uracil, which are not supplied by 
the casamino acids, were added as required to 20mg/i. 
Pre-sporulation: 8g bacto-yeast extract, 3g bacto-tryptone, lOOg glucose. 
Sporulation: lOg potassium acetate, ig bacto-yeast extract, 0.5g glucose, 2mg each 
relevant amino acid. 
YMGlyLacCas: 6.7g yeast nitrogen base and lOg vitamin assay casamino acids were 
dissolved in 800ml H20 and autoclaved. When cool, lOOml sterile 20% lactic acid 
pH5.7 and lOOmi sterile 20% glycerol were added to make 11. For galactose 
induction 50ml sterile 40% galactose was added to a final concentration of 2% (w/v). 
5-FOA: 6.7g yeast nitrogen base without amino acids, 20g glucose, 2g vitamin 
assay casamino acids and 50mg uracil were dissolved in 500 ml H 20, lOg bacto agar 
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was added and the mixture autoclaved and cooled to below 85°C. ig 5-fluoroorotic 
acid was dissolved in 500ml H 20 and filter sterilised. The two solutions were mixed 
together. 
2.1.3 Bacterial strains. 
Table 2.1 E.coli strains 
Strain Genotype Description Reference/Origin 
NM522 tX('lac-proAB), General purpose Gough and 
t('hsdMS-mcrB)5, cloning, sequencing Murray, 1983 
supE, thi-1, etc. 
F' [lacP, lacZzXM15, 
proAB]. 
BW313 HfrKL16 P0/45 For site-directed Amersham 
lysA (61-62), duti, mutagenesis International 
ungi, thi-1, recA, 
SpoTi. 
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2.1.4 Yeast strains. 
Table 2.2 Yeast strains. 
Strain Genotype Reference/Origin 
S150-2B a, ura3-52, leu2-3,412, trpl -289. Wellcome 
DJy85 a/a, prp2-1, ura3, adel/ADE1, ade2, D.Jamieson, 
trpl/TRPJ, his3/H153, tyr11TYR1, (this lab.) 
lys2-801/LYS2, cani/CANJ. 
DJy36 a, ura3-2152, ade2, prp2-1. D.Jamieson, 
(this lab.) 
EFy2 a/a, PRP21PRP2.: URA3, adel/ADE1, E.Flinn, this 
trpl/trpl, lys2-801/L YS2, leu2-31LEU2, thesis. 
ura3-521ura3-52, his3-D2001his3z1. 
2.1.5 Plasmid vectors and constructs. 
Table 2.3 Plasmid vectors and constructs. 
Plasmid Description Reference/Origin 
pTZ19R Phagemid vector with multiple cloning Pharmacia 
site in lacZ a-peptide fragment. Fl 
origin allows synthesis of single-stranded 
DNA; amp'. 
pRS314 Yeast/E. coli shuttle vector, based on Sikorski and 
pBLUESCRIPT with yeast CEN6 and Hieter, (1989). 
ARSH4 sequences; 7RP1. 
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pBM125 Yeast/E.coli shuttle plasmid, (low copy Johnston and 
number) containing a 0.8 1kb EcoRI- Davis, (1984). 
BamHI fragment containing the GALl 
UAS and promoter region. ARS, CEN, 
URA3. 
pBM-PRP2 The vector pBM125 containing the 2.9kb King and Beggs, 
PRP2 gene (derived from pY2016) fused (1990). 
to the GALl inducible promoter. 
pBM-PRP2' pBM-PRP2 with a polyhistidine tag M. Plumpton 
upstream of and in frame with PRP2. (this lab.) 
Expression from GALl leads to 
production of histidine tagged PRP2 
pBMP2H-X Deletion construct based on pBMPRP2. S.Anderson (this 
The HindIII-XbaI restriction fragment lab.) 
has been removed from the PRP2 gene 
and replaced with a linker containing a 
unique Sacl restriction site. An 
additional construct was made which 
contained the polyhistidine tag in frame 
with the deleted PRP2 gene (see above). 
pT7rp28s Containing most of the yeast RP28 gene. M.Lossky, (this 
Used as template for in vitro lab. 
transcription of most of El, IVS and E2 
after linearisation with EcoRII. 
2.1.6 Antisera and antibodies. 
Table 2.4 Antisera and antibodies. 
Antiserum or Antigen Raised Against Origin 
Antibody 
Anti-55 Fusion 2.3 protein D.King, (this lab.) 
(see figure 2.1 below) 
Anti-140 Fusion 2.5 protein D.King, (this lab.) 
(see figure 2.1 below.) 
Anti-54 Fusion 2.3 protein D.King, (this lab.) 
EcoRl 	Hindlll 	Xba I 	PvuIl 	BamHI Restriction map of I I 	I the PRP2gene 
2.3 	 Regions present in 
3 -galactosidase-PRP2 fusion 
All Hill 	2.5 	 proteins against which 
antibodies were raised. 
PvLAI 
Figure 2.1 
Anti-PRP2 antibodies used in this study 
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2.1.7 Oligonucleotides used for sequencing 
All oligonucleotides were synthesised by the Oswel DNA Service (Edinburgh 
University). 
Table 2.5 Sequencing oligonucleotides 
Name Sequence 
006P 5 CCCACTTCCTTCCCAAG 3 ' 
685P 5 GCGTTCAfl'G'VFGCTG 3 ' 
036A 5 'CCCAGTCACGACGTF3 
2.1.8 Size markers. 
Size markers for nucleic acid and protein electrophoresis were as follows: 1kb 
ladder markers (BRL; cat. number 56155A) were used for agarose gel electrophoresis 
of DNA and RNA; Sigma pre-stained protein markers (cat.number SDS-7B) or high 
molecular weight markers (SDS-6H) were used for SDS-PAGE electrophoresis of 
proteins. 
2.1.9 Buffers. 
1M NaPO4: 1M NaH2PO4 and 1M Na2HPO4 at 3:2 (v/v) to pH7 
lox TAE: 0.4M Tris-acetate pH7.5, 20mM EDTA. 
lox TBE: 0.9M Tris-borate pH8.3, 20mM EDTA. 
lox TB: 0.9M Tris-borate pH8.3. 
lox TBS: 0.5M Tris-HC1, 1.5M NaCl pH7.5. 
20 	SSC: 3M NaCl, 0.3M tn-sodium citrate pH7.0. 
lox PBS: 15mM NaH2PO4 , 80mM Na2HPO4 , 1.5M NaCl pH7.2 
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2.2 GENERAL METHODS. 
2.2.1 General guidelines. 
Unless otherwise stated all procedures were carried out at room temperature. 
For small-scale procedures sterile 1 .5m1 polypropylene microfuge tubes (Treft) were 
used, larger scale procedures being carried out in either 15m1 or 30m1 sterile Corex 
tubes, lOmi Steriuin tubes, or 50m1 Greiner tubes. For harvesting 3-41 cell cultures, 
Nalgene 500m1 plastic pots were used. 
Centrifugation of volumes greater than 50m1 was carried out in a Sorvall 
Super Speed centrifuge using either a GS-A or GS-3 rotor at up to 5,000 rpm, and 
volumes between 1.5 and 50ml were centrifuged in an SS34 rotor at speeds between 
10,000 and 18,000 rpm as indicated, or in a JEC CENTRA-4X bench-top centrifuge 
at 4,500 rpm in a 215A swing-out rotor. High speed centrifugation of volumes 
greater than 1 .5m1 was performed in a Sorvall OTD ultracentrifuge (DuPont) with 
the appropriate Sorvall rotor and speed as indicated. 
Volumes less than or equal to 1 .5m1 were centrifuged in an Eppendorf benchtop 
microcentrifuge at 14,000 rpm. 
2.2.2 Sterilization procedures. 
When necessary, plastics (such as microfuge tubes) and solutions were 
sterilized by autoclaving for 20 minutes at 120°C and 15 psi. Solutions prepared in 
small volumes and those which could not be sterilized in this manner, for example 
DTT, tryptophan, SDS and antibiotics, were sterilized by filtration through a 
disposable Acrodisc filter unit (0.45 micron size; Gelman Sciences). 
In order to inactivate ribonucleases, Corex tubes, glass pipettes and other 
glassware used for work with RNA were dry-sterilised by baking at 250°C for 16hr. 
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2.2.3 Deionisation of solutions. 
Formamide and acrylamide solutions were deionised by mixing with 0.1-0.2 
volumes of analytical grade mixed-bed resin (20-50 mesh; Bio-Rad Laboratories) for 
30 minutes. The resin was removed by filtration through Whatman No.1 filter 
paper. Acrylamide and formamide were stored at 4°C. 
2.2.4 Photography. 
Photographs of agarose gels containing nucleic acids stained with ljig/ml 
ethidium bromide were taken using Polaroid 667 Professional film during 
visualisation of the nucleic acid by short-wave length ultraviolet light (254nm) from 
a transilluminator. 
2.2.5 Autoradiography. 
[32P]-labelled nucleic acids were detected by exposing pre-flashed X-ray film 
(Du Pont Cronex) to gels and filters in a light-proof cassette with a calcium-tungstate 
intensifying screen at -70°C. 
[35S]-labelled DNA was detected by exposure of X-ray film (Du Pont Cronex) 
to gels at room temperature. 
2.2.6 Cerenkov counting. 
Cerenkov counting of [32P] was performed in a Beckman LS 1701 scintillation 
counter set at program 8. 
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2.3 MICROBIOLOGICAL METHODS. 
2.3.1 Propagation and storage of bacteria. 
Growth and storage of E. coil were carried out as in Sambrook et al (1989). 
2.3.2 Preparation of competent E.coli, and transformation. 
Based on the method of Hanahan, (1983). 
500m1 of LB was inoculated with imi of a stationary phase culture of 
NM522 and grown to OD6 0.3-0.4. 
The culture was chilled on ice. Cells were harvested at 4°C, resuspended 
in lOOmi ice-cold 75mM CaC1 2 and incubated on ice for 30mm. 
Cells were spun down again at 4°C, resuspended in 20m1 TFBII, and 
incubated on ice for 30mm. 
Cells were either used immediately (see below) or snap frozen in liquid 
nitrogen and stored at -70°C. 
For transformation, cells were aliquoted into 50pJ volumes, DNA added 
(about 50-100ng plasmid, or a portion of a ligation mixture) and incubated on ice for 
10mm. 
Cells were heat shocked at 42°C for 90 seconds and placed on ice for 2 
mm. 
200d of LB was added, and the cells incubated at 37°C for lhr to allow 
expression of the antibiotic resistance gene. 
The cells were plated onto LB-amp plates and incubated at 37°C overnight. 
Buffers: 
TFBII - 10mM MOPS (pH6.8, adjusted with KOH), 10mM RbC1, 75mM CaC1 2 , 
15% (v/v) glycerol. Sterilised by autoclaving. 
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2.3.3 Propagation and storage of yeast. 
Yeast cells were grown and stored as described in Rose et a! (1990). 
2.3.4 Sporulation and spore recovery. 
Diploid strains to be sporulated were grown overnight in presporulation 
medium. lOmi of sporulation medium was inoculated with imi of the overnight 
culture and incubated for 3 days at 25°C or 30°C to allow sporulation to take place. 
Asci were resuspended in 10041 spore buffer (1.2M sorbitol, 10mM EDTA, 
100mM citric acid) and 20d 0-glucuronidase (Boehringer Mannheim) was added to 
digest the ascus walls. After incubation for 20 minutes at room temperature, 
dissection of asci was carried out using a Singer MSM micromanipulator (Singer 
Instrument Co.), the four haploid spores being placed separately in a row on a 
YPDA plate. The plate was incubated at the appropriate temperature to allow the 
growth of spores into discrete colonies (approximately 5 days). 
2.3.5 Transformation of yeast. 
Yeast transformation was carried out either by the method of Ito et al (1983; 
below), or by electroporation using a geneZAPPER (IBI) according to the 
manufacturer's instructions. 
A lOOmi yeast culture was grown in the appropriate medium to OD 6 0.4-
0.6. (mid-log phase). 
Cells were harvested, washed with 20m1 sterile TE and resuspended finally 
in 5m1 TB. 208jz1 2.5M lithium acetate was added and the cells incubated with 
gentle mixing at room temperature for Mr. 
1-10g DNA in a volume of 100d sterile dH20 was added to 200d cells 
which were incubated at room temperature for 30mm. 
0.7ml freshly prepared filter sterilised 50% (wlv) PEG-4000 was added, 
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mixed and incubation continued for lhr at room temperature. 
5) Cells were heat-shocked at 42°C for 5mm, washed in imI sterile dH 20 and 
plated onto medium, selecting for cells containing the plasmid. 
2.4 NUCLEIC AC!]) METHODS. 
2.4.1 General. 
Many standard DNA and RNA manipulations were carried out either 
according to Sambrook et al (1989) or according to enzyme and equipment 
manufacturers' instructions. These included: quantitation of nucleic acids by 
spectrophotometry, deproteinisation of nucleic acid solutions with phenol/chloroform 
(phenol was glass-distilled grade, water-saturated; Rathburn Chemicals), precipitation 
of nucleic acids with ethanol, restriction endonuclease digestion of DNA, agarose gel 
electrophoresis of DNA, isolation of DNA fragments from agarose gels (using the 
Qiaex kit, Diagen Inc.) and dephosphorylation of DNA, ligation of DNA fragments. 
All DNA and RNA solutions were stored in sterile distilled water (dH 20) unless 
otherwise stated (DNA at 4°C, RNA at -20°C). 
2.4.2 Plasmid DNA preparations. 
2.4.2.1 Small scale. 
Based on the method of Birnboim and Doly, (1979). 
5m1 LB-amp was inoculated with a single bacterial colony and incubated 
at 37°C with shaking overnight. 
1.5m1 of the culture was harvested in an Eppendorf tube by spinning in a 
benchtop microfuge for 1mm. 
The LB-amp was discarded, cells resuspended in 100zl solution A and 
incubated at room temperature for 3-5mm. 
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2001L1 solution B was added and the iysed cells mixed by gentle inversion. 
150il solution C was added, the tube was vortexed briefly and placed on 
ice 3-5mm. 
Cell debris was removed by spinning for 5min in a benchtop microfuge 
and the supernate transferred to a fresh tube. 
The supemate was extracted once with phenol/chloroform. 
DNA was precipitated by adding 80041 cold absolute ethanol (-2(rC), 
mixing by inversion, and sedimented by spinning at 4°C in a benchtop microfuge for 
1 5mm. 
The pellet was washed once with 70% (v/v) ethanol, dried in a vacuum 
desiccator and dissolved in 301l sterile dH 20. 
Buffers: 
50mM glucose, 25mM Tris-HC1 (pH8.0), 10mM EDTA. 
0.2M NaOH, 1 % (w/v) SDS (freshly prepared). 
3M sodium acetate pH5.3. 
2.4.2.2 Medium scale. 
40m1 LB-amp was inoculated with a single bacterial colony and incubated 
overnight at 37°C. 
The cells were pelleted by spinning in 50m1 tubes in a benchtop centrifuge 
for 10mm. 
The cells were resuspended in 2m1 ice cold TEG, then 4m1 solution B and 
3ml solution C were added. 
Cell debris was removed by spinning in 15m1 Corex tubes at 4°C for 
10min at 10 krpm in a pre-cooled Sorvall centrifuge. 
The supernate was transferred to a 30m1 Corex tube and 16m1 cold ethanol 
added to precipitate nucleic acids. 
The nucleic acids were sedimented by spinning at 4°C in a Sorvall 
centrifuge at 10 krpm for 10mm. The pellet was resuspended in 2m1 solution D. 
After one phenol/chloroform extraction, 4m1 cold ethanol was added to the 
aqueous phase and DNA was precipitated by incubating at -20°C for 20mm. 
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The DNA was pelleted at 10 krpm and the pellet resuspended in 4001d TE. 
RNaseA was added to a concentration of 0.2jg/zl and incubated at 37°C 
for Mr. 
RNase treated DNA was extracted with phenol/chloroform until the 
interface was clear, and finally once with chloroform to remove any remaining 
phenol. 
The DNA was precipitated with 2 volumes ethanol and 0.1 volumes 4M 
NaCl, the pellet washed with 70% (v/v) ethanol, dried in a vacuum desiccator and 
dissolved in 200d sterile dH 20. 
This method routinely yielded 100-200kg of plasmid DNA. 
Buffers: 
Solutions B and C as above. 
TEG: solution A (as above) with 4mg/ml lysozyme (Sigma) added just before use. 
Solution D: 0. 1M NaOAc pH5.2, 1mM EDTA, 0.1% SDS, 40mM Tris-HC1 pH8.0. 
2.4.3 Sequencing. 
All sequencing reactions were carried out using the Sequenase version 2.0 kit 
(USB) according to the manufacturers instructions. Templates for the reactions were 
single-stranded preparations of the phagemid, pTZ19R (Pharmacia). Products of 
sequencing reactions were run on 6% (w/v) denaturing polyacrylamide gels in lx 
TB buffer, fixed in 10% (v/v) methanol 10% (v/v) acetic acid for 20min at room 
temperature and dried on a vacuum gel drier (Bio-Rad). 
2.4.3.1 Preparation of single-stranded pTZ templates. 
A 5m1 culture of NM522 transformed with the recombinant pTZ was 
grown overnight in M9 medium with thiamine and ampicillin. 
1.5m1 2XYT was inoculated with 30d of the overnight culture and grown 
at 37°C for 30mm. with vigorous shaking. 
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4.5d M13 K07 helper phage was added and the culture grown for a 
further 5-6hr at 37°C with vigorous shaking. 
The cells were pelleted in a microfuge tube and the supernate transferred 
to a fresh tube. This step was repeated until no pellet was observed. 
1501.il PEG/NaCl was added and incubated at room temperature for 20mm. 
Phage were pelleted by spinning for 10mm, and any tubes with no visible 
pellet discarded. 
The supernate was removed, the tubes spun for a further 2min and any 
residual supemate removed. 
The pellet was resuspended in lOOizl T 10E01 and extracted once with 
phenol/chloroform. 
DNA was precipitated with 2 volumes ethanol and 0.1 volume 3M NaOAc 
pH5.3, the pellet washed in 70% (v/v) ethanol and vacuum dried. 
The pellet was dissolved in 25il T 10E01 and 741 used in the annealing step 
of the Sequenase reaction. 
Buffers: PEG/NaCl: 20% (w/v) PEG 6000, 4M NaCl. 
T10E01 : 10mM Tris pH 7.5, 0.1mM EDTA. 
Note: M13 K07 helper phage was prepared as recommended by the supplier 
(Pharmacia). 
2.4.4 Site-directed mutagenesis. 
For the directed introduction of point mutations in vitro into PRP2 DNA 
sequences present in the phagemid vector pTZ19R, a modified version of the method 
described by Kunkel et al (1987) was used. The advantage of this procedure is the 
very high mutagenesis rates (routinely 65-85%), allowing clones to be screened 
directly by sequencing. The method involves 5 steps: 
Generation of uracil-containing template DNA: 
The recombinant double-stranded pTZ DNA clone to be mutated was 
transformed into the mutant E. coil strain BW3 13, and a single transformant grown 
overnight in 5ml LB-amp. This culture was used to prepare single stranded template 
DNA as described in section 2.4.3.1. Since BW313 lacks the enzyme dUTPase 
responsible for metabolising dUTP, DNA synthesis proceeds with dUTP rather than 
dTTP incorporation. 
Kinasin g the synthetic oligodeoxyribonucleotide: 
The appropriate oligodeoxyribonucleotide carrying the desired mutation (listed 
in table 2.5) was kinased by assembling the kinase reaction as follows: 200pmol 
oligodeoxyribonucleotide, 31 1M Tris-RCl pH8.0, 1 .51d 0. 1M DTT, 1 .Oal 0.2M 
MgCl2 , 1 .01d 10mM ATP, 5 units T4 polynucleotide kinase, and dH 20 to 30/Ll. The 
reaction was allowed to proceed for lhr at 37°C, then the enzyme was inactivated 
by incubation at 68°C for lhr. 
Annealing the synthetic oligodeoxyribonucleotide to template DNA: 
0.5pmol uracil-containing single-stranded DNA, lOpmol kinased oligo, 241 
Sequenase (annealing) buffer and sterile dH 20 to 101.d were mixed together and 
heated for 10 min to a temperature 20°C higher than the melting temperature of the 
synthetic oligo. The tube was then allowed to cool slowly to 15°C. 
Polymerisation reaction and elongation: 
The annealed oligo was extended from the 3' terminus to copy the U-
containing template strand using the enzymes E. coil DNA polymerase. The reaction 
was assembled as follows: 101 annealed oligo/template, i/hl buffer B, 441 
deoxyribonucleotide mix, 1.d 10mM ATP, 2 units T4 DNA ligase, 2 units E. coil 
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DNA polymerase 1 Kienow fragment (Boehringer) and 31.d dH 20. The reaction was 
allowed to proceed for 20hr at 15°C. 
5) Introduction into wild type E. coli: 
To destroy the "non-mutated" uracil-containing strand in vivo, the double 
stranded DNA produced as a result of polymerisation and ligation was used to 
transform the DUT, UNG strain, NM522. During replication any U-containing 
plasmid strands should be destroyed, ensuring propagation only of the mutated T-
containing strand. To identify mutant clones, single transformants were grown 
overnight in LB-amp, single-stranded template DNA was produced (section 2.4.3.1.) 
and analysed by sequencing. 
Buffers: 
Buffer B: 0.2M Tris-HC1 pR7.5, 0- 'M MgC12 , 0. 1M Dfl'. 
Deoxynucleotide mix: 2mM each of dATP, dTTP, dCTP, dGTP. 
2.4.5 Yeast genomic DNA preparation. 
A 20m1 yeast culture was grown overnight in the appropriate medium. 
Cells were harvested and resuspended in 400/Al sorbitol/NaPO 4 . 
lOOjzl lyticase at 2500U/ml in sorbitol/NaPO 4 was added and cells 
incubated for lhr at 37°C with gentle shaking. 
Sphaeroplasts were pelleted and resuspended in 0.5m1 TE. 
50.d 20% SDS was added, mixed well and incubated at 65°C for 30mm. 
2O0d 5M KOAc pH5.7 was added and left on ice for lhr. 
Cell debris was pelleted by spinning for 5mm. in a microfuge, and the 
supemate transferred to a clean tube. 
DNA was precipitated by the addition of an equal volume of isopropanol, 
mixing and leaving at room temperature for 5 mm. 
The DNA was harvested by spooling on a sealed Gilson pipette tip and 
resuspended in 300d TB. 
Buffers: 
Sorbitol/NaPO4 : 1.2M sorbitol, 50mM NaPO4, 5mM Dfl (added immediately 
before use). 
TE: 50mM Tris-HC1, 20mM EDTA pH8.0 
2.4.6 Extraction of RNA from yeast. 
1) A 200m1 yeast culture was grown in the appropriate medium to OD 6w 0.3- 
0.7. 
The cells were harvested in Sorvall 500m1 pots at 4 krpm for 10min in a 
GS3 rotor at 4°C. 
The cell pellet was washed in 9m1 TNE (ice-cold), transferred to a 15m1 
corex tube, spun down and resuspended in lml TNE. 
To fracture the cells, approximately 30mg acid-washed glass beads were 
added and the tube vortexed vigorously for 1mm. 
Rapidly, 3ml TNE, 0.2m1 20% (w/v) SDS, and 4ml phenol were added 
and the tube vortexed again for 1 .5mm. 
After spinning for 5min at 4krpm the aqueous phase was transferred to a 
fresh tube and re-extracted with 4m1 phenol/chloroform. This was repeated, 
transferring the aqueous phase to a fresh tube each time until the interface was clear. 
One chloroform extraction was performed and the RNA precipitated with 
2 volumes ethanol and 0.1 volume 3M NaOAc pH5.3. 
The RNA was sedimented by spinning at 10krpm in an SS34 rotor at 4°C 
for 30mm, the pellet washed with 70% (v/v) ethanol, air dried and dissolved in 
2001Ll sterile dH20. 
61 
RNA was stored at -20°C as an aqueous solution. 
Yield is 0.1-1.0mg RNA/200m1 cells at OD 6w 0.4 
Buffers etc.: 
TNE: 50mM Tris-HC1 (p117.5), 5mM EDTA, 100mM NaCl. 
Acid-washed glass beads (100 mesh; BDH) were prepared by boiling for 
20min in 1M HC1, cooling, washing well in dH20, drying and baking at 250°C for 
l6hr. 
Note: 
When it was inconvenient to extract RNA from cells immediately after 
harvesting they were stored at -20°C in absolute ethanol. 
2.4.7 Labelling restriction fragments by random priming. 
Modified from Feinberg and Vogelstein (1984). 
2-101tg plasmid DNA was digested to completion and electrophoresed 
through an agarose gel to separate the fragments. 
The DNA fragment required was purified using the Qiaex procedure. 
The concentration of the fragment was assessed by running a small volume 
on an agarose gel. The DNA was stored at -2(°C. 
The oligo labelling reaction was set up by adding together the following 
in this order: 50-100ng fragment made up to 35d with dH20 and denatured by 
boiling for 3-5min and then cooling on ice; lO/Ll OLB, 2z1 BSA at lOmg/ml, 3l 
[a32-P]dCTP at lOmCi/ml, 2 units E.coli DNA polymerase 1 Kienow fragment. 
The reaction was incubated at room temperature overnight. 
The unincorporated nucleotides were removed by passing the reaction mix 
over a gel exclusion column (NAP-5 column, Pharmacia) equilibrated with 10mM 
sodium phosphate (pH7.0). 
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Buffers: 
OLB was made from the following: 
Solution 0: 1.25M Tris-HC1 (pH8.0),0. 125M MgC12 . 
Solution A: lml solution 0, 1841 0-mercaptoethanol, S/Li at 0.1M each dATP, 
dTTP, dGTP. 
Solution B: 2M Hepes (pH6.6 with 5M NaOH). 
Solution C: Hexadeoxyribonucleotides (Pharmacia) at 90 OD units/ml in TE. 
A:B:C were mixed in the ratio 2:5:3 to produce OLB which was stored at -2(PC 
2.4.8 Denaturing agarose gel electrophoresis of RNA. 
A 1.4% (w/v) agarose gel containing MOPS buffer and formaldehyde was 
used. Ethidium bromide was included to allow the visualisation of RNA following 
electrophoresis. As formamide releases a dangerous vapour, gels were poured in a 
fume hood whenever possible. 
2. ig agarose was added to 15m1 lox MOPS buffer and 130.5m1 dH20, and 
boiled to dissolve the agarose. 
After cooling to below 65°C, 7.65m1 formaldehyde (37%) and 7.5/Al 
5mg/ml ethidium bromide were added and the gel poured. 
RNA (30/Lg total yeast RNA is adequate for northern analysis) was made 
up to 20d with dH2O, 20d Formamide Sample Buffer (FSB) was added and the 
samples were heated to 65°C for 5 min to denature and snap cooled on ice. 
Samples were loaded into dry wells and run in before covering the gel with 
running buffer. To follow the course of the electrophoresis, an extra well was 
loaded with gel loading buffer. 
The gel was run at lOV/cm using a peristaltic pump to recirculate the 
buffer. Following electrophoresis, the RNA could be visualised using a 
N. 
transilluminator and the gel photographed. 
Buffers: 
FSB: 100zl lOx MOPS, 200d formamide, 120j.d formaldehyde (37% w/v). 
Gel loading buffer: 0.25% bromophenol blue, 0.25% xylene cyanol FF, 15% Ficoll. 
lox MOPS: 41.86g MOPS, 6.81g sodium acetate, 3.72g EDTA in 11. The pH was 
adjusted to 7.0 with 5M NaOH. 
2.4.9 Capillary blotting of DNA and RNA. 
DNA or RNA from agarose gels was blotted onto Hybond-N nylon membrane 
(Amersham) by drawing up lOX SSC through the gel into a stack of paper towels 
as described by Sambrook et al (1989). Prior to assembling the blot, agarose gels 
were treated as follows: 
RNA gels were washed twice in lox ssc, each for 20mm. 
DNA gels were washed twice in denaturation buffer (0.5M NaOH, 1 .5M NaOH) 
each for 20 mm, followed by soaking twice in neutralisation solution (0.5M Tris/HC1 
pH7.4, 1.5M NaCl) again each for 20 mm. 
After transfer, RNA and DNA were fixed to the membrane by exposure to 
UV light in a UV Stratalinker 1800 (Stratagene) using the auto-crosslink setting. 
2.4.10 Hybridisation of Southern and northern blots with random primed 
probes. 
Northern and Southern blots were hybridised in bottles in a Hybaid 
hybridisation oven used according to the manufacturer's instructions. Pre-
hybridisation, hybridisation and washing were as below, probes were [a 32P]-labelled 
restriction fragmants made as in section 2.4.7: 
1) Pre-hybridisation was carried out at 65°C for 2hr in lOml hybridisation 
buffer (Church and Gilbert, 1984). 
The probe was added following denaturation by boiling for 5min and 
chilling on ice. 
Hybridisation was carried out for 24 hr at 65°C. 
The membrane was washed 3 times 15 min in wash buffer at 65°C. 
The membrane was covered in Saran Wrap and exposed to X-ray film. 
Buffers: 
Hybridisation: 7% SDS, 0.5M NaPO4 pH7.2, 1mM EDTA 
Wash: 5% SDS, 40mM NaPO 4 pH7.2, 1mM EDTA. 
2.4.11 In vitro transcription. 
T7 RNA polymerase-directed in vitro transcription reactions were performed 
essentially as described by Davanloo et al (1984). Radiolabelled transcripts were 
produced using the plasmid pT7rp28s (described in table 2.3) as the template. 
0.21.Lg linearised plasmid DNA (taken directly from a restriction 
endonuclease digest), 1jl lOX reaction buffer, 141 nucleotide mix, 30jCi [a-
32P]UTP (800Ci/mmol) and 10 U RNasin (Promega) were made up to 9.5/Li with 
dH2O. 
O.S/Ll T7 RNA polymerase was added and the reaction mix incubated at 
37°C for 12 mm. 
The reaction was stopped on ice and used directly in splicing reactions or 
frozen at -20°C for up to three days. 
Buffers: 
lOX buffer: 400mM Tris-HC1 pH8.0, 100mM MgC1 2 , 100mM DTT, 100mM NaC1 
Nucleotide mix: 5mM each ATP, GTP, CTP, 0.25mM UTP (Pharmacia, T7 Grade). 
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2.4.12 Denaturing polyacrylamide gel electrophoresis of DNA and RNA. 
DNA and RNA were electrophoresed through 6% (w/v) acrylamide, 8M urea 
gels at 35W. Gels for running DNA samples contained 1X TB buffer, gels for 
running RNA samples contained 1X TBE (recipes for buffers are given in 2.1.9). 
2.5 PROTEIN AND IMMUNOLOGICAL METHODS. 
2.5.1 Quantitation of proteins. 
Protein concentration was estimated using the Bradford assay (Bradford, 
1976) with a dye concentrate purchased from Bio-Rad and used as recommended by 
them. BSA was used to generate standard curves. 
2.5.2 Extraction and SDS-polyacrylamide gel electrophoresis of yeast proteins. 
2.5.2.1 Extraction of yeast total protein 
lOOmi cultures were grown to OD6000.4 in appropriate medium (galactose 
induction was for 5 hours from OD6 0.3). 
Cells were harvested in 250m1 Sorvall pots at 4 krpm. 
The cell pellet was washed once in 1X PBS and spun down at 3 krpm for 
5 min in a benchtop centrifuge. 
Cells were resuspended in 0.4m1 PBS, 0.1% NP40, 1mM PMSF. 
The cell suspension was sonicated on ice 3 times for 30sec each with 30sec 
intervals between pulses. 
Cell debris was removed by spinning for 30sec in an Eppendorf centrifuge. 
The supernate was spun at 4°C for 10min to remove any further debris. 
The supemate was snap frozen in liquid nitrogen or dry ice and stored at - 
70°C. 
Buffers: 
50mM PMSF: 8.71mg/mi in ethanol (made up fresh). 
2.5.2.2 SDS-PAGE of proteins 
Proteins were separated by SDS -discontinuous polyacrylamide gel 
electrophoresis (SDS-PAGE) as described by Laemmli (1970). 7.5% gels were cast 
between 16xl6cm glass plates with 1.5mm spacers and 0.5cm wide wells, the 
stacking gel being at least as deep as the wells. Samples were prepared by adding 
an equal volume of 2X sample buffer, heating to 100°C for 10min and centrifuging 
for 3-5min to remove any precipitated material. Gels were run in an ATTO 
electrophoresis tank at 30-150V in SDS-PAGE buffer. 
Buffers: 
2X sample buffer: 125mM Tris-HC1 (pH6.8), 200mM DTT, 4% (w/v) SDS, 
40%(v/v) glycerol, 0.02% (w/v) bromophenol blue; stored at -2C) 
SDS-PAGE buffer: 25 m Tris base, 192mM glycine, 0.1 % (w/v) SDS). 
Resolving gel buffer: 1.5M Tris-HC1 pH8.8, 0.4%(w/v) SDS. 
Stacking gel buffer: 500mM Tris-HC1 pH6.8, 0.4%(w/v) SDS. 
2.5.3 Staining SDS-polyacrylamide Gels. 
Detection of proteins at concentrations below 0.5g/cm 2 of gel was by silver 
staining. 
2.5.3.1 Silver staining of protein gels. 
This method is taken from Ansorge (1985) and was used for the detection of 
trace impurities during protein purification procedures. Prior to staining the 
polypeptides were impregnated with a weak solution of KMnO 4 and a copper salt. 
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Gels were soaked in 200mls 10% (v/v) methanol 10% (v/v) acetic acid for 
upto 2hr and then treated as shown in table 2.6. Unless otherwise stated, volumes 
of lOOmi were used and were shaken on a platform shaker (at about 40 rpm). 
Table 2.6 Silver staining procedure 
STEP TREATMENT TREATMENT 
TIME 
1 50% methanol, 12% trichloroacetic acid, 
2% CuCl2 
20 mm 
2 Solution A: 10% ethanol, 5% acetic 
acid 
10 mm 
3 0.01% KMn04 10 mm 
4 Solution A 10 mm 
5 10% ethanol 10 mm 
6 dH20 10 mm 




8 10% K2CO3 1 mm 




10 solution A 1-2 mm 
2.5.4.1 Far Western blot 
As Western blot (section 2.5.4) but after step 3: 
renature blot in renaturation buffer +5 %BSA for 24-48 hours at 4°C. 
incubate renatured blot with 500ng purified protein in lOmi renaturation buffer ±5% 
BSA at 4°C for 24 hours. 
wash blot in renaturation buffer and continue with Western blot procedure from step 5 
using renaturation buffer to wash, not blocking buffer or 1xTBS. 
Renaturation buffer: 20mM HEPES pH7.9, 3mM MgC1 2 , 0. 1 m EDTA, 0.1 % Tween 20, 
10% glycerol, 1mM DTT, 100mM KC1 
2.5.4 Western blotting. 
After SDS-PAGE proteins were electrophoretically transferred to Immobilon 
P membrane (Millipore) in a Trans-Blot Electroblotting Cell (Bio-Rad) with plate 
electrodes. The membrane was stained with Ponceau S (Sigma) to visualise 
molecular weight markers and verify transfer. Anti-PRP2 antibodies were used to 
detect PRP2. 
The blot was set up following the manufacturers instructions (Bio-Rad). 
The gel was placed in transfer buffer in an electroblot apparatus with two 
cooling coils (Immobilon P towards the anode). Transfer was for lhr at 100V. 
After transfer the membrane was stained in Ponceau S and rinsed with 
dH20 to remove excess stain. 
The membrane was incubated in blocking solution for Mr. 
Blocking solution was discarded and the membrane incubated with primary 
antibody (either 300/Al affinity purified or 20d crude antibody in 15m1 10% blocking 
solution) at room temperature for 2hr or overnight at 4°C. 
The membrane was washed in lx TBS for 4 times 5 min at room 
temperature. 
The filter was then incubated in 15m1 alkaline phosphatase-conjugated goat 
anti-rabbit antibodies (Promega Biotec) at the recommended dilution (1:7500) in 
1XTBS. 
As 6). 
The membrane was incubated in 5-10mi development solution containing 
0.33mg/mi NBT and 0.165mg/ml BCIP (both Promega Biotec.) to detect bands. 
The development reaction was terminated by washing the membrane in 
several changes of water. The membrane was dried, covered in Saran Wrap and 
stored in the dark to prevent the colour fading. 
Buffers: 
lox Ponceau S: 2% (w/v) in trichioroacetic acid (30% w/v) and sulfosalicyclic acid 
(30%w/v). 
Transfer buffer: 20mM Tris base, 150mM glycine. 
Blocking solution: 5% (wlv) Marvel milk powder, 1X TBS. 
Development solution: 100mM Tris-HC1 (pH9.5), 100mM NaCl, 50mM MgC12 . 
2.5.5 In vitro splicing. 
2.5.5.1 Preparation of yeast splicing extracts. 
Modified from Lin et al (1985). 
The appropriate medium was inoculated with a fresh stationary yeast 
culture and grown overnight to OD 6 0.5-0.7. (31 at OD6000.6 gave 4m1 extract). 
Cells were spun down at room temperature, resuspended in = 50m1 50mM 
potassium phosphate pH7.5, spun down again and resuspended in 40m1 lyticase 
buffer. 1-1.5ml lyticase (Sigma)(made up in buffer at 2500U/ml) was added and 
incubated for 30min-lhr at 30°C. 
Cells were checked for sphaeroplast formation, spun down slowly at 3 
krpm and washed twice in 1.2M sorbitol, resuspending gently and spinning down 
slowly. 
Cells were spun down slowly again, washed once with SB-3 (ice cold) and 
placed on ice. Everything was done at 4°C from this point on. 
The cell pellet was weighed, resuspended in imi buffer A/g cells and 
homogenised with 10-13 slow strokes in a chilled Dounce homogeniser. 
The homogenate was transferred to a beaker on ice. The volume was 
measured and 1/9th  volume of 2M KC1 was added dropwise. The extract was stirred 
for 30mm. 
The cell debris was pelleted by spinning in a chilled polycarbonate SS-34 
tube at 17 krpm for 30min at 4°C. 
The supernate was transferred to a Ti50 polycarbonate bottle avoiding the 
top (lipid) layer, and spun at 37 krpm for lhr at 4°C in a pre-cooled Ti50 rotor. 
The supernate was transferred to dialysis tubing, again avoiding the lipid 
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layer and dialysed for 3hr against 11 buffer D with change of buffer after 1.5hr. 
The extract was spun for 10min in microfuge tubes (at 4°C) and snap 
frozen in aliquots. 
Extracts were stored at -70°C, and were not thawed and refrozen more 
than 3 times as this causes loss of activity. 
Buffers: 
Lyticase buffer: 1.2M sorbitol, 50mM potassium phosphate pH7.5, 30mM DTFS 
SB-3: 50mM Tris-HC1 pH7.5, 10mM MgC1 2 , 1.2M sorbitol, 3mM DTTS 
Buffer A: 10mM HEPES-KOH pH7.5, 1.5mM MgC12, 10mM KC1, 0.5mM D1T 
Buffer D: 20mM HEPES-KOH pH7.5, 0.2mM EDTA pH8.0, 0.5mM DTF, 50mM 
KC1, 20%(v/v) Glycerol. 
DTT was added immediately prior to use. 
2.5.5.2 In vitro splicing reaction. 
Assays for the production of splicing intermediates and products were carried 
out essentially as described by Lin et al (1985). The standard reaction lO/Ll was 
assembled at room temperature. Splicing extract was thawed and incubated for 3- 
5min at 25°C before use. Substrates were produced by in vitro transcription (section 
2.4.11). 
The splicing mix was prepared as follows: lO/Li 30% (w/v) PEG 8000 
(Sigma), 8d IgG buffer, 6.d 1M potassium phosphate (pH7.5), 2.51d 100mM 
MgC12, 1.d 20mM ATP, - 0.5Ci substrate RNA from an in vitro transcription 
reaction, sterile dH20 to 50d. 
The splicing mix was aliquoted into 5d volumes and 541 splicing extract 
added to each aliquot. The reaction mix was incubated at 25°C for 2-30mm. 
The reactions were stopped on ice. 
To analyse the RNA, 2/Al 1mg/mi proteinase K (in 50mM EDTA, 1% 
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(w/v) SDS) was added and incubated at 37°C for 30mm. 
lOOjzl splicing cocktail was added and the sample extracted with 
phenol/chloroform and precipitated with ethanol with tRNA as a carrier. 
The pellet was resuspended in 31zl Sanger dye and heated to 90°C for 3 
minutes prior to electrophoresis. 
Samples were electrophoresed through a 6% (w/v) denaturing acrylamide 
gel and detected by autoradiography. 
Buffers: 
IgG buffer: 0.5M KPO4 pH7.5, 33mM citrate pH3.0, 16.67% glycerol 
Splicing cocktail: 50mM sodium acetate pH5.3, 1mM EDTA, 0.1% (w/v) SDS, 
251g/ml E.coli tRNA. 
Sanger dye: 50%(v/v) formamide, 20mM EDTA, 0.3% xylene cyanol FF, 0.3% 
bromophenol blue. 
2.5.6 Native gel electrophoresis of splicing complexes. 
Native gel electrophoresis was carried out according to Pikielny et a! (1986) 
except that the EDTA concentration in the gel was 10mM (1mM in Pikielny et al 
(1986)). This system separates three splicing complexes designated I, II, and III, 
complex II (the final complex formed) being the active spliceosome, as verified 
previously by the analysis of the RNA species in the three complexes (J.D.Brown, 
PhD. thesis). 
1) 150x150x1.5mm composite gels were made and run in an ATTO 
electrophoresis tank by dissolving 0.25g agarose in 40ml dH20 and cooling to 
approximately 50°C. 2.5ml 1OXTB, lml 0.5M EDTA, Sml 30% (w/v) acrylamide 
(60:1 acrylamide:bis-acrylamide) were added quickly and the volume made up to 
45m1. 0.4m1 10% APS and 501fl TEMED were added and the solution poured into 
warm plates (37C). A comb with ten 9mm slots was inserted and the gel allowed 
to set, then chilled to 4°C. 
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2) The gel was pre-electrophoresed at 4°C for lhr in 0.5X TB, 10mM EDTA 
at 80V. 
Splicing reactions were set up as in section 2.5.5.2 and stopped on ice. 
5l ice cold Q buffer was added to 51 aliquots of the reactions. The samples were 
incubated on ice for 10 mm. 
2.51.d 5X RNP load buffer was added to each sample,and they were loaded 
onto the gel and run at 4°C for 8-10hr at 80V or overnight at 40V. 
NOTE: as the gel tended to slide out from between the plates, a layer of "blocking" 
acrylamide was poured into the bottom of the plates prior to pouring the gel. 
Buffers: 
Q buffer: 1.6M KC1, 8mM Mg-acetate, 80mM EDTA, 64mM Tris-HC1 (pH 7.5), 
2.6mg/ml yeast total RNA (prepared as in section 2.4.6). 
5X RNP load buffer: 5X TB, 50mM EDTA, 50% (v/v) glycerol, 0.25% (w/v) each 
bromophenol blue and xylene cyanol FF. 
"Blocking" acrylamide: lml 30%(w/v) acrylamide, 10041 0.5M EDTA, 250141 
1OXTBE, 3.65ml dH20, 50il 10% APS, 20j4l TEMED. 
2.5.7 Preparation of APRP2 AATP spliceosomes. 
1001d reactions were set up as follows: 50%(v/v) DJy85 heat inactivated 
extract, 2pmol [c- 32P] pre-mRNA, 1.5mM ATP and 50%(v/v) splicing buffer. The 
reaction mix was incubated at 25°C for 25 mm. 
The reaction mix was incubated at 25°C for 5 mm. with 1.5mM glucose. 
This exploits the hexokinase activity endogenous to yeast splicing extracts in order 
to deplete the ATP in the extract. 
The spliceosomes were isolated on a Sephadex G25 column (NAP-5, 
Pharmacia LKB). The column was equilibrated with splicing buffer (without ATP), 
and the reaction mix was made up to lml with splicing buffer prior to gel filtration. 
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The spliceosomes were eluted with splicing buffer and 120/Ll fractions 
were collected and numbered 1-10. Fractions 3-7 contained spliceosomes. 
The spliceosomes were stored at -70°C for up to 24hr. 
2.5.8 Iminunoprecipitation. 
Immunoprecipitation of splicing complexes from splicing reactions (as 
prepared in sections 2.5.5.2 or 2.5.7) was carried out essentially as in Lossky et a! 
(1987). Antibodies were pre-bound to protein-A sepharose (PAS) beads. In order 
to lower the background caused by nonspecific binding of RNA to PAS, a blocking 
step was included following binding of antibodies to PAS. 
PAS beads (Sigma) were swollen in lml NTN for 20min and washed 3 
times with imi NTN. 50.il (7.5 mg dry mass) of beads were used per reaction. The 
antibody was added at sufficient titre to give maximal precipitation of antigen, and 
incubated in 0.3m1 NTN for lhr with mixing. 
0.2m1 blocking buffer was added and the incubation continued for 45mm. 
The beads were washed 5 times with lml NTN, and placed at 4°C until the splicing 
reaction mix was ready. 
A 10d splicing reaction was added to lO/Ll ice-cold Q buffer and incubated 
on ice for 10mm. The quenched reaction was diluted in NTN to give a final volume 
of 300l and was then added to the antibody-bound PAS beads and incubated at 4°C 
for 2hr with mixing. 
The beads were washed twice with lml NTN and once with NT removing 
the final (NT) wash carefully. 
To analyse RNA, 50d proteinase K solution was added and incubated at 
37°C for 30min with mixing. 
50al dH20 was added and the sample extracted 3 times with 
phenol/chloroform. 
RNA was precipitated with ethanol adding 1l E. coli tRNA at 20mg/ml 
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to each sample as a carrier. 
8) The samples were electrophoresed through a 6% (wlv) denaturing 
polyacrylamide gel, the gel covered with Saran Wrap and exposed to X-ray film. 
Buffers: 
Block buffer (freshly made): BSA, glycogen, E.coli tRNA each at 100g/ml. 
Q buffer: 450mM KC1, 2.3mM Mg-acetate, 23mM EDTA, 18mM Tris-HC1 (pH 
7.5), 1 .2mg/ml yeast total RNA (prepared as in section 2.4.6 and phenol: chloroform 
extracted a further 5-6 times). 
NTN: 50mM Tris-HC1 (pH7.5), 150mM NaCl, 0.1% (v/v) NP-40. 
NT: As NTN but without NP40. 
Proteinase K solution: 50mM Tris-HC1 (pH7.5), 300mM NaCl, 5mM EDTA, 1.5% 
(wlv) SDS, 2mg/mi proteinase K (store at -20 °C). 
2.5.9 Purification of polyhistidine-tagged PRP2 protein from yeast. 
This 2-step small-scale system was developed by M.Plumpton (PhD thesis, 
1993) to purify soluble PRP2 protein from yeast extracts prepared from cells induced 
to overexpress polyhistidine-tagged PRP2. 
2.5.9.1 Preparation of yeast extracts for purification of PRP2 protein. 
The yeast strain S150-2B harbouring the GALl-regulated histidine-tagged 
PRP2 gene (present in pBMPRP2HIS) was grown in 41 YMGlyLacCas (repressing 
conditions) to OD6 0.3. 
40% galactose was added to the culture to a final concentration of 
2%(w/v). Cells were grown under these inducing conditions for 5 hr and harvested 
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using 500m1 Nalgene pots. 
Cells were washed, sphaeroplasted, homogenised and subjected to 
centrifugation using essentially the same procedure as for the preparation of splicing 
extracts (section 2.5.5.1, steps 2-9). The only changes made to this protocol were 
as follows: 
DTT was not added to buffer A or to SB3, as reducing agents are not compatible 
with the use of nickel-chelating resin. 
The final dialysis in buffer D (step 10) was omitted, the extract being snap 
frozen following the 37krpm spin, and stored at -70°C until required. 
A 41 culture gave 6-7mls of extract. 
2.5.9.2 Assembling and running purification columns: 
Columns were run at 4°C, and all buffers were pre-cooled to 4°C prior to use. 
A peristaltic pump was used to control the flow rate of extracts and buffers over the 
columns. The volume of each column refers to the volume of resin packed into Bio-
Rad Econo-columns. 4ml nickel-chelating resin (Invitrogen) was packed into a 
1.77cm2 5cm length column (cat. no. 737 1506), imi polyuridylic acid agarose 
(Sigma) was packed into a 0.2 cm 2 5cm length column (cat. no. 737 0506). 
STEP I - Nickel-chelating column. 
Adapted from Hoffman and Roeder, (1991). 
A 4m1 nickel-chelating column was equilibrated with 20mM Tris-HC1 
pH7.9, 0.5 M NaCl, by passing 40ml of buffer over the column at a rate of 20m1/hr 
(all procedures were carried out at 4°C). 
An equal volume of 2X sample buffer was added to yeast cell extract 
prepared from 41 of cells and imidazole.HC1 pH7.9 was added to a concentration of 
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1mM before loading onto the N?'-NTA column. 
The extract was circulated over the column at a flow rate of approximately 
15m1/hr, for 2 hr. 
The column was washed with 30m1 BC 100 containing 20mM 
imidazole.HC1 pH7.9, followed by 20m1 BC 100 containing 50mM imidazole.HC1 
pH7.9 at a flow rate of 15ml/hr. 
PRP2 protein was step-eluted with 5m1 BC 100 containing 150mM 
imidazole.HC1 pH7.9 followed by 5m1 BC100 containing 200mM imidazole.HC1 
pH7.9, at a flow rate of 4m1/hr. imi eluate fractions (numbered 1-12) were 
collected and analysed by SDS-PAGE and silver staining to identify the peak elution 
fractions. Those containing the highest PRP2 protein concentration were reproducibly 
fractions 6-9. 
Buffers: 
2X Sample buffer: 20% glycerol, 20mMTris-HC1 pH7.9, 1M NaCl. 
BC100: 20% glycerol, 20mM Tris-HC1 pH7.9, 100mM KC1. 
STEP II - Poly(U) agarose column. 
Adapted from Kim et a! (1992). 
Peak fractions from the nickel-chelating column were pooled and dialysed 
against 31 BP containing 50mM KC1 for 2hrs with a change of buffer after Mr. 
During the dialysis, a imi poly(U) agarose column was washed with 20m1 
BP containing 50mM KC1 at a flow rate of 15m1/hr. 
The dialysed protein sample was circulated over the column at a flow rate 
of 15 mi/hr for 2hr. 
The column was washed with 20mi BP containing 100mM KC1, followed 
by lOmi BP containing 150mM KC1 at a flow rate of 15ml/hr. 
PRP2 was step eluted with 5mi BP containing 200mM KC1 followed by 
Sm! BP containing 250mM KC1 at a flow rate of 4m1/hr. 0.5m1 eivate fractions 
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(numbered 1-20) were collected and analysed by SDS-PAGE and silver staining to 
identify the peak PRP2 containing fractions. Essentially pure PRP2 was 
reproducibly eluted in fractions 11 and 12. 
Buffers: 
BP:20mM HEPES-KOH pH7.7, 0.5mM EDTA, 5mM DTF, 0.01% NP40, 10% 
glycerol 
• DY!' was added immediately prior to use. 
2.5.10 ATPase assays (Schwer and Guthrie, 1992) 
20d reactions were set up as follows: 8/Al 2X reaction mix, 10jg poly(U) 
RNA, lmM['y-32P]ATP,  60ng protein, ddH20 to 20d. 
The reaction mix was incubated at 25°C for 60mm. 
The reaction was stopped on ice and 200.d activated charcoal was added 
and incubated on ice for 10mm. 
After spinning for 10min in an Eppendorf centrifuge, the supernate was 
removed to a clean tube, ensuring no charcoal was carried over. 
[32P]Pi released in the assay was estimated by Cerenkov counting (section 
2.2.6). 
Buffer: 
2X reaction mix: 50mM triethanolaminepH8.2, 75mM KOAc, 1mM DT!', 1.25mM 
MgC12, 1mM ATP (make up fresh). 
Activated charcaol was washed three times in 50mM HC1/5mM H 3PO4 before use. 
2.5.11 Crosslinking of PRP2 to substrate RNA 
50l splicing reactions were set up using 40d LPRP2LATP spliceosomes 
(section 2.5.7), 30ng purified PRP2 protein and 25mM MgC1 2. 2mM ATP was 
included where required. 
The reactions were incubated at 25°C for 20 min and then stopped on ice. 
ll lOmgml' E. coil tRNA was added to each sample and the entire 
sample was transferred to a well of a microtitre plate (Stenhin) on ice. 
Cross-linking was performed for 25 min at 3.7mW/cm2 on ice in a UV 
Stratalinker 1800 (Stratagene), as close to the bulb as possible. 
2l RNaseTl (at 100U/i1) was added and each sample was incubated at 
37°C for 30 mm. 
151.d 10% SDS, 81 10% Triton X100 and 7d 1M DTT were added the 
samples which were heated to 90°C for 1.5 min to disrupt non-covalent interactions. 
7001.d NTN was added to each sample to dilute the SDS sufficiently to 
allow immunoprecipitation. 
Immunoprecipitation of PRP2 was carried out as in section 2.5.8 (steps 1- 
4). 
After the final NT wash, 501d SDS PAGE loading buffer was added and 
the samples boiled for 10 min at 100°C. The PAS was sedimented by spinning in 
an Eppendorf centrifuge for 5 mm. 
Samples were analysed by SDS PAGE (section 2.5.2.2). Following 
electrophoresis, the gel was dried and exposed to X-ray film at -70°C to detect cross-
linked proteins. If necessary, a second SDS PAGE gel was run and PRP2 detected 
by Western blotting (section 2.5.4). 
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CHAPTER 3 
Production and in vivo characterisation of three 
dominant negative mutants of PRP2 by site- 
directed mutagenesis. 
3.1 Introduction 
Much of the progress to elucidate the components of the yeast splicing 
pathway has been made through the use of genetic studies of S. cerevisiae. Large 
scale screening of temperature-sensitive splicing mutants (Hartwell, 1967; Hartwell 
et al, 1970; Vijayraghavan et al, 1989; Strauss & Guthrie, 1991) has identified over 
thirty different PRP genes whose products are involved in the splicing reaction. 
Isolation of suppressors of prp mutants can provide information about interactions 
between PRP and other proteins during the splicing reaction. A large-scale screen 
for suppressors of temperature-sensitive pip2 alleles failed to produce any 
informative mutants (M. Plumpton, PhD thesis 1993), so an alternative method was 
adopted in the search for proteins interacting with PRP2. This was the isolation of 
conditional dominant negative PRP2 mutants which cause a defect when 
overproduced in the cell even in the presence of a wild-type copy of PRP2. The 
dominant negative PRP2 protein may compete with wild-type PRP2 for binding to 
the spliceosome or to a particular protein factor, but because it does not have normal 
wild-type activity, is unable to perform its normal function so that the splicing 
reaction is effectively stalled at the point at which PRP2 acts. Figure 3.1 shows a 
diagrammatic representation of the model proposed for the dominant negative effect. 
This system provides a basis for a genetic screen for high copy-number suppressors 
as well as for biochemical studies to identify the malfunction within the protein that 
stalls the reaction. 
PRP2 is a putative ATP-dependent RNA helicase and has the motifs common 
Of 
Figure 3.1 Schematic diagram to explain the dominant negative phenotype, using 
PRP2 as a model 
(i) The normal wild-type situation: PRP2 interacts transiently with other splicing 
factors. Splicing occurs as normal and the cells are viable 
(II) A mutant form of PRP2 competes with PRP2 for interaction with other splicing 
factors. The mutant PRP2 binds to and sequesters the factor so PRP2 is unable to 
interact with it. The mutant PRP2 is non-functional, so splicing does not occur and 
the cells fail to grow. This is the DOMINANT NEGATIVE phenotype. 
(iii) By using an inducible/repressible system, such as expression of the mutant gene 
from the GALl promoter, the production of mutant protein is dependent on the 
external conditions. On glucose GALl is repressed and only wild-type PRP2 is 
expressed, normal splicing and growth is observed. On galactose, GALl is induced 
to overexpress the mutant PRP2 which is in vast excess to wild-type PRP2. The 
dominant negative protein will bind to and sequester the splicing factor, splicing will 
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to the DEAD/H-box family of putative RNA helicases. Motif I of this family: 
GXXXXGKT/S is common to all nucleotide triphosphate-binding proteins, not just 
helicases. It is, for example also found in the GTP-binding RAS proteins of both 
mammals and yeast. During a screen for GTP-binding mutants of the mammalian H-
ras protein, a dominant inhibitory mutant was isolated (Feig & Cooper, 1988). The 
mutant isolated bound GDP with a higher affinity than GTP, so that the ras protein 
was inactive and even in the presence of wild-type protein, NIH 3T3 cells were not 
transformed. Sequence analysis of the mutant protein showed it had a single amino 
acid change in the conserved GXXXXGKS motif, the serine residue had been 
changed to an asparagine (N). X-ray crystallographic studies have shown that the 
final serine or threonine residue is involved in complexing which is 
associated with bound NTP (Pal et al, 1989; Pal et al, 1990). It was hypothesised 
that the -OH side chain of the serine was important in this interaction and that the 
mutant H-ras which has lost the -OH group, was unable to bind Mg correctly and 
thus exhibited the aberrant GTP/GDP binding. To test the -OH theory, several other 
H-ras mutants were produced, each having the serine altered to an amino acid with 
another type of side chain (Farnsworth & Feig, 1991) As expected, all those 
mutants which had lost the -OH group, showed an increased affinity for GDP over 
GTP and had a dominant inhibitory phenotype. The conserved serine to threonine 
change (which retains the -OH) did not affect RAS function in any way. 
Using a random mutagenesis approach a dominant negative PRP2 mutant has 
been isolated with a change within the conserved SAT motif (Plumpton et al, 1994). 
By using a directed approach mutations can be introduced into other motifs in PRP2 
to try to produce more dominant negative mutants. The H-ras work offered both a 
number of mutations to try and a well documented model which might help in 
elucidating the mode of action of PRP2. 
It is imperative to ensure that it is the mutant protein itself that is causing the 
inhibition of growth on galactose and not just a strain-dependent galactose 
intolerance. Similarly, the growth inhibition must be shown to be caused by a 
splicing defect before these dominant negative mutants can be used to investigate the 
role of PRP2 in the splicing reaction. 
FX 
3.2 Methods and materials 
3.2.1 Synthetic oligonucleotides used for site directed mutagenesis. 
Mismatched bases are underlined. 
NAME SEQUENCE AMINO 
ACID 
CHANGE 
634N 5 GGTAACTGTGTGFITITACCAG 3 T-'N 
717R 5 GGTAACTGTGTGCATrFACCAG3 T-'C 
718R 5 'GGTAACTGTGTGGA1TFACCAG3 ' T-->S 
719R 5 'GGTAACTGTGTGGCTflACCAG3 ' T-A 
3.2.2 Generating the PRP2 GKT motif mutants 
PRP2 mutants were produced using site-directed mutagenesis (section 2.4.4). 
The HindIII-XbaI fragment of the PRP2 gene was subcloned into the phagemid, 
pTZ19R and this was used as a template for the mutagenesis reactions. The 
synthetic oligonucleotides used were complementary to the GKT region, except at 
the point at which the mutation was to be introduced. 
Mutant clones were identified directly by sequencing using the oligonucleotide 
036A (table 2.4). Nucleotide sequences of the GKT region are shown in figure 3.2 
for both wild-type and mutant constructs. The entire HindIII-XbaI region was 
sequenced to ensure that there were no other base changes due to errors during the 
elongation reaction. The mutated PRP2 HindIII-XbaI region was cloned into the 
PRP2 deletion construct pBMP2zH-X replacing the HindIII-XbaI linker with the 
mutated fragment. The plasmids were then introduced into wild-type S150-2B and 
transformants were tested for growth on glucose and lack of growth on galactose. 
Figure 3.2 Amino acid substitutions at the PRP2 GKT motif. 
Nucleotide sequences of the GKT region of the wild-type and four mutant PRP2 
alleles. Single stranded sequencing was carried out using the primer 036A. The 
mutated bases are underlined. The amino acids coded for by this region are shown 
using the single letter code. Mutant residues are underlined. This is the non-coding 
strand. 
The additional T at the bottom of the sequence for the GKC mutant was a sequencing 
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3.3.1 Preparation of plasmid constructs carrying the mutated PRP2 gene under 
GALl promoter control 
Site-directed mutagenesis using the method described in section 2.4.4 
produced about 80% mutant clones for each reaction. Transformation of the U-
containing plasmids into the unf strain NM522 provides a strong selection for the 
plasmids which have one U-containing strand and one T-containing strand, which can 
only have been produced during the elongation reaction of the site-directed 
mutagenesis. In order to check the fidelity of the Kienow enzyme, the entire 
HindHI-XbaI region was sequenced. A set of three oligonucleotide primers was 
synthesised to facilitate the sequencing (036A, 006P & 685P (table 2.4)). The 
sequencing results showed that the only change which had been introduced into the 
HindIII-XbaI region was that encoded by the SDM primer. 
The mutated HindIII-XbaI regions were subcloned into the vector pBMP2H-
X and transformed into NM522. Plasmid DNA from the transformants was analysed 
by restriction enzyme digests to identify clones which carried the full-length PRP2 
gene, replacing the much shorter HindIII-XbaI linker. 
3.3.2 Wild-type cells carrying the mutant PRP2 gene under GALl promoter 
control fail to grow on galactose. 
As the dominant negative mutations are potentially lethal to the yeast cells, 
it is important to have a regulated expression system. This is provided by fusing the 
mutant PRP2 gene to the GAL] promoter. The GAL] promoter provides a tight 
carbon source-dependent regulation of expression at the transcriptional level 
(Johnson, 1987). In glucose medium, expression from the GAL] promoter is 
repressed. In galactose medium, however, GAL] is induced and PRP2 is 
overexpressed, leading to overproduction of PRP2 protein. 
All the mutant PRP2 genes were expressed in this system, thus the putative 
dominant negative proteins will be overproduced on galactose medium. If the mutant 
protein is lethal in high copy, then cells carrying the mutant will fail to grow on 
galactose. However, the plasmid can be effectively propagated without being 
detrimental to the cells, by growing on selective glucose medium. 
The plasmids carrying the putative dominant negative PRP2 mutants were 
transformed into the wild-type yeast strain, S150-213. Single transformant colonies 
were resuspended in sterile water and equal volumes of the suspension were spotted 
onto selective YMG1uCas and YMGalRafCas plates. The plates were incubated at 
30°C for three days. Figure 3.3A shows the results of the screen. The mutations 
in which the -OH group of the threonine had been substituted for an alternative side 
chain, resulted in dominant negative phenotypes of PRP2 (the cells failed to grow 
on galactose), as was observed in FI-ras. Similarly, the conserved threonine to 
serine change appears not to affect cell viability; cells carrying this mutant grow 
normally on galactose. Growth on galactose at other temperatures (ie 18°C, 23°C 
and 36°C) was tested; none of the dominant negative proteins exhibited a 
temperature-sensitive phenotype (results not shown). 
3.3.3 Overproduction of PRP2GI  causes a decline in cell growth rate. 
Growth curves were used to demonstrate that galactose induction of the 
mutant PRP2 was the cause of cell death and also to estimate the time after galactose 
induction at which the growth defect of cells carrying the mutant protein became 
evident. 
S150-213 cells carrying either pBM-PRP2 or pBM-PRP2 ° were grown in 
non-inducing YMGlyLacCas medium. The cells grew with a doubling time of 3.5 
hours. Once a constant growth rate had been established, galactose was added to the 
cultures, to a final concentration of 2%(w/v). Induction of the GAL] promoter 
should occur within 15-60 minutes Q. Hopper, pers. comm.). As can be seen from 
figure 3.313, both strains initially grew with a doubling time of approximately 3.5 
hours, until the growth rate of the strain harbouring the dominant negative plasmid 
M. 
Figure 3.3 In vivo analysis of the dominant negative allele PRP2 1 . 
Analysis of growth on glucose and galactose 
Following colony purification, single colonies of the S150-2B transformants carrying 
pBM-PRP2, pBM-PRP2, pBM-PRP2 °', pBM-PRP2° and pBM-PRP2 were 
resuspended in sterile distilled water to a concentration of about 106  cells/mi. 10j.il  
drops of each suspension were spotted onto selective YMGluCas (Glucose) and 
YMGalRafCas (Galactose) plates and incubated at 30°C for three days. 
Growth curves 
200m1 YMGlyLacCas was inocculated with lOml of stationary phase S150-2B 
carrying either pBM-PRP2 or pBM-PRP2 (time:-5). After five hours growth 
at 30°C, 40% galactose was added to a final concentration of 2%(w/v) (time: 0) and 
incubation continued at 30°C for a further 18 hours. The cells were diluted, when 
necessary in pre-warmed YMGlyLacCasGal to maintain logarithmic growth. The 
OD6w of the cultures was measured to determine the growth rate. The arrow 
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began to decrease after 4 hours of induction. In contrast, the cells with wild-type 
PRP2 continued to grow normally. The only difference between the two strains was 
the presence or absence of the mutant PRP2 gene on the plasmid, thus the growth 
defect can be attributed to the presence of the mutant PRP2 protein. The slightly 
slower initial doubling time of the cells carrying pBM-PRP2 is probably due to 
a low level of PRP2°' being produced as the GAL] promoter is not completely 
repressed in the absence of glucose. 
3.3.4 Induction of the GALl promoter leads to overproduction of PRP2 
The growth defect in cells carrying the dominant negative PRP2 allele is 
evident after 4 hours galactose induction. It is necessary to demonstrate that PRP2 
protein is actually being overproduced in the cells. Using Western blotting 
techniques it is possible to analyse the amounts of protein in cell extracts. Cells 
carrying wild-type and mutant PRP2 genes under GAL] control were grown under 
repressing and inducing conditions, for 5 hours. Total protein extracts were 
prepared from induced and repressed cells (section 2.5.2) and analysed by SDS-
PAGE followed by Western blotting. The Western blot in figure 3.4A shows the 
results. After 5 hours in galactose medium, PRP2 is strongly overproduced (tracks 
2 and 4). The PRP2 signal from glucose-grown extracts is barely detectable (tracks 
1 and 3). 
3.3.5 Overproduction of PRP2GI  and PRP2 GKA  causes a defect in pre-niRNA 
splicing. 
The results presented in sections 3.3.3 and 3.3.4 show that overproduction 
of the mutant PRP2 protein is concomitant with a decline in cell growth rate, 
suggesting that the PRP2 mutant has a detrimental effect on normal functions in the 
yeast cells. As PRP2 is an essential splicing factor, it is reasonable to assume that 
a defect will be seen in pre-mRNA splicing. Northern blot analysis was used to 
Figure 3.4 
Western blot analysis 
Sonicated extracts were prepared from S 150-2B cells carrying either pBM-PRP2" 
or pBM-PRP2 grown under repressing conditions (GLU, tracks 1 and 3) or under 
inducing conditions (GAL, tracks 2 and 4) for 5-6 hours. Each track contains 100g 
protein (as determined by Bradford assay). The extracts were electrophoresed 
through 7.5% SDS-polyacrylamide gel and blotted onto Immobilon P membrane. 
PRP2 was detected using affinity purified anti-PRP2 antibodies (a-140) and anti-
rabbit IgG alkaline phosphatase conjugate secondary antibody (Promega). 
M represents size markers, sizes indicated in kDa. 
Northern blot analysis 
Total RNA was extracted from S150-2B cells carrying either pBM-PRP2 , pBM-
PRP2° or PBM-PRP2'KA grown under repressing conditions to OD 0.6 (GLU, 
tracks 3, 5 and 7) or under inducing conditions (GAL, tracks 4, 6 and 8) for 5 
hours. RNA from the prp2-J temperature-sensitive strain RY26 was extracted from 
cells grown at the permissive temperature (23°C, track 1) or shifted to the non-
permissive temperature for 2 hours (36°C, track 2). 30/.Lg of each RNA preparation 
was denatured and electrophoresed through a 1.4% agarose gel. The RNA was 
transferred to Hybond N membrane and hybridised to 32-P labelled actin DNA. The 
unspliced (pre-mRNA) and spliced (mRNA) actin RNAs are indicated. 
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investigate whether or not pre-mRNA transcripts were spliced normally. Total RNA 
was prepared from S150 cells carrying pBM-PRP2, pBM-PRP2 °' or pBM-
PRP20 ' < grown under repressing and inducing conditions. The RNA was analysed 
by Northern blotting using an actin probe (figure 3.4B), one of the intron-containing 
genes in yeast. Unspliced transcripts are longer and therefore do not run as far 
down the gel as the spliced message, so accumulation of the longer, unspliced 
transcript indicative of a splicing defect can be easily identified. As a control, RNA 
prepared from RY26, a heat-sensitive prp2-1 strain grown at the permissive (23°C) 
or shifted to the non-permissive (36°C) temperature for two hours was also analysed. 
At 23°C the RY26 actin RNA is efficiently spliced (track 1) and similar results are 
seen for the non-induced dominant negative mutants (tracks 3 & 7). At 36°C the 
RNA from RY26 is unspliced and accumulation of actin pre-mRNA is observed 
(track 2). An accumulation of unspliced actin pre-mRNA is also seen for the 
induced dominant negative mutants PRP2 °' (track 4) and PRP2GI  (track 8) but not 
for PRP2, (tracks 5 & 6). 
3.4 Discussion 
This chapter describes the use of site-directed mutagenesis to introduce 
specific single amino acid changes within one of the conserved motifs of PRP2. The 
GKS/T motif is involved in nucleotide triphosphate binding and X-ray 
crystallography has shown that the T/S residue is involved in complexing a Mg 
ion which is associated with bound NTP. The mutations engineered in the GKT 
motif of PRP2, replaced the threonine with other residues. As was reported for H-
ras, mutations that replaced the -OH side chain with another group which would be 
expected to disturb the Mg interaction, generated dominant inhibitory proteins. 
One dominant negative protein was made by changing threonine to cysteine, 
consistent with the fact that sulphur is known to bind Mg" much less efficiently 
than oxygen. Another change, from threonine to alanine removes the reactive 
oxygen as does the threonine to asparagine mutation, both these mutations generated 
dominant negative proteins. As expected, the conserved threonine to serine change, 
all 
which retains the reactive hydroxyl group did not appear to affect PRP2 function. 
The results presented in sections 3.3.3, 3.3.4 and 3.3.5, all reinforce the 
theory that overproduction of the mutant PRP2 proteins within yeast cells leads to 
inhibition of growth caused by a defect in pre-mRNA processing. This inhibition 
can be alleviated by simultaneous overproduction of wild-type PRP2 in the cells (M. 
Cooper pers. comm.). Suppression of the dominant negative effect by wild-type 
PRP2 suggests that the competition model for the mode of action of the dominant 
negative is correct (section 3.1). Thus, overproduction of a dominant negative 
protein in a wild-type haploid cell will be detrimental due to the vast excess of 
mutant protein over wild-type. 
The growth curve shown in figure 3.3B shows that when the GAL] promoter 
is not efficiently repressed (i.e. in the absence of both glucose and galactose), the 
low level of expression of the dominant negative allele, PRP2GI  causes a slight 
decrease in growth rate. This suggests that even at low cellular levels, the dominant 
negative protein is detrimental to the cell. This may explain the failure of several 
attempts to put the dominant negative allele on the genome under the control of the 
normal genomic promoter. Using 5-FOA as a selective agent, the PRP2GIcIV  allele 
was transformed into EFy2 which has one genomic copy of PRP2 and a disrupted 
PRP2..'URA3 copy. All transformants which grew on 5-FOA had lost the URA3 
marker but were shown by tetrad analysis to have two functional PRP2 alleles. As 
pp2GIC1 must be non-functional, two spores should fail to germinate and grow. 
Since other gene replacement experiments had been successful using the same 
system, it was hypothesised that any replacements of PRP2:: URA3 with PRP2 
were so detrimental to the cell that, even in the presence of wild type PRP2, the 
transformants failed to grow. This hypothesis suggests that PRPr KN can 
successfully compete with PRP2 when the two proteins are at equal cellular levels. 
Experiments in which simultaneous overproduction of PRP2' could alleviate the 
dominant negative phenotype were carried out using two different plasmid 
overexpression systems, so it may be that in this case, the PRP2 was produced at 
higher levels than PRP2GI. 
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CHAPTER 4 
In vitro characterisation of pjp2GKN 
4.1 Introduction 
The preceding chapter described the in vivo investigation of the effects of 
ppG and other mutations of the same region (threonine at position 253). 
Development of efficient systems to allow transcripts to be correctly spliced 
in vitro provide the means to study both the splicing reaction and spliceosome 
assembly in a cell-free system (Kole & Weissman, 1982; Kramer et a!, 1984; Lin 
et al, 1985). This chapter describes experiments carried out on extracts from cells 
in which either PRP2Wt  or  PRP21  is overproduced. It is essential to ensure that the 
dominant negative mutations also result in a splicing defect in vitro because most 
other investigations of these mutants must be carried out in cell free systems. The 
nature of the block to splicing and the inhibitory activity of the mutant protein is 
investigated further by examining splicing complex assembly. Immunoprecipitation 
reactions show whether or not the mutant protein is associated more strongly with 
the spliceosomes than is the wild-type protein. 
4.2 Methods 
4.2.1 Preparation of splicing extracts. 
Wild-type S 150-213 cells carrying either pBM-PRP2 or pBM-PRP2 GKN were 
grown in YMGlyLacCas at 30°C. For non-induced extracts, the cells were grown 
to an OD600of about 0.6 and then harvested. For induced extracts, cells were grown 
to OD6w 0.4, then 40% galactose was added to the culture to a final concentration 
of 2%. Incubation was continued for a further 4-5 hours before the cells were 
harvested, normally at OD 0.5-0.9, depending on the plasmid present. Extracts 
were prepared from harvested cells as described in section 2.5.5.1. 
4.2.2 In vitro splicing reactions. 
The RNA substrate used for all splicing reactions was 32P-labelled rp28, 
produced by in vitro transcription from linearised pT7rp28S by bacteriophage 17 
RNA polymerase, as described in section 2.4.11. 
A 101 standard splicing reaction contained 5al of yeast splicing extract and 
l 4 11 of a 2-fold dilution of labelled transcript. 
4.2.3 Immunoprecipitation reactions. 
For immunoprecipitation reactions using LPRP2 AATP spliceosomes, splicing 
reactions were set up as follows. 
40d of purified spliceosomes (section 2.5.7) were mixed with ll of a 1 in 
12.5 dilution of splicing extract (a 500-fold final dilution). After incubation at 25°C 
for 30 minutes, the reactions were stopped on ice. 5l of reaction mix was removed 
for analysis of the splicing intermediates and products. Immunoprecipitation was 
performed on the remaining 35d as described in section 2.5.8. 
4.3 Results 
4.3.1 Overproduction of PRP2GI  causes a splicing defect and accumulation of 
inactive splicing complexes in vitro. 
To ensure that a splicing defect is observed in vitro on overproduction of 
PRP2° , splicing reactions were performed on S 150-213 cell extracts in which either 
PRP2 or PRP2G  was overproduced. A non-induced PRP2 ° extract was assayed 
as a control. The intermediates and products of the splicing reactions were analysed 
by denaturing gel electrophoresis and autoradiography to detect the labelled 
transcript. Figure 4. 1A shows the results from a typical set of reactions. Extracts 
prepared from cells carrying pBM-PRP2' and grown under non-inducing 
conditions (-GAL) are active and in the presence of ATP, normal splicing is 
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observed (tracks 3 and 4), this is consistent with in vivo data. Extracts prepared 
from the same strain but grown in the presence of galactose (inducing conditions) are 
not active and splicing is not observed even in the presence of ATP (track 5). 
Extracts prepared from cells overproducing wild-type PRP2 are active on addition 
of ATP (tracks 1 and 2). The galactose-induced overproduction of wild-type PRP2 
is not detrimental to splicing. Thus, splicing is inhibited by the presence of high 
levels of the dominant negative protein PRP2 in vitro as well as in vivo. 
The spliceosome complexes formed during the course of a splicing reaction 
can be analysed by native gel electrophoresis. The gel system used resolves three 
complexes: I, II and III as described by Pikielny et al (1986). The order of 
formation of the complexes is: III-I-II. The final complex (II) has been shown by 
others to contain the intermediates and products of the splicing reaction and 
represents the active spliceosome (J. Brown, PhD thesis, 1992). A normal time 
course for complex assembly is shown in figure 4. lB (tracks 1-4). Complex III was 
formed first and was converted to complex I after about 10 minutes. The conversion 
of complex I to II was rapid and complex II formation was also apparent by 10 
minutes. The level of complex II gradually decreased with time suggesting that it 
was unstable and dissociated easily. Tracks 5-8 show a similar time course, for 
reactions with a dominant negative extract rather than wild-type. The formation of 
complexes III and I occurred with the same kinetics as was observed for wild-type. 
However, the conversion to complex II was not seen and even after 60 minutes 
incubation, no complex II was detected (result not shown). Instead, complex I 
accumulated, suggesting either that conversion of complex I to H was extremely slow 
(over 60 minutes as compared to almost instantaneously in wild type extracts) or that 
the spliceosomes were stalled at complex I and unable to convert to complex II. 
There was a weak trace of a band which might correspond to complex H, visible in 
tracks 5-8. However, no splicing activity was observed for this extract (section 
4.3. 1) and the appearance of the band at 2 minutes did not follow the kinetics for 
wild-type assembly, thus it is probably not complex II. Cheng and Abelson, (1987) 
identified a fourth complex (A2-1) which is an intermediate between complexes III 
and I, it is possible that the band in tracks 5-8 was A2-1. 
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Figure 4.1 In vitro analysis of the dominant negative allele PRP2 GKN  
In vitro splicing assays 
Splicing extracts were prepared from S150-2B carrying either pBM-PRP2 or pBM-
PRP2 	grown either under repressing conditions (-GAL, tracks 3 and 4) or 
inducing conditions for 5 hours (+ GAL, tracks 1,2 and 5). Standard 10d splicing 
reactions were set up containing 5.d splicing extract and 32P-labelled rp28 transcript, 
in the presence (+ATP, tracks 1, 3 and 5) or the absence (-ATP, tracks 2 and 4) of 
2mM ATP. The RNA was isolated and electrophoresed through a 6% (w/v) 
denaturing polyacrylamide gel and detected by autoradiography at -70°C. 
Abbreviations used: IVS-E2: lariat-intron-exon 2 intermediate 
IVS: lariat-intron product 
pre-mRNA: unspliced precursor mRNA 
mRNA: spliced, mature mRNA. 
Analysis of spliceosome complexes by native gel electrophoresis 
101d splicing reactions were assembled using galactose grown extracts of S150-213 
carrying either pBM-PRP2 (tracks 1-4) or pBM-PRP2 ° (tracks 5-8) and with 
2mM ATP in each reaction. The reactions were incubated at 25°C for 2, 5, 10, 20 
and 30 minutes. The whole reaction mix was then electrophoresed through a 0.5% 
agarose, 3% polyacrylamide non-denaturing gel at 4°C. The complexes containing 
32P-labelled RNA (rp28) were detected by autoradiography at -70°C. The three 
complexes are denoted I, II and III after Pikielny et al (1986). 
Inhibition of a wild-type extract by a dominant negative extract. 
Galactose-grown extracts of S 150-213 carrying either pBM-PRP2" or pBM-PRP2 °' 
and buffer D were mixed in a standard splicing reaction. The extract:extract/buffer 
mixtures were incubated at 25°C for 5 minutes prior to adding to the splicing 
reaction mix. The reaction in track 1 contains 2/Al of dominant negative extract and 
3j.d buffer D, the reaction in track 6 contains 2d wild-type extract and 31d buffer 
D, the remaining four tracks (2-5) contain mixtures of wild-type and dominant 
negative extracts to 5l. Abbreviations: as above. 
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4.3.2 PRP2" and PRP2 G104  compete for interaction with other components of the 
splicing reaction. 
The model for dominant negative action described in section 3.1 suggests that 
the wild type and mutant proteins compete with each other for interaction with the 
spliceosome or other splicing factors. The model showed that as the dominant 
negative mutant protein is produced in excess, it will successfully out-compete 
PRP2 for binding. Thus lowering the amount of dominant negative protein or 
increasing the amount of wild-type should decrease the competitive advantage of the 
dominant negative and when it is at a great enough dilution, it will no longer be able 
to inhibit the splicing reaction. 
Figure 4. 1C shows the effects of mixing dominant negative and wild-type 
extracts together in different proportions. Each reaction mix contained a total of 5d 
of splicing extracts or buffer. Track 6 shows that when 2jzl of wild-type extract only 
was present, splicing took place as normal. In contrast, track 3 shows that in the 
presence of 3.d of dominant negative extract, the splicing activity of the wild-type 
extract was inhibited. Addition of more wild-type extract and a decrease in the 
amount of dominant negative extract caused some restoration of splicing (tracks 4 
and 5). However, in order to see a normal level of splicing activity, the dominant 
negative extract must be diluted even further. Thus, by decreasing the amount of 
dominant negative protein in the splicing reaction mix, splicing can take place as the 
wild-type protein now has the competitive advantage. This interpretation assumes 
that although it has lost or altered function, the dominant negative protein still retains 
the ability to bind to another factor/s involved in splicing or even to form a 
functional heterodimer with wild-type PRP2. 
4.3.3 The interaction of PRP2GI  with spliceosomes is not transient. 
Immunoprecipitation experiments were used to investigate the 
spliceosome:PRP2°'° interaction. It has already been demonstrated that the 
interaction of wild-type PRP2 with the spliceosome is transient and that the 
temperature-sensitive prp2-1 protein fails to interact with the spliceosome when it has 
been inactivated (King and Beggs, 1990). Furthermore, PRP21I,  another dominant 
negative protein has been shown to become jammed in the splicing complex, thus 
preventing the active spliceosome from being formed (Plumpton et a!, 1994). If 
PRP2°' has a stable interaction with the spliceosome, then 32P-labelled pre-mRNA 
should be co-precipitated from mutant splicing reactions with PRP2-specific 
antibodies. 
For the immunoprecipitation reactions, spliceosomes were prepared that 
lacked both PRP2 and ATP (LWRP2, AATP spliceosomes, section 2.5.7). In heat-
inactivated prp2-1 extracts, although no splicing is observed, the spliceosome is fully 
assembled (complex I). The prp2-1 protein is unable to interact with the 
spliceosome at all (King and Beggs, 1990). Thus on addtion of only PRP2 protein, 
splicing can take place. Kim and Lin (1993) showed that if the preformed 
spliceosomes produced from an inactivated prp2-1 splicing extract were incubated 
with glucose, then the intrinsic hexokinase activity of the extract was activated and 
the ATP present in the extract was effectively depleted during the hexokinase 
reaction. Addition of PRP2 protein and suitable concentrations of ATP (2mM) could 
restore splicing but addition of either PRP2 or ATP alone could not restore splicing. 
Using these APRP2 AATP spliceosomes, it is possible to investigate the interactions 
of wild-type PRP2 and the dominant negative PRP2 proteins with the spliceosome 
by immunoprecipitation with anti-PRP2 antibodies. In the presence of ATP, PRP2 
has a transient interaction with the spliceosomes (which had previously been 
demonstrated by immunoprecipitation from splicing extracts, King & Beggs, 1990), 
and co-immunoprecipitation of labelled pre-mRNA transcripts with PRP2 by PRP2-
specific antibodies cannot be detected. However, in the absence of ATP, although 
splicing does not occur, the labelled transcript is co-immunoprecipitated with PRP2 
suggesting that entry of PRP2 into the spliceosome is ATP-independent (Teigelkamp 
et al, 1994). So, addition of any PRP2-containing extract to the LPRP2, AATP 
spliceosomes in the absence of ATP should result in the co-immunoprecipitation of 
pre-mRNA, if the PRP2 protein is able to enter the spliceosome. As ATP hydrolysis 
is not required for the initial interaction of PRP2 with the spliceosome (Kim and Lin, 
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1993; Teigelkamp et al, 1994), addition of PRP2 alone did not allow the splicing 
reaction to take place and pre-mRNA could be immunoprecipitated. Addition of 
purified PRP2 (section 2.5.9) and ATP (2mM) allowed the splicing reaction to 
proceed and no pre-mRNA could be detected after immunoprecipitation. In contrast, 
even on addition of ATP, Teigelkamp et a! (1994), pre-mRNA could still be 
immunoprecipitated from reaction mixes of iPRP2, AATP spliceosomes and PRP2` 
extract. 
For the immunoprecipitation experiment shown in figure 4.2, lOng purified 
PRP2 or PRP2" protein or a 1 in 500 final dilution of a cell extract carrying 
overproduced PRP2G  protein was used in each reaction. These concentrations of 
PRP2 protein have been demonstrated to give optimum immunoprecipitation activity 
by avoiding saturation of the antibodies by free PRP2 molecules (M. McGarvey, 
pers. comm.). Excess antibody was also used to ensure efficient precipitation 
despite the high levels of PRP2 protein. 
Anti-PRP2 antibodies strongly precipitated pre-mRNA from all splicing 
reactions if ATP was not added (tracks p1 and p3) and no splicing occurred (tracks 
si and s3). On addition of ATP, no pre-mRNA was precipitated from the wild-type 
splicing reaction (track p2), showing the transient interaction of PRP2. The splicing 
intermediates and products in track s2 show that normal splicing takes place. 
However, in both dominant negative reactions, the pre-mRNA was still precipitated 
on addition of ATP (tracks p4 and p5) indicating that PRP2 as well as PRP21I 
remained stably associated with the spliceosome, and as expected, splicing 
intermediates are not observed (tracks s4 and s5). 
Figure 4.2 Immunoprecipitation reactions 
50d splicing reactions were set up using 401.d preformed i.WRP2 iATP 
spliceosomes and either 11 of a 1 in 12.5 dilution of a galactose grown splicing 
extract from S150-2B carrying pBM-PRP2 °' (tracks 3 and 4) or lOng of purified 
PRP2 (tracks 1 and 2) or PRP2dhhl  (track 5),both in the presence (+ATP, tracks 2, 
4 and 5) and absence (-ATP, tracks 1 and 3) of 2mM ATP. The reactions were 
incubated at 25°C for 30 minutes and then stopped on ice. 5l of each reaction was 
removed for analysis of the RNA in a splicing reaction (tracks sl-s5) and the 
remaining 45d was mixed with PAS-bound anti-PRP2 antibodies (80J aSS) for 2 
hours at 4°C. The co-immunoprecipitated RNA was isolated and electrophoresed 
through a 6% (w/v) denaturing polyacrylamide gel and detected by autoradiography 
(tracks pl-p5). 
Abbreviations used: IVS-E2: lariat-intron-exon 2 intermediate 
IVS: lariat intron product 
pre-mRNA: unspliced precursor mRNA 
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The results presented in this chapter have shown that the splicing defect 
caused in vivo by overproduction of the dominant negative protein PRP21  is 
reproduced in vitro. Having demonstrated that splicing is inhibited in vitro, the cell 
extracts have been used to further investigate the nature of the block to splicing using 
a variety of analytical techniques. 
Denaturing gel electrophoresis of labelled transcripts showed that extracts 
obtained from cells overproducing dominant negative PRP2 protein are unable to 
splice the transcript. Neither intermediates nor products of the splicing reaction 
were seen, indicating that the dominant negative protein blocked the splicing reaction 
prior to the first cleavage-ligation step. In contrast, extracts from cells 
overproducing wild-type PRP2 can splice pre-mRNA efficiently. 
Investigation by native gel electrophoresis of splicing complex formation 
showed that the presence of the dominant negative protein prevented the conversion 
to the active spliceosome (complex II) and that instead, an accumulation of complex 
I occurred. The three complexes resolved resemble those identified by Pikielny et 
a! (1986) and thus, complex I corresponds to the fully assembled but inactive 
spliceosome. Step 1 is thought to occur at about the same time as conversion to the 
active spliceosome. 
Evidence that the dominant negative protein competes with wild-type for 
interaction with other splicing factors or the spliceosome itself has been demonstrated 
by mixing a wild-type extract (in which PRP2 was overproduced) with various 
amounts of an extract in which the dominant negative protein PRP2 is 
overproduced. Decreasing the amount of the dominant negative extract gradually 
allowed splicing to be restored. Thus, when wild-type protein is in excess, it can 
out-compete the dominant negative protein. This competition effect has also been 
shown in vivo (section 3.4) where simultaneous overproduction of dominant negative 
and wild type PRP2 allowed growth on galactose. 
The use of a procedure to produce preformed spliceosomes, deficient for both 
PRP2 and ATP has facilitated the investigation of the nature of the interaction of 
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PRP2 with the spliceosome. Previous work by Teigelkamp et a! (1994) had shown 
that wild-type PRP2 protein interacts stably with the spliceosome in the absence of 
ATP. On addition of ATP, the interaction is transient. However, using a dominant 
negative PRP2 protein (PRP2thI),  they showed that the dominant negative protein 
remained stably associated with the spliceosome even in the presence of ATP. 
Immunoprecipitation reactions using zPRP2 LATP spliceosomes and cell extracts 
overproducing PRP2 showed that PRP2 °' also has a stable interaction with the 
spliceosome in both the absence and presence of ATP. Even on addition of ATP, 
the pre-mRNA was still immunoprecipitated. This result confirms that PRP2 and 
PRP2° compete for binding to the spliceosome rather than PRP2' binding to and 
sequestering some other, non-spliceosomal factor essential for PRP2 function. 
The last two chapters have described the isolation and characterisation of 
dominant negative alleles of PRP2. By analysing RNA extracted from cells in which 
the mutant proteins were overproduced, it was possible to confirm that the mutant 
proteins were affecting the splicing reaction, in vitro analysis of one of the 
dominant negative alleles, PRP2', showed the splicing defect to be evident in cell-
free splicing assays. These dominant negative proteins offer a powerful tool with 
which to investigate the role of PRP2 in the splicing reaction. Two approaches are 
possible. First, the biochemical defects of the dominant negative proteins can be 
analysed which may help to explain why it remains associated with the spliceosome 
and prevents the conformational change and step 1 from occurring. Second, a 
genetic approach to isolate suppressors of the defect can be used. Alterations in 
other proteins with which PRP2 interacts may alleviate the galactose-induced growth 
defect. Chapter 5 describes the biochemical analysis of PRP2N. 
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CHAPTER 5 
Biochemical analysis of partially purified 
ppGKN 
5.1 Introduction 
Chapters 3 and 4 have described the production by site directed mutagenesis 
and in vivo analysis of three dominant negative alleles of PRP2, and the in vitro 
analysis of one of these, PRP2GI.  The single amino acid changes were engineered 
within the conserved Motif I of the PRP2 protein. Motif I is hypothesised to be 
involved in binding of ATP. This motif is involved in binding the phosphate groups 
and thus, a similar binding motif is found in many other proteins which bind other 
NTPs. Thus, by following work on H-ras (a GTP-binding protein) it may be 
possible to draw some conclusions about the mode of action of PRP2, using the well 
documented ras proteins as a model. The dominant inhibitory mutants of H-ras 
described in Chapter 3 had a higher affinity for GDP than for GTP (Feig & Cooper, 
1988; Farnsworth & Feig, 1991) so, because the mutations to produce the dominant 
negative PRP2 proteins were the same as those in If-ras, it is reasonable to assume 
that the binding of ATP may be affected. PRP2 is an RNA-dependent ATPase (Kim 
et al, 1992) so, if binding of ATP is changed in some way, then the dominant 
negative proteins may have altered ATPase activity. By analogy with the H-ras 
model, ADP-bound PRP2 may well be in an inactive state, requiring ATP binding 
to become activated. Alternatively, PRP2 may be unable to bind either ATP or 
ADP or may bind ATP incorrectly. These alternatives would mean that PRP2 does 
not function in a manner analogous to ras which would not then be a valid model. 
This chapter describes the purification of PRP2 and PRP2 cKN proteins and 
the assays performed on the purified proteins to investigate the altered properties of 
the mutant protein. 
102 
5.2 Methods and materials 
5.2.1 Histidine tagging 
The construct used for histidine tagging was pTZP2E-H. This plasmid 
carried the GALl promoter and the first 800 base pairs of PRP2 with the his tag 
inserted into the Ba,nHl site between them. The histidine tag had actually been 
designed for use in tagging another protein and site directed mutagenesis was used 
to add one nucleotide 5 bases upstream of the PRP2 ATG initiation codon in order 
that PRP2 was translated in the correct reading frame. 
The oligonucleotide used for the site-directed mutagenesis was: 
-the additional nucleotide is underlined. 
NAME SEQUENCE 
574S 5 GACATGCGGACTCGGCCCTCG3 ' 
Site-directed mutagenesis was carried out as described in section 2.4.4. The 
EcoRI-HindIll restriction fragment was isolated and sub-cloned into pBM-PRP2 or 
pBM-PRP2°' to produce the plasmids pBM-PRP2 and pBMPRP2G.  Figure 
5.1 shows the major steps involved in producing these plasmids. By transforming 
these plasmids into S150-2B and testing for growth on glucose and galactose, it was 
possible to demonstrate that the his tag was not detrimental to wild-type function or 
dominant negative inhibition. 
5.2.2 Purification procedure and concentration determination 
Purification of wild-type his-tagged PRP2 was carried out as described in 
section 2.5.9. The abberant RNA-binding properties of PRP2G  (section 5.3. 1) 
meant that only the first step of the purification could be used. The fractions of the 
200mM imidazole elution step used for assays were pooled fractions 7 and 8 (7/8) 
and fraction 9 which contains a lower amount of contaminating proteins. A fraction 
of the 50mM wash containing the 45 and 50 kDa proteins at approximately the same 
concentrations as those in fractions 7/8 was used as a negative control (w6). 
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Figure 5.1 Production of the plasmids pBM-PRP2 and pBMPRP2G. 
Site directed mutagenesis using oligo 574S was used to insert one base (*) upstream 
of PRP2 in pTZP2HIS in order to put the his-tag in frame with the PRP2 gene. The 
0.9kb HindIII-EcoRI fragment was cut out and isolated by gel electrophoresis. The 
small 1.6kb EcoRI-HindIII fragment was cut out and removed from pBM-PRP2 or 
pBM-PRP2'. The two Eco-Hin fragments (0.9kb and 9.9kb) were ligated together 
to produce pBM-PRP2 and pBM-PRP2° . The construct containing PRP2 fused 
to the his-tag could be identified by cutting with KpnI as an additional diagnostic 
KpnI site is located within the his-tag. 
Abbreviations used: his6 : histidine tag 
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The concentrations of all proteins purified by one- or two-step procedures 
were estimated by comparing the intensity of staining on a Western blot with known 
concentrations of PRP2 protein. 
5.2.3 In vitro splicing assays 
Standard lO/Ll reactions were set up as described in sections 2.5.5.2 and 
4.2.2. Extracts were mixed with purified proteins to a final volume of 5i.d which 
was then incubated at 25°C with 5d splicing reaction buffer. 
Splicing and immunoprecipitation reactions performed with LPRP2 LATP 
spliceosomes were carried out as described in section 4.2.3. For each reaction, lOng 
purified protein was added to the spliceosomes, and where appropriate, ATP was 
added to 2mM. 
5.2.4 ATPase assays 
ATPase assays were performed as described in section 2.5.10. In each 
reaction, 60ng of purified protein was used. The assay mix was incubated at 25°C 
for 60 minutes. For reactions involving alternative RNA substrates, the RNA 
concentration is indicated in the figure legend. 
5.3 Results 
5.3.1 PRP2 GKN does not bind poly(U) RNA. 
The two step reaction procedure described in sections 2.5.9 and 5.2.2 exploits 
two properties of the histidine-tagged (his-tagged) PRP2 proteins, namely, that poly 
histidine tracts bind to nickel chelating resin and that PRP2 can bind poly(U) RNA 
well. Wild-type PRP2 can be easily purified to homogeneity using this system (M. 
Plumpton, PhD thesis 1993). His-tagged PRP2 can be bound to and eluted off 
the Ni-NTA column under the same conditions as wild-type, with a comparable yield 
of partially purified protein. However, the threonine-'asparagine mutation appears 
105 
Figure 5.2 Poly(U) agarose column purification of PRP2 protein 
A wild-type purification (provided by M. Plumpton, this lab) 
Aliquots of fractions from the second step of the purification were electrophoresed 
through a 7.5% SDS-polyacrylamide gel which was silver stained to detect proteins. 
Track 1: pooled PRP2-containing fractions from Ni-NTA column (NV) (301.d); track 
2: run through after sample had been circulated on column (rt) (301.d); tracks 3 and 
4: the first and last fractions of the 100mM KC1 wash (30/d); tracks 5 and 6: 
fractions 11 and 12 eluted during the 250mM KC1 wash (30/Ll). 
M: size markers, sizes are in kDa. 
A pRp2GKN  purification 
Aliquots of fractions from the second step of the purification were electrophoresed 
as above. The concentrations of the proteins were too low to be detected by silver 
staining, this is a Western blot probed with crude anti-PRP2 antibodies (a 140). 
Track 1: original extract before Ni-NTA (x) (2d); track 2: run through (rt) (protein 
is in 50mM KC1) (30d); tracks 3 and 4: fractions from the 100mM KC1 wash 
(301.d); tracks 5 and 6: fractions 11 and 12 from the 250mM KC1 wash (30,.d). 
M: size markers, sizes are in kDa. 
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to affect the RNA-binding properties of the protein. Figure 5.2A shows a typical 
poly(U) purification profile for wild-type PRP2 protein. PRP2 was not seen in the 
run-through (rt) tracks and was eluted at 250mM KCI in a concentrated peak. 
Figure 5.2B shows a similar profile for PRP2. Not only was the protein eluted 
in the lowest molarity washes, but a large proportion actually failed to bind at all and 
can be detected in the run-through track. Instead of eluting essentially pure PRp2G 
in a 2m1 peak, the protein isolated from the Ni-NTA column was diluted in wash 
buffer and eluted in approximately 40m1. 
The results from the poly(U) binding step show that, unlike PRP2, purified 
PRP2' has a very low affinity for RNA and fails to bind poly(U) agarose. As 
described in section 5.2.2, the poly(U) step was left out of the purification procedure 
and the partially purified ppGKN  fractions were used in all assays. 
5.3.2 Purified PRP2 is functional and partially purified PRP2G  inhibits 
splicing in vitro. 
The properties of the purified proteins were investigated using the LPRP2 
ATP spliceosome system (section 2.5.7 and 4.2.3). Without addition of PRP2 and 
ATP, no splicing of the pre-mRNA carried in the spliceosomes occurs. If purified 
PRP is functional, then addition of the protein and ATP(2mM) should allow 
splicing to take place. If the dominant negative protein PRP2 ° is still inhibitory 
when partially purified, then even on addition of ATP, no splicing will be observed. 
Figure 5.3A shows a series of reactions performed on the APRP2 i&ATP 
spliceosomes using the two purified or partially purified proteins. Once again, 
splicing and immunoprecipitation reactions were carried out simultaneously on 
aliquots of each reaction mix. 
Addition of purified PRP2 and ATP to the spliceosomes resulted in splicing 
of the pre-mRNA (track si) and the immunoprecipitations showed the transient 
nature of the interaction of PRP2 with the spliceosome (track p1). Absence of ATP 
led to inhibition of splicing and the purified PRP2WI  remained associated with the 
spliceosome (tracks s2 and p2). Addition of partially purified PRP2 to the 
spliceosomes in the absence or presence of ATP prevented splicing from taking place 
(tracks s3 and s4) and the PRP2 1' protein remained associated with the spliceosome 
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(tracks p3 and p4). 
These results are identical to those obtained from similar experiments using 
cell extracts in which PRP2 °' was overproduced. (section 4.3.3). Thus, it appears 
that purified PRP2" is fully active and does not require any cofactors for its function 
other than those already present in the spliceosome and ATP. Similarly, PRP2GJ 
still displays its dominant negative phenotype when partially purified. The 
possibility that the 45 and 50 kDa "contaminants" which are co-purified with 
ppGKN are also required for the dominant negative effect cannot be ruled out, but 
this seems unlikely as they are not necessary for PRP21 function nor for the 
dominant negative effect shown by PRP2' (M. Plumpton, PhD thesis, 1993) nor 
do they have any effect on the ATPase activity of PRP2 (section 5.3.4). 
5.3.3 Partially purified PRIP2(;KN inhibits splicing in a wild-type extract and 
causes accumulation of complex I. 
The competition model described in section 3.1 demonstrated how the 
dominant negative protein could compete with the wild-type protein for binding to 
other splicing factors. By mixing cell extracts in which either PRP2 or PRP2 11  
was overproduced it was possible to prevent the splicing reaction from occurring 
despite the presence of high amounts of PRP2. As the dominant negative extract 
was diluted, splicing was restored (section 4.3.2). By using the partially purified 
Pm2G dominant negative protein in splicing reactions with wild-type extracts, it 
was possible to ensure that it was the presence of overproduced PRP2 protein 
which was stalling the splicing reactions. 
Figure 5.3B shows the effect of partially purified PRP21I  on the splicing 
activity of a wild-type extract. Previous results (not shown) had shown that 31d of 
partially purified PRP2 was able to inhibit splicing of 2l of wild-type extract. 
The dominant negative protein was then diluted in buffer D by 2-, 10-, 100- and 
1000-fold while the extract remained undiluted (tracks 2, 3, 4 and 5 respectively). 
As the protein was diluted, splicing intermediates and products were detected by 
denaturing gel electrophoresis, indicating a gradual restoration of splicing. 
Addition of inhibitory concentrations of partially purified PRP2 	to wild- 
type splicing reactions, followed by native gel electrophoresis allowed the analysis 
Figure 5.3 In vitro analysis of partially purified PRP2G 
Splicing and iinmunoprecipitation assays 
50d reactions were assembled using 40jzl pre-formed LPRP2 iATP spliceosomes 
and lOng of purified PRP2 (tracks 1 and 2) or partially purified PRP2 (tracks 
3 and 4) in the presence (+ATP, tracks 1 and 3) and the absence (-ATP, tracks 2 
and 4) of 2mM ATP. The reactions were incubated at 25°C for 30 minutes and then 
stopped on ice. 541 of each reaction was removed for analysis of RNA in a standard 
splicing reaction (tracks sl-s4). The remaining 45d was mixed with PAS-bound 
anti-PRP2 antibodies (801.d, a55) for 2 hours at 4°C. The co-immunoprecipitated 
RNA was electrophoresed through a 6% (w/v) denaturing polyacrylamide gel and 
labelled RNA detected by autoradiography at -70°C (tracks pl-p4). 
Abbreviations used: IVS-E2: lariat-intron-exon 2 intermediate 
IVS: lariat intron product 
pre-mRNA: unspliced precursor mRNA 
Inhibition of wild-type splicing activity by partially purified PRP2GI. 
lO/Ll splicing reactions were set up each containing 2d wild-type extract and 311 
partially purified PRP2 4. The protein was diluted 2, 10, 100 and 1000-fold (tracks 
2, 3, 4 and 5 respectively). The reactions were incubated at 25°C for 30 minutes in 
the presence of 2mM ATP. The RNA was extracted and electrophoresed through 
a 6% denaturing polyacrylamide gel and visualised by autoradiography at -70°C. 
Abbreviations as before. 
Native gel electrophoresis to analyse splicing complexes formed 
10d splicing reactions were set up containing 2Ll wild-type splicing extract and 3141 
partially purified PRP2 	(track 3), 3al purified PRP2'° 1 (track 2) or 31 buffer D 
(track 1), 2mM ATP and 32P-labelled rp28 transcript. The reactions were incubated 
at 25°C for 20 minutes and the splicing complexes formed analysed by 
electrophoresis through a 0.5% (wlv) agarose 3% (w/v) polyacrylamide non-
denaturing gel at 4°C followed by autoradiography at -70°C. The complexes are 
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of the spliceosome complexes formed during the reaction. The reaction mix was 
incubated at 25°C for 30 minutes before the complexes were electrophoresed. Figure 
5.3C shows the complexes resolved from normal and inhibited splicing reactions. 
After 20 minutes incubation, complex H, the active spliceosome was present in the 
normal, wild type reaction indicating that splicing was occurring (track 1). 
However, after 30 minutes incubation, the PRP24nhibited reaction showed an 
accumulation of complex I (track 3), just as was observed for splicing reactions 
performed on an extract from cells overproducing PRP2. Thus, the partially 
purified PRP21  exhibits the same inhibitory characteristics which were assigned 
to the dominant negative extracts, confirming that it was the presence of 
overproduced PRP2 °' in the extract which caused the splicing inhibition. 
5.3.4 PRP2' has negligible RNA-stimulated ATPase activity. 
PRP2 is an RNA-stimulated ATPase (Kim et a!, 1992) that is, in the presence 
of RNA, PRP2 can hydrolyse ATP to ADP with the release of the -y-phosphate. The 
ATPase activity of PRP2 can be measured by using ['y- 32P]-labelled ATP as the 
substrate. The concentration of [-y- 32P]Pi released can be calculated by Cerenkov 
counting. The activity of PRP2G  was measured using this assay. The results of 
ATPase assays on purified PRP2 and two different fractions of PRP2 °' are shown 
in figure 5.4A. In each reaction, 60ng of PRP2 protein was incubated with 11.LCi ['y-
32P]-ATP for 1 hour at 25°C. 
PRP2 (lane 1) caused release of between 3.5 and 4 nmoles of phosphate in 
one hour, in the presence of poly(U) RNA. Lane 5 shows the non-RNA-stimulated 
activity of the same amount of PRP2. The activity of the 45 and 50kDa 
contaminants was assayed using the w6 fraction in which there is no PRP2. Even 
in the presence of RNA these two proteins showed negligible ATPase activity, 
releasing only 0.1 nmole Pi (lane 4). The two fractions containing PRP2G (lanes 
2 and 3) had activities similar to that shown by PRP2' in the absence of RNA. This 
result suggests that PRP21  is not an RNA-stimulated ATPase. Previous results 
from the purification procedure showed that PRP2G  was unable to bind poly(U) 
RNA well (section 5.3.1), therefore, it would be reasonable to expect that PRP2G 
would not be stimulated by poly(U) RNA. Various other RNA substrates were 
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Figure 5.4 ATPase assays 
60ng purified PRP2 (wt, lane 1) or partially purified PRP2G  (GKN7/8 and 
GKN9, lanes 2 and 3) were incubated in the presence of poly(U) RNA (0 .5 jLgd') 
and ['y-32P] ATP (1mM) for 1 hour at 25 °C. The y-"Pi released was measured by 
Cerenkov counting. GKN7/8 and GKN9 are different fractions eluted from a single 
Ni-NTA column purification. W6 (lane 4) is a fraction containing only the 45 and 
50kDa contaminating proteins. The activity of PRP2 in the absence of poly-U was 
also measured (-RNA, lane 5). 
The effect of alternative RNA substrates on PRP2 ATPase activity 
60ng purified PRP2" (wt) or partially purified PRP2 	(GKN) were incubated as 
above but in the presence of various different RNA substrates. 
The RNA concentrations in the assays were: poly(U): 0.5/g/Ll'(lane 1) 
poly(A): 0.5jgd'(lane 2) 
poly(G): O.5gjz1'(lane 3) 
E. coli tRNA: O.5/Lg/Lt 1 (lane 4) 
yeast total RNA: O.5jgd'(lane 5) 
Additionally, 60ng PRP2 was mixed with approximately 50 (lane 7) or lOOng (lane 
8) or Ong (lane 6) of 45 and 50 kDa contaminating proteins before proceeding with 
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tested to identify any that might cause increased ATPase activity in PRP2N.  Figure 
5.4B shows that poly U was the most effective stimulatory substrate for PRP2 (lane 
1) and that none of the other RNAs tested was able to stimulate PRP2 GKN to an 
activity greater than the -RNA level (lanes 2, 3, 4 and 5). 
To ensure that the 45 and 50kDa proteins did not have a detrimental effect 
on PRP2 activity, PRP2 protein was mixed with w6 fraction so that the 
contaminating proteins were at the same or higher concentrations as found in the 
PRP2 fractions. The PRP2:w6 mixture was assayed to determine the ATPase 
activity, which was at normal wild-type levels, indicating that the presence of w6 in 
the reaction did not cause a decrease in the RNA-stimulated ATPase activity of the 
wild-type protein (lanes 6, 7 and 8). 
5.3.5 Partially purified PRP2GKN  and PRP2 can be cross-linked to the pre-
mRNA 
Proteins which are in close contact with RNA can be covalently linked to the 
RNA by UV cross-linking. By using a labelled RNA species, it is possible to detect 
cross linked proteins by autoradiography. Using 32P-labelled pre-mRNA in 
preformed LPRP2 AATP spliceosomes, Teigelkamp et al (1994) showed that PRP2WI 
protein became cross-linked to the pre-mRNA in the absence of ATP but no cross-
linking was detected on addition of ATP. The dominant negative PRP2" protein 
could be cross-linked to the pre-mRNA in both the absence and presence of ATP. 
Thus, PRP2 binds to the pre-mRNA within the spliceosome complex until 
hydrolysis of ATP, when the contact is released. The mutant proteins PRP2 and 
PRP2 (chapter 6) do not bind to single-stranded poly(U) RNA (sections 5.3.1 and 
6.3.2.3) so it was important to test whether these two mutant proteins could bind to 
the pre-mRNA in the spliceosome. 
Figure 5.5 shows the results of UV irradiation and the subsequent 
immunoprecipitation of PRP2 from zPRP2zATP spliceosomes. In each reaction, 
60ng of purified or partially purified PRP2 protein was added to the spliceosomes. 
Tracks 3 and 4 show the results of cross-linking and immunoprecipitation of PRP2 
in the absence (track 3) and presence (track 4) of 2mM ATP. The band detected 
corresponded to PRP2 protein on a Western blot and confirmed that PRP2 could 
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Figure 5.5 Cross-linking analysis 
60ng of purified PRP2 (tracks 1-4), PRP2' (track 5), PRP2IT (track 6) or 
PRP2 (track7) were incubated with 40/Ll preformed LPRP2 zATP spliceosomes 
carrying [a-32P] labelled rp5l transcript (provided by S. Teigelkamp, this lab) in the 
presence (+, tracks 4-7) or absence (-, tracks 1-3) of 2mM ATP. After incubation 
at 25°C for 30 minutes, the reactions in tracks 2-7 were UV-irradiated for 30 
minutes, on ice. One reaction (-UV, track 1) was not irradiated. After Proteinase 
K digestion, immunoprecipitation of PRP2 was performed at 4°C using either anti-
PRP2 antibodies (a54, tracks 1, 3-7) or pre-immune serum (P1, track 2). After 
SDS-PAGE, the gel was dried for 2 hours at 80°C before autoradiography at -70°C 
to detect labelled proteins. 
The numbers at the left-hand-side of the figure correspond to proteins size markers; 
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only be cross-linked to the pre-mRNA in the absence of ATP. Track 2 shows an 
immunoprecipitation with pre-immune serum (PT) of PRP2 from preformed 
spliceosomes, in the absence of ATP. No PRP2 was detected which confirmed that 
PRP2 was being specifically immunoprecipitated by anti-PRP2 antibodies. Track 5 
shows the result of UV irradiating and immunoprecipitating PRP2" from preformed 
spliceosomes in the presence of 2mM ATP. PRP2' remained bound to the pre-
mRNA even in the presence of ATP. Tracks 6 and 7 show the results of UV 
irradiation and immunoprecipitation of PRP2 from reactions containing PRP2GI 
(track 7) or PRP2' (track 6). Even in the presence of ATP, a labelled band 
corresponding to PRP2 was detected in both tracks. Thus PRP29  and  PRP2l(T 
were both able to bind to the pre-mRNA. Track 1 is a no cross-link control (-UV). 
The reaction with PRP2' was set up in the absence of ATP and performed as normal 
except for the UV irradiation step. The PRP2 1 immunoprecipitated was not 
labelled. 
5.4 Discussion 
This chapter describes the purification and preliminary characterisation of the 
dominant negative protein PRP2'. The two-step purification system has been used 
to purify wild-type PRP2 protein. Purified PRP2WI  is able to complement heat 
inactivated pip2-1 splicing extracts, confirming that it is functional (M. Plumpton, 
PhD thesis, 1993). Thus, the assays performed on purified PRP2 proteins probably 
give a true indication of the activity of PRP2 proteins in vivo. Partially purified 
PRP2' has been shown to retain its dominant negative phenotype because it could 
still inhibit wild-type splicing reactions, causing accumulation of complex I, the fully 
assembled but inactive spliceosome. During the purification of PRP2N,  the loss 
of ability to bind RNA was observed when the partially purified protein from the Ni-
NTA column failed to bind to poly(U) agarose. This result suggests that, by analogy 
with ras, PRP2 may be locked in an inactive form and, as such, cannot bind 
RNA. The RNA-stimulated ATPase activity of PRP2 was, as expected, equal to 
the non-RNA-stimulated activity of PRP2. It is impossible to tell whether PRP2 
actually has normal ATPase activity which cannot be stimulated due to the inability 
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to bind RNA, or whether the ATPase activity of PRP21 has also been affected by 
the mutation. 
The H-ras mutants bound GDP with a much higher affinity than normal 
which prevented the protein from be activated by GDP/GTP exchange (Feig and 
Cooper, 1988; Farnsworth and Feig, 1991). In an attempt to discover whether 
PRP2' was binding ADP with a much higher affinity than usual, ADP/ATP 
competition assays were attempted. Unfortunately, it was not possible to measure 
the exchange rate of ADP for ATP because even PRP2 was unable to bind labelled 
ADP in the first instance. Various methods were employed to force PRP2 to bind 
labelled ADP or ATP, but the results were inconclusive. PRP2 and PRP2 were 
unable to bind [a-32P]ADP, so [a- 32P]ATP, which can be hydrolysed by PRP2 was 
used instead. If the PRP2' proteins could bind and hydrolyse [a- 32P]ATP and if its 
concentration in the reaction mix was limiting, then some [a- 32P]ADP might remain 
bound to the PRP2 protein. After immunoprecipitation, the PRP2 proteins were 
analysed by Cerenkov counting to determine if they were labelled. The results 
obtained were variable and although ATP hydrolysis occured, the proteins were not 
consistantly labelled under indentical reaction conditions. PRP21' did not appear 
to bind [a-32P]ATP or [a-32P]ADP. ATP-binding has not been demonstrated for 
PRP2 which may require a cofactor for binding or exchange of bound ADP by ATP. 
Such a cofactor would be a nucleotide exchange factor although no ADP/ATP 
exchange factor has yet been identified. Exchange factors may conceivably be 
isolated as suppressors of the dominant negative phenotype of mutants such as 
ppGKN 
Preliminary cross-linking results, show that PRP2 1' protein is able to bind 
to the pre-mRNA in the spliceosome. This was a surprising result because the 
protein did not bind to the poly(U) agarose nor did it show any RNA-stimulated 
ATPase activity in the presence of a variety of RNAs. Thus, it seemed unlikely that 
PRP2GT would be able to bind to the pre-mRNA. One possible explanation is that 
PRP2Gl has lost or reduced ability to bind single-stranded RNA, but that the pre-
mRNA in the spliceosome is actually double-stranded. If PRP2 acted to destabilise 
RNA:RNA interactions, then the pre-mRNA may be half of the substrate for 
destabilisation. So, although the mutation in PRP2 ° prevents the normal 
destabilising activity from occurring and affects the ability of PRP2 91 to bind the 
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products of destabilisation (which would be single-stranded), the mutant still retains 
the ability to bind the substrate, double-stranded RNA. 
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Production and characterisation of a further 
dominant negative mutant of PRP2 
6.1 Introduction 
Chapters 3-5 have described the production and characterisation of mutant 
PRP2 proteins with substitutions of amino acid 253, the threonine of Motif I, thought 
to be involved in ATP binding. The following two chapters describe another 
mutation made within Motif I and the preliminary characterisation of the mutant 
protein. 
RAS2 is one of the yeast RAS proteins, its mode of action is similar to that 
of H-ras as it has inactive (GDP-bound) and active (GTP-bound) states. A mutant 
RAS2 protein RAS2 22  was isolated which interfered with the function of wild-type 
RAS2 in S. cerevisiae. The mutant protein appeared to block CDC25 activity as 
overproduction of CDC25 protein could overcome the block if wild-type RAS2 was 
present (Powers et al, 1989). It was proposed that the dominant RAS mutant formed 
a complex with CDC25 protein, sequestering it so that it was unable to perform its 
normal nucleotide exchange functions (Broek et al, 1987). The mutation 
glycine22-'alanine is within the conserved nucleotide binding region. The model 
proposed by Powers et al (1989) suggests that RAS2 and CDC25 normally undergo 
a transient interaction. CDC25 interacts with the GDP-bound form of RAS2, 
stabilising the nucleotide-free RAS2 as nucleotide exchange takes place. When GTP 
is bound, CDC25 is released. Thus, RAS2 proteins with an impaired ability to bind 
GTP will be unable to release CDC25 and cause a depletion of free CDC25 in the 
cell so wild-type RAS2 cannot be activated. The equivalent glycine-alanine change 
in H-ras produced a dominant inhibitory mutant in NIH 3T3 cells. Both H-ras' 5 
and all the H-ras' 7  mutants could be suppressed by overproduction of CDC25 in 
IVA 
S. cerevisiae (Powers et al, 1989; Schweighoffer et al, 1993). 
No nucleotide exchange factors have been found for ATP binding proteins so 
it is uncertain whether the exchange factor sequestering model can be used to explain 
the dominant negative phenotype of PRP2 mutants. If, however, such an exchange 
factor exists, the dominant negative proteins offer a convenient way to identify and 
isolate it. 
In order to repeat the RAS2 results, the glycine'-'alanine mutation was 
engineered in PRP2 and the properties of the resulting protein investigated. This 
chapter describes the production and in vivo and in vitro characterisation of PRP2'. 
6.2 Methods and materials 
6.2.1 Synthetic oligonucleotide used for site directed mutagenesis. 
Mismatched base is underlined. 
NAME SEQUENCE AMINO 
ACID 
CHANGE 
375V 5 'GG'rITl'AGCAGAACCGG3 ' G-A 
The mutant and wild-type sequences are shown in figure 6. 1A. 
The methods and materials sections of chapters 3-5 detail all the procedures used to 
produce the results presented in this chapter. 
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Figure 6.1 A further amino acid substitution at the GKT motif of PRP2 
Nucleotide sequences of the GKT motif region of the wild-type and mutant PRP2 
alleles. Single stranded sequencing was carried out using the primer 036A. The 
mutated base is underlined. The non-coding strand is shown. The amino acids 
encode by the region shown are denoted by the single letter amino acid code, the 
mutant residue is underlined. 
Analysis of growth on glucose and galactose 
Single colonies from the colony purification of S150-213 transformed with either 
pBM-PRP2' or pBM-PRP2 were resuspended in distilled water to a 
concentration of about iO cells/ml. 101AI drops of the suspensions were spotted onto 
selective YMG1uCas (GLUCOSE) and YMGalRafCas (GALACTOSE) plates and 
incubated at 30°C and 36°C for 3-4 days. 
Analysis of the temperature sensitivity of PR-P2 
Single colonies from DJy36 transformed with pBM-PRP2 	(DJy36: :AKT), 
untransformed S150-2B and untransformed DJy36 were resuspended in sterile 
distilled water. 101.d drops of the suspensions were spotted onto selective 
YMG1uCas (GLUCOSE) and YMGalRafCas (GALACTOSE) plates and incubated 
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6.3 Results 
6.3.1 In vivo investigations. 
6.3.1.1 Wild-type cells carrying pBM-PRP2 AFT fail to grow on galactose at 30°C, 
but do grow at 36°C. 
Once again, expression of the mutant gene, PRP2 was regulated using the 
GALl promoter. In the absence of galactose, the mutant gene is not expressed, but 
in the presence of galactose, it is overexpressed. The plasmid, pBMPRP2T was 
transformed into the wild-type strain S150-2B. Single transformants were 
resuspended in sterile water and spotted onto selective glucose and galactose plates 
(YMGluCas & YMGalRafCas). The plates were incubated at 30°C and 36°C for 
three days. Figure 6. lB shows the results of the screen. On glucose medium when 
expression from the GALl promoter is repressed, the cells grow normally at both 
30°C and 36°C. However, galactose-induced overproduction of the mutant PRP2 
prevented cells from growing at 30°C. PRP2T exhibited an interesting 
temperature-sensitive phenotype. At 36°C, the cells were able to grow as normal on 
galactose (note that cells overproducing PRP2 °' fail to grow at 36°C). Using 
DJy36, a pip2-1 temperature-sensitive strain, it was possible to demonstrate that 
PRP2T was non-functional at 36°C as overproduction of PRP2 did not 
complement the temperature-sensitive phenotype of DJy36 (figure 6. 1C). 
6.3.1.2 Overproduction of PRP2AKT causes a decline in cell growth rate. 
Using a growth curve for cells grown at 30°C, it was possible to demonstrate 
that galactose-induced production of the mutant PRP2 protein caused a decline in cell 
growth rate. S150-213 cells carrying either pBM-PRP2 or pBM-PRP2 were 
grown in non-inducing YMGlyLacCas medium for several hours. A doubling time 
of 3.5 hours was established for the non-induced cells. Galactose was added to the 
culture to a final concentration of 2%. The graph in figure 6.2A shows that both 
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strains continued to grow normally for a further four hours, after which the growth 
rate of cells carrying pBM-PRP2 declined. The cells carrying pBM-PRP2 
continued to grow at a normal rate. The slightly slower initial growth rate of the 
cells carrying pBM-PRP2 is probably because the GALl promoter is not 
efficiently inhibited in the absence of glucose, leading to a low level expression of 
PRP2. Western blots of total protein extracted from the cells after 5 hours 
galactose induction show overproduction of the PRP2 protein (result not shown). As 
the only difference between the two strains used for the growth curve is the plasmid 
they carry, the growth defect can be attributed to the presence of high levels of the 
mutant protein, PRP2T  after galactose induction. 
6.3.1.3 Overproduction of PRP2 causes a pre-mRNA splicing defect at 23°C 
but not at 36°C. 
Overproduction of PRP2T  has been shown to cause a growth defect in wild-
type cells (sections 6.3.1.1 & 6.3.1.2). It is important to ensure that the growth 
defect is due to an effect on pre-mRNA splicing because PRP2 is a splicing factor. 
Pre-mRNA splicing can be analysed by Northern blotting (figure 6.2B). The 
splicing of two interrupted genes of S. cerevisiae, actin and rp28 was investigated. 
Total RNA was extracted from cells carrying pBM-PRP2' grown in glucose or 
galactose at 23°C or in galactose at 36°C. At 30°C in glucose, the two pre-mRNAs 
were efficiently spliced (track 1) but in galactose medium at the same temperature, 
the pre-mRNAs were not spliced and an accumulation of the larger precursor RNA 
was observed (track 2). However, when the temperature was shifted to 36°C, 
galactose grown cells spliced the precursor mRNA efficiently and only the shorter, 
mature mRNA was detected (track 3). Therefore, at 36°C, when PRP2' is 
inactive, it no longer competes with wild-type protein for splicing factors, and 
normal splicing can occur. 
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Figure 6.2 In vivo analysis of the dominant negative allele PRP2" 
Growth curves 
200m1 prewarmed (30°C) YMOlyLacCas was innoculated with xml stationary 
cultures of S150-213 carrying either pBM-PRP2 or pBM-PRP2 (time:-5). The 
cultures were incubated at 30°C with vigourous shaking (200rpm). The growth rate 
was monitored by measuring the OD 6w of the cultures. After 5 hours, 40% 
galactose was added to the cultures to a final concentration of 2% (w/v) (time: 0) and 
the growth rate monitored for a further 18 hours. When necessary, the cultures 
were diluted into YMGlyLacCasGal (prewarmed to 30°C) to maintain logarithmic 
growth. The arrow indicates the time of galactose induction. 
Northern blot analysis 
Total RNA was extracted from S150-2B cells which had been transformed with 
pBM-PRP2 T  and grown under non-inducing conditions (Glu, track 1) or inducing 
conditions (Gal, tracks 2 and 3) at 23°C (track 2) or shifted to 36°C for two hours 
(track 3). The RNA (30g/sample) was denatured and electrophoresed through a 
1.4% (w/v) agarose gel and transferred to Hybond N membrane. The blot was 
hybridised with 32P-labelled actin DNA (actin), then stripped in boiling 0.1 % SDS 
and reprobed with 32P-labelled rp28 DNA (rp28). The unspliced (pre-mRNA) and 
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6.3.2 In vitro investigations. 
6.3.2.1 Overproduction of PRP2mu causes a splicing defect and accumulation 
of complex I in vitro. 
As explained in chapter 4, it is important to show that the splicing defect 
observed in vivo is also seen in vitro. A splicing extract was prepared from wild-
type S 150-213 cells overproducing PRP2 which had been grown at 30°C. A non-
induced extract was also prepared and in vitro splicing reactions were performed 
using a 32P-labelled rp28 transcript. Figure 63A shows the results of a typical set 
of reactions. The wild-type reactions (tracks 1 and 2) show that ATP was required 
before splicing could take place. Tracks 4 and 5 show the results of reactions using 
the non-induced PRP2IT  extract. Normal splicing was observed in the presence of 
ATP. However, even in the presence of ATP, no splicing was observed in the 
reaction using the extract in which ppAKT  was overproduced (track 3). So, just 
like PRP2° , PRP2T  is also inhibitory to splicing in vitro when overproduced. 
A series of dilutions of the galactose-induced extract showed that PRP2 and 
PRP21 competed with each other for splicing factors. The PRP2 1 overproducing 
extract was no longer inhibitory at a 20-fold dilution (result not shown). So the 
model proposed for dominant negative action (section 3.1) holds for PRP2. 
To further investigate the nature of the block to splicing, the complexes 
formed during the course of a reaction were analysed by non-denaturing gel 
electrophoresis. Figure 6.313 shows the complexes formed after a 20 minute wild-
type reaction (track 1) and those formed after a 30 minute incubation in which the 
dominant negative extract was added to a wild-type extract at an inhibitory level 
(track 3). Track 2 shows the result of a 20 minute incubation inhibited by the 
dominant negative allele PRP2-dnl, which caused accumulation of complex I. The 
formation of the active spliceosome or complex II was seen in the wild-type reaction 
but, in contrast, an accumulation of complex I was seen when the dominant negative 
extract was inhibiting the splicing reaction. The trace of complex II which was also 
seen probably corresponded to some splicing activity due to PRP2 being bound 
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to factor X and therefore incompletely blocking the activity of the wild-type extract 
in the reaction mix (see section 6.4). 
6.3.2.2 PRP2' appears not to interact with the spliceosome. 
Immunoprecipitation experiments involving the pre-formed LPRP2 iATP 
spliceosomes were used to investigate the interaction of PRP2AKT with the 
spliceosome. The LPRP2 LATP spliceosomes were prepared as described in section 
2.5.7. A 1 in 500 dilution of cell extract carrying overproduced PRP2 1 or lOng 
of purified PRP2 protein was used for the splicing reactions. Figure 6.3C shows 
the results of the immunoprecipitation and splicing reactions. If PRP2 is associated 
with the spliceosome, then the spliceosome and labelled transcript will be co-
immunoprecipitated with PRP2 by anti-PRP2 antibodies. The labelled transcript can 
be detected by denaturing gel electrophoresis and autoradiography. In the absence 
of ATP, PRP2 entered the spliceosome and labelled transcript was co-
immunoprecipitated (track p1) but splicing did not occur (track si). On addition of 
ATP and PRP2, splicing took place as normal (track s2) and PRP2 was only 
transiently associated with the spliceosome and so only a background level of 
transcript was detected after immunoprecipitation (track p2). In both the absence 
and presence of ATP, the dominant negative extracts prevent splicing from occurring 
(tracks s3 and s4), but in neither case did PRP21  appear to be associated with the 
spliceosome, labelled transcript was not co-immunoprecipitated (tracks p3 and p4). 
The possibility that PRP2 has a transient interaction with the spliceosome like 
wild-type protein, cannot be ruled out, however this seems unlikely as there was no 
immunoprecipitation of the transcript in the absence of ATP, when PRP2" was 
present in the spliceosome. The possibility that PRP2T was not 
immunoprecipitated for some reason was not tested for these reactions, this seems 
unlikely as these antibodies have been demonstrated to immunoprecipitate the mutant 
PRP2AKT protein as efficiently as wild-type in other reactions. 
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Figure 6.3 In vitro analysis of the dominant negative allele PRP2T 
In vitro splicing 
Extracts were prepared from S 150-2B carrying either pBM-PRP2 (PRP2, tracks 1 and 2) or 
pBM-PRP2 grown under inducing conditions for 5 hours (+ GAL, track 3) or under non-
inducing conditions (-GAL, tracks 4 and 5). Standard 10d splicing reactions were set up with 
541 of splicing extract, 32P-labelled rp28 transcript and in the presence (±ATP, tracks 1, 3 and 
5) or absence (-ATP, tracks 2 and 4) of 2mM ATP. The reactions were incubated at 25°C for 
30 minutes. The RNA was extracted and electrophoresed through a 6% (w/v) denaturing 
polyacrylamide gel and detected by autoradiography at -70°C. 
Abbreviations: IVS-E2: lariat-intron-exon 2 intermediate, IVS: lariat intron product, 
pre-mRNA: unspliced precursor mRNA, mRNA: spliced mature mRNA. 
Analysis of splicing complexes formed during the splicing reaction. 
101Li splicing reactions were set up as above using galactose-grown extracts of S 150-213 carrying 
either pBM-PRP2 or pBM-PRP2 in the presence of 2mM ATP and 32P-labelled rp28 
transcript. In each reaction 21zl wild-type extract was mixed with either 31.Ll buffer D (track 1), 
3121 purified PRP2'°' (track 2) or 3.d dominant negative PRP2 extract (which was known to 
inhibit splicing of a wild-type extract). The reactions were incubated at 25°C for 20 minutes and 
then electrophoresed through a non-denaturing 0.5 %(wlv) agarose, 3 %(wlv) polyacrylamide gel 
at 4°C. The complexes were detected by autoradiography at -70°C. The complexes are 
designated I, II and III after Pikielny et al (1986). 
Immunoprecipitation with anti-PRP2 antibodies 
50141 splicing reactions were assembled using 40d preformed APRP2 LATP spliceosomes and 
either 11zl of a 1 in 12.5 dilution of galactose-grown extracts of S150-213 carrying pBM-PRP2 1 
(tracks 3 and 4), or with lOng purified PRP2 (tracks 1 and 2) or PRP2" (track 5) in either the 
presence (+ATP, tracks 2, 4 and 5) or absence (-ATP, tracks 1 and 3) of 2mM ATP. The 
reactions were incubated at 25°C for 30 minutes and then stopped on ice. 5/21 of each reaction 
was removed and the RNA analysed by normal splicing assays (tracks sl-s5), the remaining 45/Al 
was mixed with PAS-bound anti-PRP2 antibodies (80/21, a55) for 2 hours at 4°C. The co-
immunoprecipitated labelled RNA was isolated and electrophoresed through a 6% (w/v) 
denaturing polyacrylamide gel (tracks p1-p5). The labelled RNA from both sets of reactions was 
detected by autoradiography at -70°C. Abbreviations: as above. 
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6.3.2.3 Partially purified PRP2 AKT does not bind poly(U) RNA and has negligible 
ATPase activity. 
Using the his-tagging procedure described in section 5.2.1, PRP2 was his-
tagged and partially purified using a nickel-chelating column. PRP2 co-eluted 
with 45 and 50 kDa contaminating proteins. However, PRP2 1 did not bind 
efficiently to the poly(U) agarose column, so the contaminants could not be removed. 
Previous work had shown, however, that the two contaminating proteins did not 
appear to affect the splicing or ATPase activities of PRP2 (section 5.3.4). 60ng 
of the partially purified PRP2 was used in ATPase assays as described in section 
2.5.10. Figure 6.4A shows the results of the assays. PRP2 (lane 1) released 2.7 
nmoles of phosphate during the reaction. Lane 3 shows a control sample where no 
stimulatory RNA was added to the wild-type reaction. Therefore the non-stimulated 
background ATPase activity of PRP2 was release of about 0.1 nmole of phosphate. 
Lane 2 shows that partially purified PRP2 had negligible ATPase activity as it 
caused release of less than 0. inmole of phosphate. It is probable that the negligible 
ATPase activity is connected with the inability of PRP21 to bind poly(U) RNA. 
A selection of other RNAs were used to test for increased stimulation of ATPase 
activity of PRP2T  and figure 6.4B shows that none of them was able to stimulate 
a significantly higher ATPase activity for PRP2. 
6.3.2.4 Partially purified PRP2 AKT is able to interact with pre-formed 
spliceosomes and inhibit splicing. 
Using the iPRP2 zATP spliceosome system (section 2.5.7 and 4.2.3) the 
inhibitory activity of partially purified PRP2T was investigated. Figure 6.5A 
shows the results of the splicing and immunoprecipitation experiments. Tracks si, 
s2, p1 and p2 show the results obtained when either PRP2 alone (tracks s2 and p2) 
or PRP2 and 2mM ATP (tracks si and p1) were added to the spliceosomes. In the 
absence of ATP, PRP2 can enter the spliceosome with which it remained stably 
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Figure 6.4 ATPase assays 
60ng purified PRP2 (wt, lane 1) or partially purified PRP2 	(AKT, lane 2) 
were incubated in the presence of poly(U) RNA (0.5jgjd') and [y- 32P]ATP (1mM) 
at 25°C for 1 hour. The 'y32Pi released was measured by Cerenkov counting. The 
ATPase activity of PRP2 was measured in the absence of poly(U) RNA (-RNA, 
lane 3). 
60ng of purified PRP2 (wt) or partially purified PRP2 (AKT) were incubated 
as above but with various different RNA substrates. 'y32Pi released was counted as 
before. 
The concentrations of the RNAs used were:poly(U): 0.5g.d' (lane 1) 
poly(A) : 0.5gl' (lane 2) 
poly(G) 0.5j.gd' (lane 3) 
E.coli tRNA: 0.514gil' (lane 4) 
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associated, so that pre-mRNA was co-immunoprecipitated with anti-PRP2 antibodies. 
On addition of ATP, the interaction of PRP2 1  with the spliceosome was transient 
and no pre-mRNA was co-immunoprecipitated. 	In section 6.3.2.2, the 
immunoprecipitation results presented showed that PRP2 	in an extract from 
overproducing cells failed to co-immunoprecipitate the pre-mRNA suggesting that 
PRP2 did not interact with the spliceosome. However, the result shown in tracks 
s3 and p3 show that even in the presence of ATP, PRP2 inhibited the splicing 
reaction and that pre-mRNA was co-immunoprecipitated from the reaction. The 
partially purified PRP21  protein must therefore, be able to interact stably with the 
preformed spliceosomes. 
6.3.2.5 Partially purified PRP2 AKT prevents formation of complex I. 
To investigate the spliceosomal complexes formed when a splicing reaction 
is inhibited by partially purified PRP2AKT wild-type extracts were mixed with an 
inhibitory amount of PRP2 (1 in 6.667). The reactions were incubated at 25°C 
for 2, 5, 10 and 30 minutes. Figure 6.5B shows the results of native gel 
electrophoresis following the incubation. Tracks 1-4 show the complexes formed 
after 2, 5, 10 and 20 minute incubations of a non-inhibited wild-type extract. The 
appearance of complex II indicated that the splicing reaction was proceeding as 
normal. Tracks 5-8 show the time course of complex formation in a PRP2-
inhibited reaction. Although complex III was present after 2 minutes incubation 
(track 5), even after 30 minutes, there was no sign of complex I (track 8). This 
result suggests that PRP2 AKT  was preventing the U4/U6.U5 tri-snRNP from 
interacting with the pre-mRNA. This may be because PRP2 is required for this step, 
which is unlikely as complex I is formed in heat inactivated pip2-1 extracts (Kim and 
Lin, 1993), or that PRP2T  is sequestering a factor in splicing extracts which is 
essential for the conversion of complex III to complex I. 
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Figure 6.5 In vitro analysis of partially purified PRP2 AKT  
In vitro splicing and iinmunoprecipitation 
5014 splicing reactions were set up containing 401.d preformed IPRP2 IATP 
spliceosomes and lOng purified PRP2 protein (tracks 1 and 2) or lOng partially 
purified PRP2 proteins (tracks 3 and 4) in the presence (+ATP, tracks 2 and 4) 
or absence (-ATP, tracks 1 and 2) of 2mM ATP. The reactions were incubated at 
25°C for 30 minutes, then stopped on ice. 5l of each reaction wsremoved and the 
RNA analysed by standard splicing reactions (tracks sl-s4). The remaining 451.d 
were mixed with PAS-bound anti-PRP2 antibodies (80/Ll, cv55) for 2 hours at 4°C, 
the co-innunoprecipitated RNA was extracted and analysed by denaturing gel 
electrophoresis (6% (w/v) polyacrylamide) and autoradiography (tracks pl-p4) 
Abbreviations used: IVS-E2: lariat-intron-exon 2 intermediate 
IVS: lariat intron product 
pre-mRNA: unspliced precusor mRNA. 
Note; the splicing and immunoprecipitation reactions were analysed on different gels, 
so there is a difference in separation of the pre-mRNA and X between the two. 
Analysis of splicing complex formation 
Standard lO/Ll splicing reaction were assembled, each containing either 241 wild-
type extract alone (tracks 1-4) or 2l wild-type extract and 3d partially purified 
PRP2 (tracks 5-8), 2mM ATP and 32P-labelled rp28 transcript. The reactions 
were incubated at 25°C for 2, 5, 10, 20 and 30 minutes and then electrophorsed on 
a 0.5%(w/v) agarose, 3%(w/v) polyacrylamide non-denaturing gel. The complexes 
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6.3.2.6 Partially purified PR_P2 AKr can be UV-cross-linked to the pre-mRNA in 
preformed spliceosomes. 
See section 5.3.5 for details of this investigation, and figure 5.5 for the 
results. 
6.4 Discussion 
The results presented in this chapter describe the in vivo and in vitro 
investigation of another dominant negative PRP2 allele. The single amino acid 
change was in the conserved G(X4)GKT ATP binding motif. Glycine' is thought 
to be involved in binding the 0- and 'y-phosphates of the NTP. The corresponding 
mutation in RAS2 had produced a dominant negative RAS2 protein which had an 
increased affinity for the GNRP, CDC25. 
When overproduced, the PRP2 mutant protein inhibited splicing, causing 
an accumulation of unspliced pre-mRNA (sections 6.3.1.1 and 6.3.1.3), which 
prevented cell growth. This dominant negative phenotype was temperature 
dependent, although cells carrying the mutant allele under GAL] promoter failed to 
grow on galactose at 30°C, if the temperature was increased to 36°C, the cells were 
able to grow on galactose. The PRP2' allele was unable to complement the 
temperature-sensitive prp2-1 strain DJy36 at 36°C on galactose, so the PRp2T 
protein must be non-functional at this temperature. Cells with a wild-type copy of 
PRP2 were able to grow on galactose at 36°C because PRP2T was no longer 
dominant negative at this temperature. This result suggests that the dominant 
negative protein is unstable at higher temperatures or that any interactions with other 
proteins are disrupted at the higher temperature. 
The growth curve described in section 6.3.1.2 shows that even under non-
inducing conditions, the low expression of PRP2 from the non-glucose repressed 
promoter causes a slight decrease in growth rate. This was also observed for cells 
overexpressing PRP2GIcN. Attempts to put PRP2 onto the genome in place of the 
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PRP2::URA3 gene disruption were also unsuccessful (section 3.4). Thus PRP2 
also seems to be inhibitory at normal cellular PRP2 levels. Additionally, there was 
a high reversion frequency observed for cells overproducing PRP2. Investigation 
of this showed that most revertants had a decreased level of overproduced PRP2 in 
the cells. Selection for down regulation of the GALl promoter was, therefore, very 
strong (section 7.3 expands this). 
The in vitro investigations of cell extracts in which PRP2 1 was 
overproduced and of partially purified PRP21 give contradictory results. Cell 
extracts overproducing PRP2T when mixed with wild-type extract prevent splicing 
and cause an accumulation of the fully assembled but inactive spliceosome (complex 
I, section 6.3.2.1) and the PRP2 protein in overproducing extracts fails to interact 
with preformed spliceosomes (section 6.3.2.2). In contrast, addition of partially 
purified ppAKT to wild-type extracts prevents splicing and the formation of 
complex I, an accumulation of complex III is seen instead (section 6.3.2.5). 
Partially purified PRP2 T  however, is able to interact stably with preformed 
spliceosomes (section 6.3.2.4). This contradiction can be explained if in 
overproducing extracts PRP2 binds to and sequesters another factor required for 
spliceosome assembly (called factor X here). In its bound form, PRP2 is unable 
to interact with the preformed spliceosomes, perhaps due to a change in 
conformation on binding factor X. However, during protein purification the high 
salt conditions disrupt the interaction between PRP2Al and factor X. Thus, the 
partially purified PRP2 is able to interact with the preformed spliceosome. For 
the investigations of splicing complex formation, the splicing reactions were set up 
with a mixture of wild-type extract and dominant negative extract or partially 
purified dominant negative protein. In the two-extract reactions, there may be 
enough factor X available to bind all the PRP2" present with some left over to 
allow some complex I formation. When partially purified protein is mixed with 
wild-type extract, it binds to and sequesters all the factor X so that the complex III-'.I 
change cannot take place. This explanation assumes that the cellular concentration 
of factor X is such that X can be easily depleted on addition of about 60ng of 
purified protein. A second assumption to be made is that factor X is primarily 
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involved in the complex ffl-'I change and that the PRP21 mutant has a much 
increased affinity for X than does wild-type PRP2. So, factor X may have more 
than one function in splicing. A schematic diagram illustrating this hypothesis is 
shown in figure 6.6. 
Partially purified PRP2 	has lost its RN-binding property and has a 
negligible ATPase activity (section 6.3.2.3). The partially purified protein which 
can bind to preformed spliceosomes inhibits splicing even in the presence of ATP, 
probably due to the aberrant ATPase activity. The inhibition of splicing in a 
dominant negative extract could therefore, be a combination of loss of ATPase 
activity and the sequestering of factor X by PRP2 preventing formation of 
complex I. 
As presented and dicussed in chapter 5, partially purified PRP2 can bind 
to the pre-mRNA in spliceosomes. This result suggests that PRP2 1 may be able 
to bind to one strand of a putative helicase substrate, as PRP2 GKN does. 
Partially purified PRP2<T  can be UV cross-linked to the pre-mRNA in 
preformed spliceosomes (section 5.3.4). As discussed in section 5.4, although 
PRP21  is unable to bind to poly(U) RNA during purification it appears to be able 
to bind to the pre-mRNA in the spliceosome. If PRP2 is required to destabilise an 
RNA:RNA interaction within the spliceosome, it is possible that the pre-mRNA is 
half of the destabilisation substrate. The mutation in PRP2 prevents binding of 
single-stranded RNA, the products of such a reaction, but not the double-stranded 
substrate. PRP2" does not release the pre-mRNA on addition of ATP, so release 
of the pre-mRNA is probably connected to ATP hydrolysis by PRP2. 
By analogy with the activation/inactivation cycle of RAS (section 1.8.1), 
factor X is a candidate for a nucleotide exchange factor (NEF) for PRP2. The RAS 
GTP-binding mutants all sequestered CDC25 which is the GNRP for RAS. 
Overproduction of CDC25 alleviated the dominant negative phenotype. If PRP2 
is "stuck" in an inactive ADP-bound form, then it could bind to the NEF, but 
because it is unable to exchange ADP for ATP (due to an increased affinity for 
ADP), it cannot release the NEF. Far Western blotting of cell extracts using 
partially purified PRP2 as a probe failed to identify any proteins with which the 
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Figure 6.6 Proposed model for the inhibitory action of PRP2" 
Factor X is required for complex 111-4 transition. 
PRP2 has a high affinity for X and can bind to X, preventing its normal function. 
PRP21 is also able to inhibit PRP21 function at step 1 of splicing but not in the 
X-bound form, when it is unable to enter the spliceosome. 
Abbreviations used: X: factor X; AKT: PRP2 AKT  







mutant interacted. However, this is not a very sensitive assay and if factor X is at 
low cellular concentrations it would not be easy to detect by Western blotting. 
Alternative methods to isolate or identify factor X are in vivo [ 5SJ labelling of cells 
prior to galactose induction of the dominant negative allele. If the overproduced 
PRP2 is labelled, it must be binding to another protein present in the cell in the 
absence of galactose. Low salt conditions may allow the PRP2:factor X complex to 
be isolated intact on the Ni-NTA column. Screening of a high copy number yeast 
genomic library for suppressors of the dominant negative phenotype could lead to the 
identification of the gene for factor X. 
The dominant negative PRP21  may provide the means to isolate and identify 
a factor which normally interacts transiently with PRP2, which may be a nucleotide 




Suppression of the dominant negative phenotype 
of PRP2AKT by components of the 
RAS/adenylate cyclase pathway. 
7.1 Introduction 
Chapter 6 described the characterisation of the dominant negative PRP2AICr 
allele. The analogous mutation in RAS2 (RAS2 1 ) or in H-ras had a dominant 
inhibitory effect which could be overcome by overexpression of CDC25, but only 
in the presence of wild-type RAS (Powers et al, 1989). This result suggested that 
the mutant genes interfered with the normal RAS/CDC25 interaction, probably by 
sequestering all the cellular stocks of CDC25. The mutant RAS proteins had a 
higher affinity for GDP than normal, so Powers et al (1989) hypothesised that GDP -
bound RAS binds CDC25 and only releases it after GDP/GTP exchange. More 
recent results have shown that the dominant inhibitory activity of the H-ras' 7 
mutant which also has increased affinity for GDP can be overcome by 
overexpression of the carboxy-terminal fragment (C-terminal) of SDC25 
(Schweighoffer et al, 1993), which is homologous to CDC25 (Boy-Marcotte et al, 
1989). It is unlikely that CDC25 or the C-terminal of SDC25 are also nucleotide 
exchange factors for PRP2 as they are involved in guanine nucleotide exchange and 
are membrane-bound cytoplasmic proteins (Gross et al, 1992(b)) whereas PRP2 is an 
ATPase located in the nucleus. However, if CDC25 or the C-terminal of SDC25 
were overproduced, PRP21  might be able to bind to the proteins prior to entry into 
the nucleus, such that bound PRP2 is unable to block splicing which would then 
occur as normal. It is not expected that CDC25 can function as a NEF for PRP2. 
However, to test this possibility wild-type yeast cells (S150-2B) were transformed 
with a plasmid carrying a GALl-regulated PRP2 gene and a high copy-number 
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plasmid expressing either CDC25 or the C-terminal of SDC25. To ensure that any 
suppression seen was due to CDC25/SDC25 being used as an exchange factor by 
PRP2 and not due to increased levels of cellular cAMP, plasmids carrying either 
pilel52 (cling for a RAS protein with efficient GDP/GTP exchange activity) or 
TPK1 (coding for a subunit of cAMP-dependent protein kinase) were used as 
controls. Overexpression of either of these genes will lead to an increase in cellular 
cAMP levels regardless of CDC25 levels but would not be expected to have any 
effect on PRP2 activation/repression. To test whether suppression was confined to 
the effect of overproducing CDC25 or the C-terminal of SDC25, a plasmid encoding 
PRP20 was included as a control. PRP20 protein is structurally and functionally 
homologous to the mammalian RCC1 protein (Aebi et a!, 1990; Fleischmann et a!, 
1991; Ohtsubo et al, 1991). RCC1 stimulates GDP/GTP exchange on RAN, a RAS-
related protein (Bischoff and Ponstingl, 1991). If overproduction of PRP20 could 
also suppress the dominant negative phenotype, then suppression may be due to an 
increased affinity of PRP21  for GNRPs. If PRP20 failed to suppress the dominant 
negative phenotype, then suppression by CDC25 or the C-terminal of SDC25 would 
probably be due to a cAMP effect. It is unlikely that PRP2 would have such 
stringent specificity for one GNRP over another. 
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7.2 Methods and materials 
7.2.1 Plasmid constructs used to test for suppression. 
NAME DESCRIPTION SOURCE 
pRG1 YEp352 a 2/L vector containing an 5.5kb fragment M. Jaquet 
coding for CDC25 and the URA3 selectable marker. (Orsay) 
pPIl YEp352 containing a 2kb fragment coding for the C- M. Jaquet 
terminal of SDC25 and the URA3 selectable marker. (Orsay) 
pICB23 YCp50, a centromeric plasmid containing a 2.4kb M. Jaquet 
fragment coding for TPK1 and the URA3 marker. (Orsay) 
pRYC YCp50 containing a 1.9kb fragment coding for M. Jaquet 
p5i1e152 and the URA3 selectable marker. (Orsay) 
YEpPRP20 YEp352 containing a 5.9kb fragment coding for M. Aebi 
PRP20 and the URA3 selectable marker. (Zurich) 
pEF3 pRS314, a centromeric plasmid carrying the 4kb This project 
GAL1-PRP2 	coding region and the TRP1 marker. 
7.2.2 Screening for suppression 
Following electroporation, cells were plated onto YMGluCas plates selecting 
for double transformants. Colonies which grew were colony purified on YMGluCas. 
Single colonies were resuspended in sterile dH 2O and equal volumes were spotted 
onto selective YMG1uCas and YMGa1RaICas plates and incubated at 30°C for three 
days. Cells in which the dominant negative phenotype had been suppressed grew on 
both YMG1uCas and YMGalRafCas plates. 
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7.2.3 Protein extractions 
7.2.3.1 lOOml of either YMG1uCas or YMGalRafCas were inoculated with single 
colonies of cells carrying both plasmids, which could grow on galactose. The 
cultures were grown at 30°C to OD 6w approximately 0.6. Total protein was 
extracted as described in section 2.5.2.1. 
7.2.3.2 lOOm! YMGlyLacCas was inoculated with a single colony of cells which 
were able to grow on galactose. Cultures were grown at 30°C to OD WO 0.3. 
Galactose was added (to 2% w/v) and incubation continued for a further 5 hours. 
Total protein was extracted as in section 2.5.2.1. 
7.3 Results 
7.3.1 Cells overproducing PRP2AKT and CDC25 or the C-terminal of SDC25 can 
grow on galactose. 
Wild-type S150-213 cells were co-transformed with pEF3 and either pPIl or 
pRG 1. Colony purified transformants were spotted onto selective YMGluCas and 
YMGalRafCas plates and incubated at 30°C for three days. Figure 7. 1A shows the 
results of screening two separate batches of transformants. All transformants 
carrying two plasmids were able to grow on glucose and galactose. The dominant 
negative phenotype was not seen, suggesting that overproduction of either CDC25 
or the C-terminal of SDC25 was able to suppress the inhibitory effect of PRP2. 
Western blots of protein extracts from these cells are shown in figure 7. lB. 
In almost all cases, there was still overproduction of PRP2. Track 9 shows a protein 
extract from cells which had failed to grow well in galactose. This effect was seen 
with the RAS"' 52  and TPK1 transformants (section 7.3.2) and may be due to unstable 
suppression (section 7.3.3). This result confirmed that the suppression was not just 
due to down regulation of the GAL] promoter causing a decrease in the production 
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Figure 7.1 Suppression of the dominant negative phenotype by CDC25 and the 
C-terminal of SDC25 
Single colonies were picked after colony purification on YMG1uCas of the double 
transformants of S150-2B carrying pEF3 and either pRG1 (CDC25) or pPIl 
(SDC25). The colonies were resuspended in sterile distilled water to a concentration 
of approximately 106 cells/mi. 10141 of each suspension was spotted onto YMG1uCas 
(Glucose) and YMGaiRafCas plates and incubated at 30°C for three days. 
Western blot analysis 
Sonicated cell extracts were prepared from the suppressed cells carrying pEF3 and 
either pRG1 (tracks 3-6) or pPIl (tracks 7-9) after growth in YMGalRafCas until 
OD600of the cultures was about 0.6. An extract from S150-2B carrying only pEF3 
was prepared after 5 hours growth on galactose (+, track 1) and one from 
untransformed S150-2B was included (-, track 2) to give an indication of the levels 
of production PRP2 protein. 100g of total protein (as determined by Bradford 
assay) from each extract was electrophoresed through a 7.5% SDS-polyacrylamide 
gel and blotted onto Immobilon P membrane. PRP2 was detected by affinity 
purified anti-PRP2 antibodies (cr140) and anti-rabbit IgG alkaline phosphatase 
conjugate secondary antibody. 
M represents size markers, sizes in kDa. 
Loss of CDC25/ C-terminal of SDC25 suppression 
Double transformants of S150-2B carrying pEF3 and either pRG1 (CDC25) or pPIl 
(CDC25) were colony purified on YMGluCas plates and after incubation at 30°C for 
3 days were stored at 4°C for 1-3 weeks. Single colonies were picked and 
resuspended in sterile distilled water. lOjd of each suspension were spotted onto 
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of PRP2 protein. 
There was a very low co-transformation efficiency for both the plasmid 
combinations. Co-transformation of two large plasmids is inefficient and there is 
evidence that S. cerevisiae can shuffle out large plasmids (Albury et al, 1992). 
Additionally, CDC25/SDC25 overproduction may be detrimental to cells grown on 
glucose. CDC25 is normally induced by glucose leading to phosphorylation and 
ultimately an increase in levels of activated cAMP-dependent protein kinase. cAMP-
dependent protein kinase. hyperphosphorylates CDC25 causing it to dissociate from 
the cell membrane so it cannot activate RAS any longer (Gross et al, 1992(a)). 
7.3.2 Overproduction of other components of the RAS/adenylate cyclase 
pathway can also suppress the dominant negative effect of PRP2'. 
In order to investigate whether the suppression by CDC25 and the C-terminal 
of SDC25 was because they were acting directly on PRP2 and not due to the 
activation of the RAS/adenylate cyclase pathway, the plasmids pICB23 and pRYC 
were co-transformed with pEF3 into S150-2B. Figure 7.2A shows the results of 
screening colony purified transformants which carried both plasmids. The cells 
could grow on glucose and galactose, indicating once again that the dominant 
negative effect had been suppressed. Plasmid YEpPRP20 was used as a control. 
PRP20 is involved in nuclear export of mRNA (Amberg et al, 1993) and as such, 
should not interfere with the function of PRP2 nor should it have any effect on 
cellular cAMP levels. However, it is a GNRP for the RAS-related protein, RAN. 
If PRP2T  is binding to CDC25/SDC25 because they function as NEFs, then PRP20 
may also suppress the dominant negative phenotype. The vector YEp352 was used 
to construct YEpPRP20, pRG1 and pPIl. The co-transformants carrying pEF3 and 
YEpPRP20 failed to grow on galactose. Therefore the dominant negative effect was 
not suppressed by the YEp352 vector itself nor by the presence of a gene coding for 
a GNRP not involved in the cAMP pathway. 
The Western blots of protein extracts from the suppressed cells grown on 
galactose are shown in figure 7.2B. From the blots it can be seen that some of the 
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Figure 7.2 Suppression of the dominant negative phenotype by other 
components of the RAS/adenylate cyclase pathway. 
Single colonies were picked after colony purification on YMG1uCas of the double 
transformants of S 150-2B carrying pEF3 and either pICB23 (FPK1) or pRYC 
(RAS1k152) or YEpPRP20 (PRP20). The colonies were resuspended in sterile distilled 
water to a concentration of approximately 106  cells/mi. 1Oii of each suspension was 
spotted onto YMGluCas (Glucose) and YMGalRafCas plates and incubated at 30°C 
for 4 days. 
Western blot analysis 
Sonicated cell extracts were prepared from the suppressed cells carrying pEF3 and 
either pICB23 JPK1, tracks 3-10) or pRYC (RAS' 52 , tracks 3-10) after growth in 
YMGalRafCas until OD600  of the cultures was about 0.6. An extract from S150-2B 
carrying only pEF3 was prepared after 5 hours growth on galactose (+, track: 
RAS1152: 1; TPK1: 2) and one from untransformed S150-2B (-, track: RAS 152 : 2; 
TPK1: 1) was included to give an indication of the levels of production of PRP2. 
100g of total protein (as determined by Bradford assay) from each extract was 
electrophoresed through a 7.5% SDS-polyacrylamide gel and blotted onto Immobion 
P membrane. PRP2 was detected by affinity purified anti-PRP2 antibodies (cd40) 
and anti-rabbit IgG alkaline phosphatase conjugate secondary antibody. 
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"suppressed" cells were able to grow on galactose because the GAL] promoter had 
apparently been down-regulated and there was a much lower level of PRP2 protein 
detected (tracks: RAS:3, 5, 7, 8 and 9; TPK1:3, 4, 6 and 7). This result indicates 
the strong selection within a pool of cells for those in which the level of production 
of the dominant negative protein is lowered. However, in some cases the PRP2 
protein was still overproduced (lanes: RAS :4, 6 and 10; TPK 1:5, 8, 9 and 10) and 
so expression of the plasmids pICB23 and pRYC was causing suppression of the 
dominant negative phenotype. Growth of isolated revertant colonies of cells carrying 
only pBM-PRP2 can be seen after five days on galactose plates. Therefore, it is 
not surprising that after electroporation and several generations on glucose or 
galactose many of the "suppressed" cells had decreased levels of PRP2 expression. 
7.3.3 The suppression by CDC25/C-terminal of SDC25 is unstable 
The cells in which the dominant negative effect of PRP2T  was suppressed 
by CDC25 or the C-terminal of SDC25 were propagated on selective glucose plates. 
When, after a week or more on glucose, the colonies were retested on galactose 
many of them failed to grow despite the continued presence of plasmids pRG1 or 
pPIl. This loss of suppression is shown in figure 7. 1C. Subsequently, all 
suppressed double transformants were propagated on galactose plates and suppression 
was maintained. This result may be another indication that growth on glucose could 
be detrimental to cells overproducing CDC25 or SDC25. Additionally, some co-
transformations of pEF3 with pRG1(CDC25) or pPIl(SDC25) did not result in 
suppression (M. Cooper, pers. comm.). 
7.4 Discussion 
This chapter has described some preliminary results which show that 
overproduction of CDC25, the C-terminal of 5DC25 and other components of the 
RAS/adenylate cyclase pathway can suppress the dominant negative effect caused by 
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overproduction of PRP2. 
CDC25 and the C-terminal of SDC25 are homologous and both are GNRPs 
for RAS2 in S. cerevisiae (Powers et al, 1989; Crechet et al, 1990; Damak et a!, 
1991). These two proteins can also be used as GNRPs for H-ras in in vitro assays 
(Schweighoffer et al, 1993). CDC25 is a membrane-bound cytoplasmic protein 
which is activated in response to external glucose signals (Gross et al, 1992(b)). 
The dominant inhibitory phenotype caused by RAS 2 can be overcome by 
overexpression of CDC25 and it has been suggested that RAS 2 is able to bind to 
CDC25 but because no GDP/GTP exchange occurs (due to the high affinity of 
RAS 2 for GDP), the CDC25 cannot be released (Powers et al, 1989). In this way, 
overproduction of RAS 2 in cells leads to a depletion of cellular CDC25 so that 
none is available to activate wild-type RAS. PRP2 has the same mutation in the 
NTP-binding motif as RAS 2 (glycine-.alanine). If PRP2 has an 
activation/inactivation cycle analogous to RAS (section 1.8.1) then PRP2" which 
may have a high affinity for ADP could sequester the NEF for PRP2. 
Overproduction of the other protein for which PRP2 has increased affinity should 
suppress the dominant negative phenotype. 
It was, however surprising that overproduction of CDC25 and the C-terminal 
of SDC25 did allow growth on galactose when PRP21 was also overproduced in 
wild-type cells. CDC25 is an unlikely candidate for the NEF of PRP2. The result 
that both TPK1 and RAS 152 could also suppress the dominant negative phenotype 
confirmed that it was not the CDC25 and SDC25 proteins in particular that caused 
suppression but instead, activation of the RAS/adenylate cyclase pathway. Activation 
of this pathway leads to an increase in the cellular levels of cAMP which in turn 
activates cAMP-dependent protein kinase (cAPK) which is involved in cell growth 
and transcriptional regulation (figure 1.9). Normally, a feedback mechanism ensures 
that the amount of cAMP produced is controlled. However this appears to rely on 
hyperphosphorylation of CDC25 by cAPK (Gross et a!, 1992(b)). Overproduction 
of CDC25 or the C-terminal of SDC25 will activate RAS more efficiently and 
perhaps, the inactivation by hyperphosphorylation will take longer than normal. 
RAS 152  does not require CDC25 for activation and therefore its activity is not 
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subject to feedback control by cAPK. TPK1 is a subunit of cAPK and is therefore 
acting downstream of cAMP. Overproduction of TPK1 should not affect the cAMP 
levels, but it may have an effect further down the signalling pathway which is also 
seen on increasing the levels of cAMP. 
The conclusions drawn about the suppression of PRP2 1 can only be 
tentative. There is certainly some correlation of increased cAMP levels and 
suppression of the dominant negative phenotype and further work to identify other 
components of the RAS/adenylate cyclase pathway which act as suppressors may 
show the exact cause of the suppression. Preliminary results have also indicated that 
overproduction of CDC25 or the C-terminal of SDC25 could also suppress the 
dominant negative phenotype of PRP2. As yet, suppression of the PRP2-dnl 
dominant negative phenotype has not been tested. The mutation in PRP2" is in the 
SAT motif and ATPase activity is only slightly affected. It is unlikely that PRP2' 
is sequestering an NEF and it would be interesting to see what, if any effect 
stimulating cAMP production would have on the ability of cells carrying PRP2' to 
grow on galactose. 
The instability of the suppression is also a cause for concern. Growth on 
glucose will activate the RAS/adenylate cyclase pathway and the activation pathway 
will be controlled as normal by hyperphosphorylation of CDC25. Perhaps the 
glucose stimulation causes enough cAPK to be activated to regulate the activity of 
CDC25 even when it is being overproduced, leading to regulation of the levels of 
cAMP, so that whatever is causing the suppression is no longer activated or 
inactivated and thus loses its suppressing ability. This hypothesis assumes that the 
effects of prolonged growth on glucose are maintained on the transfer to galactose 
and several doubling times while the dominant negative protein is overproduced and 
has time to inhibit splicing sufficiently to prevent further growth. There is evidence 
that RNA splicing is carbon source sensitive. Hileren and Siliciano (CSH, 1993) 
report that yeast cells are viable in the absence of SNP1 which codes for the yeast 
homologue of the Ui snRNP 70k protein. Although growth of a null strain on 
glucose led to severe temperature-sensitivity and increased doubling time, growth of 
the same strain on non-glucose carbon sources restored the doubling times to wild- 
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type and reduced the temperature-sensitivity. This is a strain-dependent phenotype 
which is proposed to be dependent on the presence of the SRN1/REG1 gene. Tung 
and Hopper (CSH, 1993) have shown a connection between RAS-cAMP signal 
transduction and RNA splicing. REG1 encodes a protein that is a negative regulator 
of glucose-repressible proteins and which also functions in the RAS/adenylate cyclase 
pathway. A mutant REG1 protein can suppress the RNA processing defects caused 
by rnal-1 and some prp mutations (Tung et al, 1992) This is hypothesised to be due 
to an indirect effect where REG1 normally negatively regulates the expression of 
another gene whose expression is only required for efficient RNA splicing in the 
absence of glucose Constitutive expression of this gene due to a mutation in REG1 
might compensate for the defects of the splicing gene mutation. Tung et a! (1992) 
also reported that alteration of the carbon source from glucose to glycerol could also 
suppress these mutations. Here, once again there is expression of the gene which 
is usually only negatively regulated by RIEG1 in the presence of glucose. By altering 
the levels of cAMP, Tung and Hopper (CSH, 1993) were able to suppress the rnal-1 
mutation. Other studies of pre-mRNA and pre-tRNA splicing have led to the 
proposal that phosphatases that are controlled by cAMP may have a role in splicing 
(Mermoud et a!, 1992; Turcq et al, 1992). Additionally, an increase in the 
efficiency of splicing of introns with a mutant branch-point is observed on non-
fermentable carbon sources (S. Anderson, pers. comm.). A recent publication by 
Klein and Struhl (1994) has described how ribosomal protein mRNA levels are 
increased in cells with high levels of cAMP protein kinase (cAPK). They 
hypothesised that cAPK was reponsible for modulating the transcriptional activity of 
RAP 1, a transcription factor required for expression of most ribosomal protein 
genes. High levels of cAPK increased the activity of RAP 1. Genes which are 
controlled by RAP I. have the consensus: RMACCCANNCAYY (where M represents 
either A or C and N represents any nucleotide). PRP2 has this consensus at the 5' 
end of the gene (J. Beggs, pers. comm.) and thus, it may be subject to control by 
RAP1. Klein and Struhi (1994) showed that although cAPK is normally induced 
only in reponse to glucose, in bcyl cells where cAPK is constitutively activated, 
RAP 1-controlled transcription of ribosomal protein genes is increased even in the 
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absence of glucose. Thus, if PRP2 transcription is also RAN controlled there may 
be increased transcription of PRP2, even on galactose in cells where the 
RAS/adenylate cyclase pathway has been activiated. Initial investigation of this 
hypothesis by transforming plasmid pICB23 (coding for TPK1, a subunit of cAPK) 
into DJy36 and analysis of PRP2 protein levels by Western blotting did not show any 
significant increase in the level of PRP2 protein. However, Western blotting is not 
a very sensitive method for detecting small increases in protein levels. 
It seems therefore, that RNA splicing can be affected by the levels of cAMP 
in the cell and that the effect may be due to phosphorylation or dephosphorylation 
of components of the splicing reaction. The carbon source effect on splicing is 
important too, especially since all the dominant negative PRP2 alleles are only 
expressed in the presence of a particular carbon source, galactose. 
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CHAPTER 8 
Final discussion and future work. 
The results presented in this thesis describe the production by site-directed 
mutagenesis, of dominant negative mutants of PRP2, an essential yeast splicing 
factor. PRP2 protein has sequence motifs characteristic of the DEAD/H-box family 
of putative ATP-dependent RNA helicases. As it has been proposed that the splicing 
reaction mechanism involves many RNA:RNA interactions, there are a great many 
potential unwinding or destabilisation points during the reaction for which putative 
RNA helicases could be required. 
One of the conserved motifs of PRP2 is the GX 4GKT motif which is involved 
in ATP binding. This motif is also found in GTPase proteins where it is required 
for GTP binding. GTP binding studies in H-ras and RAS2 had identified point 
mutations within the GTP binding motif which caused aberrant affinity for GDP and 
these mutants had a dominant negative phenotype. The role of CDC25 as a guanine 
nucleotide release protein was partly elucidated using these mutants. PRP2 has no 
known exchange factor like CDC25 nor is there any experimental evidence to 
suggest that it has a mode of action similar to that of RAS2 or H-ras, but it is 
interesting to speculate that PRP2 may exist in two states- an active ATP-bound state 
and an inactive ADP-bound state analogous to the RAS model. The site-directed 
mutagenesis of the ATP binding motif of PRP2 to produce the dominant negative 
mutants altered the amino acid residues crucial for binding the (3- and -y-phosphate 
groups of ATP. The same mutations in H-ras and RAS2 had produced the dominant 
negative proteins. 
Extensive in vivo and in vitro studies have confirmed that the mutant PRP2 
alleles were causing inhibition of splicing, leading to an accumulation of pre-mRNA. 
Further analysis of two of the mutants (PRP2' and PRP2') showed that the 
dominant negative proteins caused inhibition either of the complex I—II conversion 
(PRP2) or of the complex III-'I conversion (PRP2). The two partially purified 
proteins were shown by immunoprecipitation to be able to interact stably with 
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preformed spliceosomes (complex I) and that unlike wild-type PRP2, the interaction 
was stable in the presence of ATP. Addition of either partially purified protein to 
wild-type splicing extracts inhibited splicing causing a slight accumulation of 
complex I, the fully assembled but inactive spliceosome. The apparent contradiction 
of complex assembly results seen for PRP21 extract and partially purified protein 
can be explained if PRP2 has a higher-than-normal affinity for an extra-
spliceosomal factor (X) required for complex assembly. With PRP2 1 bound to it, 
X is unable to carry out its normal function and PRP2:X complexes are unable 
to interact with preformed spliceosomes. However, during the purification, the 
interaction of PRP2 and X is disrupted, leaving partially purified PRP2 
unbound and able to interact with the preformed spliceosomes. The amount of X 
must be limiting and can be titrated out on addition of partially purified PRP2T to 
extracts. If the mutant proteins are similar to the H-ras and RAS2 mutants in having 
a higher affinity for the nucleotide diphosphate than the triphosphate, then factor X 
is a candidate for a nucleotide exchange factor for PRP2. Although there appeared 
to be no inhibition of complex III-I conversion in any reactions involving PRP2 
there was very little accumulation of complex I observed, compared to the huge 
accumulation seen with another mutant (PRP2'). This may suggest that PRP2 
has a lower affinity for X than PRP2 but a higher affinity than wild-type PRP2. 
Thus, PRP2 	has a less pronounced affect on the complex assembly and the 
inhibition of splicing is mainly due to loss of some other important function. The 
observation that partially purified PRP2 	can interact with spliceosomes but still 
prevent splicing also suggests a loss of function of the mutant PRP2 protein in 
addition to the increased affinity for factor X. Theoretically, on addition of purified 
wild-type PRIP2 protein to reactions in which all the PRP2T  is bound to factor X 
but where spliceosomes are assembled (for example, when PRP2 extract is added 
to preformed spliceosomes), splicing should occur as normal. 
Neither of the partially purified proteins bound to the poly(U) agarose column 
during purification, although PRP2 binds well. In ATPase assays, the amount of 
phosphate released in reactions with the dominant negative proteins was similar to 
the amount released in wild-type assays in the absence of stimulatory poly(U) RNA. 
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Although the two dominant negative proteins appear to have negligible ATPase 
activity, it is possible that the basal ATPase activity of the proteins is normal but 
cannot be RNA-stimulated due to the loss of RNA binding activity. 
Preliminary results from cross-linking studies have shown that both partially 
purified proteins are in close contact/bound to the pre-mRNA in preformed 
spliceosomes. If the pre-mRNA is part of the putative substrate that PRP2 may 
destabilise, then the mutants may have lost the ability to bind to the single stranded 
RNA product of destabilisation or to another part of the substrate such as an snRNA 
or even another cofactor which might be required for "helicase" activity. The loss 
of ATPase activity or even (by analogy with RAS) the loss of ability to exchange 
ADP with ATP may prevent the destabilisation reaction from proceeding as normal. 
Future work could be focused on the identification of the factor with which 
PRP2T appears to interact, which may be a nucleotide exchange factor. Using 
genetic screening for high copy-number suppressors of the PRP2 dominant 
negative phenotype, such a factor could be identified. Additionally, if PRP2 1 is 
stably bound to the factor X, then the PRP2:X complex could be isolated on a Ni-
NTA column under very low salt conditions to stabilise the interaction. As factor 
X appears to be important for complex III-'I conversion, it could normally be 
associated with the snRNPs. The putative DEAD-box helicases, PRP5 and PRP28 
are proposed to be required for U2 binding and U4/U6 destabilisation respectively. 
If either or both of these proteins has an ATP/ADP activation/deactivation cycle, 
then this would be another point at which a NEF would be required. If PRP2 is 
sequestering the NEF also needed for PRP5 or PRP28 function, then it is likely that 
the spliceosome assembly cycle might be stalled until PRP5 and/or PRP28 could be 
activated by exchange of ADP by ATP. In such a situation, accumulation of 
complex III might be observed. 
The additional phenotype of negligible ATPase activity shown by both 
PRP2AKT and PRP20KN appears to be at least partly responsible for inhibition of 
splicing. These two mutants can be used to investigate further the role of PRP2 
protein in the splicing reaction. Looking for suppressors of the PRP2G  dominant 
negative phenotype may identify factors with which PRP2 interacts in the 
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spliceosome. 
Finally, suppression of the dominant negative phenotype by overproduction 
of components of the RAS/adenylate cyclase pathway poses many questions about 
the carbon source dependence of the splicing reaction. If increased levels of cAMP 
are responsible for the suppression, it would be interesting to find out exactly how 
the suppression is occurring. It may also be that like the REG1 suppression, there 
are splicing factors required only in non-glucose conditions, which are normally 
suppressed on glucose. These glucose-repressed factors will be expressed on 
galactose and may also be affected by high levels of cAMP, leading to indirect 
suppression of the dominant negative phenotype by components of the RAS/adenylate 
cyclase pathway. It is interesting to speculate that there might be an indirect link 
between two previously unconnected metabolic processes and that control of splicing 
is to some extent dependent on carbon source. 
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